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Summary 
  The healthy intestinal mucosa is home to the largest population of m! in 
body.  Like  all  tissue  m!,  intestinal  m!  play  vital  roles  in  maintaining  tissue 
homeostasis by removing apoptotic cells and any other cellular debris. In addition 
they maintain the integrity of the epithelial barrier and support the differentiation 
and  maintenance  of  regulatory  T  cells  in  the  mucosa.  By  virtue  of  their  high 
phagocytic and bactericidal activity, these m! are also vital members of the innate 
immune system and are strategically positioned adjacent to the epithelium so that 
they can capture and eliminate any invading organism(s). However unlike other 
tissue m!, those found in the normal gut have several functional adaptations, such 
as  hyporesponsiveness  to  toll-like  receptor  (TLR)  ligands,  which  allow  them  to 
function  without  provoking  overt  inflammation.  M!  are  also  abundant  during 
intestinal  inflammation,  where  they  show  increased  TLR  responsiveness,  pro-
inflammatory cytokine and chemokine production and enhanced phagocytic ability. 
Under these conditions, m! perpetuate inflammation. It remains unclear whether 
these  distinct  roles  in  healthy  and  inflamed  intestine  roles  are  carried  out  by 
discrete populations of m!, or if the resident m! alter their behaviour and become 
pro-inflammatory. 
  One  of  the  main  obstacles  to  gaining  a  better  understanding  of  the 
immunobiology of intestinal m! during steady state and inflammatory conditions is 
discriminating them from other mononuclear phagocytes (MP) in the mucosa, such 
as dendritic cells (DC). At the time of starting my project, it was becoming clear 
that  markers  such  as  F4/80  and  CD11c  were  insufficient  for  distinguishing 
between m! and DC when used in isolation. Therefore, the aims of this thesis 
were to first establish reliable multi-parameter flow cytometry staining protocols to 
allow precise phenotypic and functional characterisation of m! in the healthy and 
inflamed  mouse  colon,  and  secondly,  to  explore  the  origins  of  these  m! 
populations  to  assess  whether  they  were  derived  from  distinct  precursors,  or 
whether  a  relationship  existed  between  them.  Lastly,  I  examined  the  potential 
mechanisms underlying the characteristic TLR hyporesponsiveness that intestinal 
m! exhibit, focusing on the role of the inhibitory CD200R1-CD200 axis. 
  In  Chapter  3,  I  first  set  out  to  characterise  phenotypically  the  m! 
populations present in the steady state mouse colon using multi-parameter flow   16 
cytometry.  These  studies  revealed  that  expression  of  the  chemokine  receptor 
CX3CR1  could  be  used  to  identify  two  main  populations  of  myeloid  cells,  the 
bigger  of  which  was  a  homogeneous  population  of  CX3CR1
highCD11b
+ 
F4/80
+MHCII
+  Ly6C
neg m !  that  dominated  the  resting  mucosa.  A  smaller 
population of CD11b
+ cells expressing intermediate levels of CX3CR1 (CX3CR1
int) 
was  also  present  in  the  steady  state  mucosa,  but  this  was  remarkably 
heterogeneous, with at least 4 subsets distinguishable on the basis of Ly6C, class 
II  MHC,  F4/80  and  CD11c  expression.  These  included  F4/80
+Ly6C
highMHCII
neg 
CD11c
neg cells that were phenotypically indistinguishable from blood monocytes, 
F4/80
+Ly6C
+MHCII
+CD11c
+/neg cells and F4/80
+Ly6C
negMHCII
+CD11c
+/int cells that 
were phenotypically and morphologically similar to CX3CR1
high m! except for their 
lower  level  of  CX3CR1.  Finally  there  was  a  minor  subset  of  F4/80
negLy6C
neg 
MHCII
+CD11c
high  cells  that  expanded  markedly  in  response  to  in  vivo f l t 3 L  
treatment  and  appeared  to  be  genuine  DC.  CX3CR1
neg  cells  were  also  found 
within the CD11b
+ population in the healthy mucosa, most of which were Siglec F
+ 
eosinophils, together with a few neutrophils. In the second half of Chapter 3, I 
examined how these populations changed during acute colitis induced by feeding 
dextran  sodium  sulphate  (DSS).  These  experiments  demonstrated  that  the 
CX3CR1
int  compartment  expanded  dramatically  during  acute  inflammation,  with 
preferential  accumulation  of  the  Ly6C
high  subsets  and  relative  loss  of  the 
CX3CR1
high population as colitis progressed. Together these studies suggested 
that CX3CR1
high and CX3CR1
int cells represent resident and pro-inflammatory m! 
respectively.  
  I next set out to explore the in vivo origin of the CX3CR1
int and CX3CR1
high 
populations, to address whether they were derived from independent precursors 
as  would  be  predicted  by  current  theories  of  monocyte  heterogeneity,  or  if  a 
relationship  existed  between  them.  By  using  adoptive  transfer  of  purified  BM 
monocytes, the studies described in Chapter 4 show that 'inflammatory' Ly6C
high, 
but  not  Ly6C
low  'resident'  monocytes  replenished  the  CX3CR1
high  resident  m! 
population  in  the  steady  state  mucosa.  This  appeared  to  involve  local 
differentiation  of  Ly6C
high  monocytes  through  CX3CR1
int  intermediary  stages, 
which  was  accompanied  by  the  acquisition  of  class  II  MHC,  loss  of  Ly6C  and 
upregulation of F4/80 and CX3CR1. In vivo BrdU incorporation studies supported 
the idea that the majority of CX3CR1
int cells in the resting intestine represented 
short-lived  intermediaries  on  their  way  to  becoming  CX3CR1
high m !.  Together   17 
these studies suggested that rather than representing independent m! subsets, 
the  CX3CR1
int  and  CX3CR1
high  cells  in  the  resting  colonic  mucosa  comprise  a 
differentiation  continuum  from  Ly6C
high  monocytes  to  mature  CX3CR1
high m !. 
Analysis  of  BM  chimeric  mice  confirmed  that  BM-derived  monocytes  were  the 
source of the vast majority of colonic LP m!. These findings were supported by the 
fact  that  CCR2  KO  mice,  in  whom  Ly6C
high m o n ocyte  egress  from  the  BM  is 
blocked, lack Ly6C
high colonic monocytes and have markedly reduced numbers of 
mature colonic m!. In Chapter 4, I also explored whether factors present in the 
normal  mucosa,  such  as  colony  stimulating  factor  (CSF)-1,  TGF! a n d  t h e  
chemokine CX3CL1, could direct monocytes to acquire the phenotype of mucosal 
m!. Although initial in vitro studies suggest that none of these were effective on 
their own, in vivo administration of recombinant CSF-1 appeared to promote in situ 
monocyte  differentiation  in  the  gut.  Taken  together,  the  results  in  this  chapter 
highlight  that  the  CX3CR1
high m !  population  is  maintained  by  Ly6C
high b l o o d  
monocytes and that their differentiation is controlled by local factors in the mucosa.  
  In Chapter 5, I went on to investigate whether the phenotypically identifiable 
differentiation of mucosal m! was accompanied by alterations in their functional 
capacity. Intracellular cytokine staining, qRT-PCR and reporter gene expression 
revealed that as Ly6C
high monocytes differentiate locally through the CX3CR1
int 
stages into CX3CR1
high m!, they progressively acquired the ability to produce IL10 
and  have  reduced  production  of  pro-inflammatory  mediators.  In  addition,  the 
maturation of monocytes was accompanied by an increased ability to phagocytose 
and kill bacteria. Their response to exogenous stimulation by TLR ligands also 
altered  as  differentiation  proceeded,  with  the  Ly6C
high  monocytes  responding 
robustly to TLR2 and TLR4 ligation in a TNF! dominated manner, whereas the 
CX3CR1
high m !  responded  less  vigorously  and  their  TNF!  production  was 
balanced by IL10. This pattern was retained during experimental colitis, where the 
CX3CR1
int cells showed enhanced spontaneous TNF! production, whereas IL10 
remained the dominant product of CX3CR1
high m!. Adoptive transfer experiments 
in Chapter 6 then showed that donor Ly6C
high monocytes were recruited to the 
mucosa  of  colitic  mice,  but  unlike  in  resting  mice,  they  failed  to  acquire  the 
CX3CR1
high  phenotype.  These  results  supported  the  idea  that  in  inflammation, 
local  differentiation  of  monocytes  is  arrested  at  an  early  stage  before  anti-
inflammatory m! can develop and that this allows inflammation to be perpetuated.   18 
  In Chapter 6 I also examined the role of inflammatory monocytes in the 
pathogenesis of colitis, again taking advantage of CCR2 KO mice. These mice 
showed reduced susceptibility to acute DSS colitis and this was associated with a 
lack of monocytes and their immediate descendents in the colon of resting KO 
animals.  In  parallel,  CCR2  KO  monocytes  were  unable  to  migrate  to  inflamed 
colon and together these findings confirmed that Ly6C
high monocytes are essential 
for the development of the pathology. Further experiments in Chapter 6 examined 
how the colonic m! populations changed during the resolution phase of colitis. 
Within  two  weeks  of  withdrawing  DSS,  there  was  partial  restoration  of  the 
CX3CR1
high m! population and this was paralleled by a loss of the CX3CR1
int cells 
that had accumulated during inflammation. However, in vivo BrdU-labelling studies 
revealed that the reappearance of CX3CR1
high m! was probably not due to the 
subsequent differentiation of recruited CX3CR1
int cells. These results imply that 
many of the Ly6C
high monocytes recruited during inflammation give rise to short-
lived effector cells and that restoration of the resident m! population may involve 
de novo recruitment of blood monocytes. 
  Finally,  in  Chapter  7,  I  explored  some  of  the  mechanisms  that  might 
underlie  the  hyporesponsiveness  that  intestinal  m! e x h i b i t .  I n  particular,  I 
examined  the  role  of  the  CD200R1-CD200  regulatory  axis,  as  this  has  been 
shown  to  control  m!  activity  in  other  tissues.  First,  I  established  that  resident 
colonic m! express CD200R1 and that its ligand is expressed in the resting colon 
by both haematopoietic and non-haematopoietic cells. I then went on to examine 
the impact of CD200R1-deficiency on the colonic m! pool by taking advantage of 
CD200R1  KO  mice.  This  revealed  that  although  these  mice  had  an  additional 
population of F4/80
+MHCII
int colonic m!, these lacked Ly6C expression and so 
were unlikely to represent recently recruited pro-inflammatory m!. Colonic m! from 
CD200R1 KO mice also expressed comparable levels of costimulatory molecules 
and  TLR  to  WT  mice,  and  showed  no  signs  of  hyper-reactivity  to  exogenous 
stimuli. Furthermore, neither CD200R1-deficiency nor lack of CD200 resulted in 
the  development  of  spontaneous  intestinal  inflammation,  or  increased 
susceptibility  to  DSS  colitis.  Final  experiments  in  this  chapter  suggested  that 
deliberate ligation of CD200R1 on CSF-1 generated BM-derived m! had little or no 
effect on the responsiveness of these cells to innate stimuli. Taken together, the 
data in Chapter 7 suggested that unlike alveolar m! and microglia, the CD200R1-
CD200 axis plays little or no role in controlling colonic m! activity.    19 
  Collectively,  the  results  presented  in  this  thesis  make  important  steps 
forward in our understanding of the complex network of MP in the colon during 
homeostasis  and  inflammation.  By  using  precise  characterisation  of  mucosal 
myeloid  cell  subsets,  I  have  been  able  to  show  that  'inflammatory'  Ly6C
high 
monocytes  constantly  enter  the  steady  state  mucosa,  where  they  differentiate 
locally  through  a  series  of  CX3CR1
int  intermediaries  to  replenish  the  majority 
CX3CR1
high m! population. This maturation process is accompanied by alterations 
in  function,  so  that  resident  CX3CR1
high m !  are  relatively  desensitised  to 
exogenous  stimuli,  but  retain  high  phagocytic  activity  and  produce  IL10 
constitutively. The exact factors that influence monocyte maturation and control 
m!  activity  in  the  normal  gut  are  still  unclear,  although  signalling  through 
CD200R1 alone appears to play no role in this. My studies have also established 
that  pro-inflammatory  m!  in  the  colon  arise  from  the  same  Ly6C
high  monocyte 
precursor  and  accumulation  of  these  cells  during  chemically  induced  colitis  is 
partly  due  to  the  arrest  in  the  local  differentiation  process.  The  recruitment  of 
Ly6C
high monocytes and their derivatives in acute inflammation is dependent on 
CCR2 and is central for pathology, probably due to their readiness to produce pro-
inflammatory mediators such as TNF!. To the best of my knowledge, these results 
demonstrate for the first time that 'resident' and 'pro-inflammatory' m! in the colon 
are not independent cell types, but rather represent alternative, context-dependent 
differentiation  outcomes  of  the  same  monocyte  precursor.  These  findings  have 
important implications, as targeting of inflammatory monocyte infiltration has been 
considered as a potential strategy for the treatment of inflammatory bowel disorder 
(IBD). However given my observations that these monocytes also replenish the 
resident m! population, the depletion or blockade of these monocytes may have 
impact on 'resident' m! populations and might impair their immunoregulatory roles.  
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1.1 Introduction 
  The immune system has evolved to be able to successfully detect, isolate 
and  eliminate  infections  agents.  The  innate  and  adaptive  arms  of  the  immune 
system work in tandem to ensure that this process is highly efficient. The innate 
immune system provides a robust and rapid response to pathogenic challenge and 
tissue damage, but this response is not antigen-specific. In contrast, although the 
adaptive immune system's response is delayed, it is specific to individual antigens 
and long-lived immunological memory is generated to allow rapid responses upon 
re-exposure to the same antigenic stimulus. However the immune system must 
also  tolerate  exposure  to  other  foreign  antigens,  such  as  dietary  components, 
environmental antigens and commensal and mutualistic bacteria. Active immune 
responses targeted against these antigens would not only be wasteful, but also 
potentially  dangerous  to  the  host.  As  discussed  in  more  detail  below,  this  is 
particularly important in the intestine, which encounters more foreign antigen than 
any other part of the immune system. 
1.2 Macrophages and the Mononuclear Phagocyte System 
  Since being first described by Elie Metchnikoff in the 19th century, it has 
been appreciated that macrophages (m!) are present in almost every tissue of the 
body (Table 1.1). M! are large, tissue resident myeloid cells that display stellate 
morphology and are characterised by the presence of pseudopodia, non-specific 
esterases  and  phagocytic  granules,  which  give  m!  a  'foamy'  appearance. 
Although most immunologists regard m! as effector cells of the innate immune 
system, they play a much wider role in the body. As implied by their name, m! are 
highly  efficient  phagocytes  and  they  contribute  to  the  maintenance  of  tissue 
homeostasis through the clearance of apoptotic, senescent and damaged cells 
generated by tissue wear and tear. Their ability to scavenge dying material means 
that m! also play a vital role during organogenesis in embryonic development, 
where they are highly concentrated at sites of high cell death, such as developing 
limb  buds  (1).  These  tissue  remodelling  functions  are  maintained  in  the  adult, 
where m! are crucially involved in wound healing after infection, injury or insult. 
However m! also perform tissue-specific functions. For example, m! in the liver 
(Kupffer  cells)  aid  the  removal  of  toxins  from  the  circulation,  while  m! i n  t h e  
alveolar  space  of  the  lung  are  specialised  at  engulfing  and  eliminating  inhaled   22 
environmental  antigens,  and  osteoclasts  are  essential  for  bone  remodelling. 
Although  scavenging  cellular  debris  may  be  their  primary  role  under  normal 
conditions,  m!  also  secrete  a  raft  of  soluble  mediators  that  contribute  to 
maintenance  of  homeostasis,  including  enzymes,  cytokines,  chemokines, 
arachidonic acid derivatives and glycoproteins such as fibronectin (2). 
  As members of the innate immune system m! function as sentinels in all 
tissues, where they are strategically located close to the body's epithelial surfaces. 
Using a plethora of germ-line encoded pattern recognition receptors (PRR), such 
as  toll-like  receptors  (TLR),  Nod-like  receptors  (NLR),  C-type  lectin  receptors 
(CLR) and other scavenger receptors, m! can detect conserved structural motifs, 
or  so-called  pathogen  associated  molecular  patterns  (PAMP),  allowing  them  to 
rapidly  capture  and  engulf  any  invading  microorganisms.  Ingested  material  is 
encapsulated  in  a  phagosomal  compartment  which  then  fuses  with  highly 
degradative lysosomes ensuring that engulfed material is eliminated. Furthermore, 
by virtue of their ability to acquire antigen and their expression of class II MHC, as 
well as production of regulatory cytokines, m! can also contribute to the adaptive 
arm of the immune system by influencing T cell behaviour. As a result, m! play a 
critical  role  in  protective  immune  responses.  However  aberrant  m!  activity  has 
been  shown  to  be  associated  with  many  inflammatory  conditions  such  as 
rheumatoid  arthritis,  atherosclerosis  and  inflammatory  bowel  disease  (IBD),  as 
well as malignant disease.    
1.2.1  How to Identify a Macrophage 
  In mice, the best and most commonly used marker to identify m! is F4/80 
(Table 1.2). Although some m! fail to express F4/80, such as splenic marginal 
zone m! and osteoclasts, and others such as alveolar m! express it only at low 
levels, it still proves to be the most reliable marker of murine m! (3, 4). In addition 
to  F4/80,  most  murine  m!  populations  also  express  the  pan-myeloid  marker 
CD11b and CD68 (macrosialin), as well as CD115, the receptor for CSF-1 (5), 
consistent  with  their  derivation  from  monocytes.  As  discussed  in  detail  below, 
some m! in mice also express the DC marker CD11c. F4/80 is not a useful m! 
marker in man, as it is expressed predominantly by eosinophils (6) and therefore 
expression  of  CD68  or  CD33  is  used  to  characterise  human  m!.  Interestingly,   23 
murine eosinophils have also been shown to express F4/80, albeit at lower levels 
than m! (7).  
Table 1.1: Tissue Macrophage Populations during Homeostasis 
Tissue  Macrophage Population(s)  Phenotype 
Central Nervous 
System 
Microglia  CX3CR1
high F4/80
+ CD11b
+ CD68
+ MHCII
neg 
 
Lung  Alveolar macrophages 
 
CX3CR1
neg F4/80
low CD11b
neg CD11c
+ MHCII
neg 
Liver  Kupffer cells  CX3CR1
neg F4/80
+ CD11b
low CD68
+ MHCII
+ 
Spleen  Metallophilic macrophages 
Marginal zone macrophages 
 
CX3CR1
neg F4/80
low/neg CD11b
low/- CD68
+ MHCII
neg 
Bone Marrow  Bone marrow macrophages 
Osteoclasts 
CX3CR1
neg F4/80
+ CD11b
low CD68
+ MHCII
+ CD169
+ 
Skin  Langerhans cells 
 
CX3CR1
+ F4/80
neg CD11b
+ MHCII
+ Langerin
+ 
Gastrointestinal 
Tract 
Intestinal macrophages  CX3CR1
high F4/80
+ CD11b
+ CD68
+ MHCII
+ 
Uterus  Uterine macrophages  
Decidual macrophages 
CX3CR1
+ F4/80
+ CD11b
+ MHCII
+/neg 
Peritoneum  Peritoneal macrophages   CX3CR1
neg F4/80
high CD11b
+ CD68
+ MHCII
neg 
 
Table 1.2: Cell Surface Markers of Tissue Macrophages 
Surface 
Marker 
Gene  Expression/Comments  Proposed Function 
F4/80  Emr1  Pan-m! marker 
Variable levels of expression 
Unknown ligand 
Adhesion 
Maintaining peripheral 
tolerance 
CD11b  Itgam  Pan-myeloid integrin 
Expressed by numerous cells 
Component of complement receptor 3 (CR3) 
 
Phagocytosis 
Adhesion to endothelium 
CD11c  Itgax  Expressed by most, if not all tissue m!  
Typically associated with DC 
Component of complement receptor 4 (CR4)  
 
Phagocytosis 
Adhesion  
CD68  Cd68  Expressed by all mouse and human m! 
Expressed intracellularly - limited usefulness 
for functional analysis 
 
Phagocytosis 
Potentially involved in 
regulating antigen processing 
CD115  Csf1r  Receptor for CSF-1 
Expressed on all cells of the m! lineage 
 
Receptor for CSF-1 
Survival, proliferation and 
differentiation of m! 
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1.2.2  Macrophage Development 
  M!, along with monocytes and DC, are part of the mononuclear phagocyte 
system (MPS). The concept of the MPS was originally proposed by van Furth and 
colleagues (8) in the 1970's and was described as a family of cells that are derived 
from a common BM progenitor that differentiates into blood monocytes, which in 
turn give rise to tissue resident m! and DC throughout the body. Although the 
basic concept of the MPS still remains, this linear model is rather simplistic and it 
is now appreciated that there is considerable heterogeneity within the MPS (9).  
  Monocytopoiesis in the BM involves the differentiation of monocytes from 
haematopoietic  stem  cells  (HSC)  through  a  number  of  morphologically  distinct 
intermediate  stages,  from  the  common  myeloid  progenitor  (CMP),  to  the 
granulocyte/m! progenitor (GMP) and the m!/dendritic cell progenitor (MDP) (Fig. 
1.1).  At each of these stages there is progressive lineage commitment and cells 
lose the potential to give rise to the other cell types. The MDP, which has lost 
granulopoietic potential, has been shown to give rise to monocytes and m!, as 
well as both classical DC (cDC) and plasmacytoid DC (pDC) (10). The MDP is 
characterised by expression of CD115, CD117 (c-kit) and CD135 (flt3), together 
with the chemokine receptor CX3CR1 that is proposed to mark dedication to the 
myeloid lineage (10). Development of mature monocytes involves differentiation 
into monoblasts and pro-monocytes, both of which have a rapid turnover in the BM 
(11).  Unlike  their  pro-monocyte  precursors,  newly  differentiated  monocytes  are 
thought to exit cell cycle, thereby losing their proliferative potential (11, 12).  
  The development of cells of the MPS is reliant on a panel of transcription 
factors, which can be split into two groups. First, there are transcription factors that 
are essential for the direct control of myeloid cell differentiation in the BM, such as 
PU.1 and AML (13-15). This group also includes transcription factors that maintain 
survival of stem cells or pluripotent precursors in the BM, such as GATA-2, SCL 
and  c-Myb  (16-18).  The  second  group  of  transcription  factors  activates  or 
represses key m! genes, but are not essential for m! development and these 
include NF-M/C/EBP!, HOXB7 and c-Myc (19). Furthermore, specific transcription 
factors including C/EBP", EGR-1, NF-Y, IFN-regulatory factor (IRF)-1, -4 and -5, 
as well as Jun/Fos and STAT proteins involved in cytokine signalling, have been 
shown to be involved in specific aspects of m! differentiation/maturation (19).   25 
  PU.1  is  the  most  vital  of  these  transcription  factors  and  it  has  been 
described as the 'master regulator' of m! development, although it also plays a 
role in B cell development (13, 14). PU.1 belongs to the Ets transcription factor 
family and is in turn dependent on the activity of the Runt-related transcription 
factor (RUNX)-1 (20). Although not essential for initial commitment to the myeloid 
lineage,  PU.1  is  indispensible  for  the  subsequent  differentiation  of  myeloid 
progenitors into m!. It not only activates specific genes such as CSF-1R, but also 
causes specific histone modifications in the enhancer regulatory elements of m!-
specific genes, thereby generating open DNA for other transcription factors such 
as NF-#B to bind (21). Knockout of PU.1 is embryonic lethal, but whether this is 
due  solely  to  a  defect  in  m!  development  is  unclear,  as  PU.1  KO  mice  have 
defects in multiple haematopoietic lineages including m! and granulocytes, as well 
as in B- and T-lymphocytes (14). 
  Once  generated,  monocytes  leave  the  BM  in  a  process  that  is  highly 
dependent upon the chemokine receptor CCR2 and as a result CCR2-deficient 
mice  have  a  significant  defect  in  their  circulating  monocyte  reservoir  (22). 
Monocytes remain in the circulation for up to 2 days before migrating into tissues 
and  differentiating  into  m!  (23).  Although  it  is  clear  that  monocytes  have  no 
proliferative potential in the bloodstream, it is poorly understood whether they can 
proliferate  after  arrival  in  tissues.  Studies  by  Geissmann  and  colleagues  have 
proposed that there may be at least two distinct monocyte subsets in mice (Figure 
1.1) (12), an idea which has been long established in man (24). In mice, these 
subsets have been distinguished on the basis of differential expression of Ly6C (or 
Gr-1)  and  CX3CR1  (12).  Monocytes  that  express  high  levels  of  Ly6C  and 
intermediate levels of CX3CR1 (referred to hereafter as Ly6C
high monocytes), also 
express  the  chemokine  receptor  CCR2  and  the  adhesion  molecule  CD62L  (L-
selectin). These Ly6C
high monocytes are termed 'inflammatory' monocytes due to 
their propensity to migrate to sites of inflammation in multiple disease models and 
to produce pro-inflammatory cytokines during infection or tissue damage (12, 22, 
25, 26). The second major monocyte subset in mice is defined by low expression 
of Ly6C, high levels of CX3CR1 and CD43, but low or no expression of CCR2 and 
CD62L  (referred  to  here  as  Ly6C
low).  These  Ly6C
low  monocytes  have  been 
denoted  'resident'  monocytes  as  they  were  found  in  both  resting  and  inflamed 
tissues  following  adoptive  transfer  (12).  However  little  direct  evidence  currently 
exists  to  support  the  notion  that  Ly6C
low  monocytes  contribute  significantly  to   26 
replenishment of tissue m! in the steady state. More recently, Auffray et al. have 
used  intra-vital  microscopy  to  show  that  Ly6C
low  monocytes  exhibit  'patrolling' 
behaviour in the vasculature, where they crawl along the blood vessel in a process 
that is independent of blood flow and dependent upon the "2 integrin and CX3CR1 
(27). It is postulated that this allows Ly6C
low monocytes to scavenge dead cells, 
lipids and blood-borne pathogens present in the vascular system and that this may 
be  their  specialised  function,  rather  than  to  replenish  m!  populations  in 
parenchymal tissues (27).   
  The  exact  relationship  between  Ly6C
high a n d  L y 6 C
low  monocytes  is 
complicated by studies suggesting the former may be the precursor of the latter.  
This concept is supported by the fact that Ly6C
high monocytes appear to have a 
very short half-life in vivo and lose Ly6C expression around 48hrs after adoptive 
transfer into congenic hosts (12, 28). Furthermore, studies employing clodronate 
liposome-mediated cell depletion strategies have demonstrated that reconstitution 
of the Ly6C
low blood monocyte compartment is secondary to the establishment of 
the Ly6C
high monocyte fraction (29). In addition, a third monocyte subset has been 
described  with  an  intermediate  phenotype  (Ly6C
intCX3CR1
+),  which  may 
represent  monocytes  in  transition  from  the  Ly6C
high t o  L y 6 C
low  phenotype  (30). 
However, other studies have suggested that Ly6C
high monocytes can be depleted 
with  little  effect  on  Ly6C
low  monocytes  (31)  and  thus  conversion  of  blood 
monocytes remains a contentious issue. 
  Analogous monocytes subsets have been identified in humans, albeit using 
different  cell  surface  markers.  Differential  expression  of  CD14,  the  LPS  co-
receptor, and CD16 (Fc$RIII) allow segregation of at least two monocyte subsets, 
and gene expression profiling and cluster analysis have enabled parallels to be 
drawn between the human and mouse (32, 33). Monocytes expressing high levels 
of  CD14  but  lacking  CD16  expression  (CD14
highCD16
neg)  comprise  80-90%  of 
human blood monocytes (12). These monocytes also express high levels of CCR2 
and are believed to be the equivalent to murine Ly6C
high 'inflammatory' monocytes 
(12, 34). However the cytokine profiles of CD14
highCD16
neg human monocytes and 
Ly6C
high  murine  monocytes  are  distinct.  Whereas  murine  Ly6C
high  monocytes 
produce a panel of pro-inflammatory cytokines (including TNF!, IL1 and IL6) upon 
stimulation  with  LPS,  CD14
highCD16
neg  human  monocytes  respond  in  an  IL10   27 
dominated manner to identical stimulation (35). Thus one must apply caution when 
drawing parallels between these monocyte populations in different species. 
  The smaller CD14
+CD16
high subset of human monocytes expresses high 
levels of CX3CR1 and low levels of CCR2 and thus is similar to murine Ly6C
low 
'resident' monocytes (12, 34). These cells also have poor phagocytic activity and 
do not produce pro-inflammatory cytokines in response to LPS stimulation, but 
their  role  in  replenishment  of  tissue  m!  remains  elusive.  As  in  mice,  a  third 
monocyte subset has been identifed in human blood. This subset also displays an 
intermediate  phenotype  (CD14
+CD16
+)  and  again  may  represent  monocytes  in 
transition  from  the  CD14
highCD16
neg t o  C D 1 4
dimCD16
high  phenotype.  However, 
these CD14
+CD16
+ monocytes possess unique functional characteristics, such as 
robust pro-inflammatory cytokine production in response to LPS stimulation in vitro 
and they expand during inflammation, suggesting they may represent a distinct 
population of blood monocytes with inflammatory functions (36). 
  Although typically associated with m! replenishment, monocytes have also 
been shown to give rise to classical DC. The differentiation of monocytes into DC 
was proposed to occur following transendothelial migration, whereas monocytes 
that remained in the subendothelial matrix differentiated into m! (37). However it is 
now  clear  that  there  are  DC-committed  precursors  which  are  independent  of 
monocytes. The MDP has been shown to give rise to plasmacytoid DC (pDC) 
directly, and to the pre-cDC, which can differentiate into classical DC, but not pDC 
or m! (10) (Fig. 1.1). Some believe that this occurs through a common dendritic 
cell precursor (CDP) intermediate (38, 39), although others have suggested that 
the MDP and the CDP are phenotypically and developmentally overlapping (40). 
Thus there are probably distinct precursors that replenish bona fide DC and tissue 
m! during steady state and inflammatory conditions. 
1.2.3  Growth Factors in Macrophage Development 
  Differentiation of HSC into monocytes via various intermediary progenitors 
is  dependent  on  the  presence  of  multiple  growth  factors,  including  colony 
stimulating factor (CSF)-1 (also known as m!-colony stimulating factor; M-CSF), 
CSF-2 (granulocyte-macrophage stimulating factor; GM-CSF), IL3, stem cell factor 
(SCF;  also  known  as  c-kit-ligand)  and  IFN$  (41,  42).  Of  these,  CSF-1  is   28 
indispensible for m! development in vivo and is the only cytokine able to drive m! 
differentiation in vitro on its own. The requirement for CSF-1 is evidenced by the 
major m! defects seen in CSF1
op/op mice, which have a naturally occurring frame-
shift mutation in the gene encoding CSF-1 (41). These osteopetrotic mice have 
significant reductions in most tissue m! populations, low body weight and skeletal 
abnormalities due to defective bone remodelling (41, 43). Mice with a targeted 
deletion of the CSF-1R display a more severe m! phenotype than op/op mice (44), 
implying that CD34, the newly identified and only other CSF-1R ligand (45), may 
also  play  a  crucial  role  in  m!  development.  In  addition  to  a  role  in  BM 
monocytopoiesis, it has been suggested that CSF-1 may play an equal, or even 
more  important  role  in  maintaining  differentiated  m!  populations  in  peripheral 
tissues.  Indeed  CSF-1
op/op  mice  have  relatively  preserved  BM  monocyte 
production,  but  vast  reductions  in  most  tissue  m!  (46).  Furthermore,  tissue-
restricted  over-expression  of  CSF-1  leads  to  increases  in  local  m!  numbers  in 
mice (47, 48) and delivery of exogenous CSF-1 has been shown to expand some 
tissue m! populations, as well as having an effect on blood monocyte numbers 
(46, 49). The exact mechanism by which CSF-1 increases tissue m! numbers in 
unclear.  Although  a  direct  effect  on  m!  proliferation  or  survival  is  the  most 
straightforward mechanism, CSF-1 has also been shown to induce resident m! 
populations to produce chemokines that facilitate recruitment of blood monocytes 
to the uterus (50) and damaged kidney (51). Interestingly, m! resident in lymph 
nodes and the thymus remain unaffected in CSF-1
op/op mice, implying that CSF-1 
independent m! may also exist (52). Alternatively, other growth factors such as 
CSF-2, fms-like tyrosine kinase 3 ligand (flt3L), vascular endothelial growth factor 
(VEGF)-A or lymphotoxin !1"2 may compensate for the CSF-1 deficiency in CSF-
1
op/op mice, a notion supported by the fact that the phenotype of osteopetrotic mice 
improves with age (53, 54).    
1.2.4  Self-Renewal of Tissue Resident Macrophages 
  Although monocytes are likely to be the origin of most tissue m!, there is 
evidence  that  tissue  resident  m!  may  also  be  maintained  through  in  situ  self-
renewal. Fate-mapping studies have demonstrated that m! are already present in 
the yolk sac as early as d7.5 of embryonic development in the mouse (55). This is 
before the establishment of the circulatory system and thus these m! are thought 
to  arise  independent  of  blood  monocytes.  M!  derived  from  these  non-  29 
haematopoietic precursors appear to persist into adult life through a process of 
self-renewal and examples include microglia of the central nervous system (CNS), 
Langerhans cells in the epidermis of the skin and alveolar m! of the lung (56-58). 
Other  studies  employing  parabiosis  of  congenic  mice  have  confirmed  that  the 
homeostatic maintenance of these m! populations under resting conditions has 
been shown to be largely independent of blood monocytes and CCR2 (57, 59-61). 
It remains unclear whether these m! are present in all parenchymal tissues and 
what  their  functions  are.  However  these  cells  could  act  as  sentinels  in  the 
periphery as sensors of tissue damage or infection and release mediators that 
trigger other components of the immune response.  
 
Figure 1.1: The Accepted View of the Mononuclear Phagocyte System 
In  the  bone  marrow  (BM), h a e m a t o p o i e t i c  s t e m  c e l l s  ( H S C )  give  rise  to c ommon  myeloid 
progenitors (CMP), which in turn give rise to the macrophage and dendritic cell precursor (MDP). 
The MDP gives rise to monocytes, which have been shown to comprise of at least two subsets 
distinguished  on  the  basis  of  Ly6C,  CX3CR1  and  CCR2  expression.  Ly6C
highCX3CR1
intCCR2
+ 
monocytes are classified as 'inflammatory' monocytes and give rise to inflammatory m! and TNF! 
and iNOS-producing (Tip) DC in inflamed tissue. Ly6C
lowCX3CR1
+CCR2
neg monocytes are termed 
'resident'  and  are  reported  to  be  involved  in  the  homeostatic  replenishment  resident  m! 
populations, as well as patrolling the vasculature. MDP also gives rise to all DC subsets. Classical 
DC arise from DC-committed precursors (pre-cDC) that are downstream of the MDP, however it 
remains controversial whether this involves progression through a common DC progenitor (CDP) 
stage. Plasmacytoid DC (pDC) arise directly from the MDP/CDP without passing through a pre-DC 
stage. 
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1.3 Macrophage 'Activation' 
  As discussed above, m! are highly plastic cells that play important roles in 
tissue  homeostasis  in  every  tissue  of  the  body.  However  disruption  of  tissue 
homeostasis by infection, inflammation or trauma results in m! activation, which is 
associated  with  phenotypic  and  functional  alterations.  Historically  m!  activation 
was regarded as a uniform phenomenon that resulted in the increased capacity to 
destroy microbial pathogens and was followed by m! 'deactivation'. However it is 
now  appreciated  that  activated  m!  can  be  'polarised'  into  distinct  phenotypes 
dependent upon the cues received from their tissue environment.   
1.3.1  Classical Macrophage Activation 
  Classical  m!  activation  results  from  the  recognition  of  PAMPs  on  the 
surface of Gram-positive and Gram-negative bacteria. M! express a range of TLR 
and other PRR which are triggered during phagocytosis of pathogenic material 
(Fig.  1.2).  As  detailed  below,  this  results  in  the  production  of  pro-inflammatory 
cytokines  including  TNF!,  IL1,  IL6,  IL12  and  IL23  and  chemokines  such  as 
CXCL9 (MIG) and CXCL10 (IP10) (62) (Fig. 1.3). Classical activation of m! is 
dependent  on  the  transcription  factors  STAT1  and  IRF5  activity  (63,  64).  Pro-
inflammatory mediators released by classically activated (or M1) m! facilitate the 
recruitment  of  inflammatory  leucocytes  such  as  monocytes  and  neutrophils,  as 
well as the polarisation of T lymphocytes to the TH1 and/or TH17 phenotype, cells 
which are known to perpetuate the inflammatory response. These m! also express 
inducible nitric oxide synthase (iNOS or NOS2) allowing them to generate nitric 
oxide  (NO)  from  L-arginine.  NO  causes  DNA  damage  and  is  essential  for  the 
elimination  of  bacteria  within  m!  (65).  M1  m!  also  produce  other  cytotoxic 
mediators  such  as  superoxide  anions  and  other  oxygen  radicals  through 
expression of the NADPH oxidase enzyme. Given that mice deficient in both iNOS 
and  NADPH  (phagocyte  oxidase)  develop  large  abscesses  which  are  rich  in 
enteric  commensal  bacteria  (66),  suggests  that  NO-mediated  mechanisms  are 
essential in the elimination of ingested bacteria by m!. In addition, patients with 
chronic granulomatous disease (CGD) suffer from recurrent bacterial and fungal 
infections due to a defect in their NADPH oxidase gene. Together these effector 
functions  demonstrate  that  classically  activated  m!  are  highly  specialised  in 
destroying intracellular microorganisms. Furthermore, their ability to upregulate the   31 
expression  of  class  II  MHC  and  costimulatory  molecules,  allows  classically 
activated m! to act as antigen presenting cells (APC) for T cells. However these 
potent pro-inflammatory properties also mean that classically activated m! must 
be tightly controlled, as aberrant or excessive activity can lead to tissue damage. 
Indeed,  m!  exhibiting  M1  characteristics  are  commonly  found  in  pathology 
associated  with  chronic  inflammatory  conditions  such  as  atherosclerosis, 
rheumatoid arthritis and IBD (67-69).   
1.3.2  Alternative Macrophage Activation  
   Although first associated with the ability to inhibit classical m! activation, it 
is now clear that the TH2 type cytokines IL4, IL13 and IL33 cause m! to polarise to 
an 'alternative' activation state, a process controlled by the transcription factors 
IRF4, STAT6 and PPAR$ (70, 71). These alternatively activated (AAM or M2) m! 
are commonly found during parasitic infection, allergy and in the healing phase 
after tissue damage (72). M2 m! are characterised by their high phagocytic activity 
and expression of CD206 (mannose receptor), FIZZ1 (also known as Relm-!) and 
Ym-1 (also known as CHI3L3) (72). Unlike M1 m!, M2 m! do not express iNOS 
and are poor producers of reactive oxygen and nitrogen species. Instead, these 
IL4/IL13/IL33 polarised m! express arginase-1 (73), allowing them to convert L-
arginine  to  L-ornithine,  which  is  a  precursor  of  polyamines  and  collagen,  and 
facilitates tissue remodelling and encapsulation of helminths (72). The chitinase-
like molecule Ym-1 has similar properties via its carbohydrate and matrix-binding 
activity  (74).  M2  m!  also  have  a  unique  cytokine  and  chemokine  expression 
profile. Whereas M1 m! produce high levels of pro-inflammatory cytokines such as 
TNF! and IL12, M2 m! produce only low levels of these cytokines and instead 
produce  high  levels  of  the  immunomodulatory  cytokines  IL10  and 
TGF", as well as the pro-angiogenic cytokine VEGF  (75).  TGF!  together  with 
platelet-derived  growth  factor  (PDGF)  has  been  shown  to  stimulate  fibroblast 
differentiation and proliferation thus adding to the tissue remodelling role of M2 m! 
(76, 77). Consistent with their associations with TH2-mediated immune responses, 
M2 m! also produce CCL17, CCL22 and CCL24 (78-80), all of which are ligands 
for CCR3 and CCR4, chemokine receptors expressed by TH2 cells, eosinophils 
and basophils. This chemokine signature confirms their possible involvement in 
TH2-polarised immune responses such as parasitic clearance and in tissue repair, 
which  is  appropriate  for  large  tissue  dwelling  organisms  that  disrupt  the  local   32 
architecture.  The  maintenance  of  M1  versus  M2  m!  also  appears  to  involve 
distinct  mechanisms.  Whereas  M1  m!  are  thought  to  derive  entirely  from 
circulating blood monocytes, it has been shown recently that alternatively activated 
m! that arise in the TH2 setting may also be maintained through self-renewal, a 
process that is highly dependent on IL4 (81).  
 
 
Figure 1.2: Pattern Recognition Receptors expressed by Macrophages 
Tissue macrophages express a diverse range of pattern recognition receptors including Toll-like 
receptors  (TLR),  complement  receptors  and  scavenger  receptors.  They  also  express  inhibitory 
receptors such as CD200R1 which has been shown to negatively regulate macrophage activity. 
Taken from (82). 
1.3.3  Regulatory Macrophages 
  There is growing appreciation that the idea of m! polarisation into M1 or M2 
states is probably over-simplistic and that these polarisation states likely represent 
two extreme ends of an activation spectrum, with many m! phenotypes in between 
(62). One particular example of this is regulatory or 'M2-like' m!, which possess 
An example of a macrophage receptor involved in the
innate immune recognition of fungal pathogens is Dectin-1,
a C-type lectin receptor which recognizes b-glucan (26). The
receptor possesses a cytoplasmic immunoreceptor tyrosine-
based activation motif-like sequence that is involved in medi-
ating proinﬂammatory cytokine production in response to
b-glucan, in cooperation with TLR2 (27, 28). Dectin-1 can
also stimulate the oxidative burst in response to b-glucans,
independently of the TLR pathway. It has been shown to play
an important role in the uptake of Candida albicans and studies
have shown uptake is dependent on the exposure of glucan by
the yeast form but not the ﬁlamentous form. This may provide
a basis for fungal evasion mechanisms (29). Another study
showed that the MR, which accumulates on phagosomes at
later stages, has a potential role in phagosome sampling, sub-
sequent to Dectin-1 (30).
The role of the above innate recognition, non-opsonic
receptors in the uptake of a variety of intracellular bacteria has
not been studied, except in the case of mycobacterial infec-
tion. SR-A was redundant for infection in mice (31), whereas
MARCO plays a role in the pro-inﬂammatory response to
trehalose dimycolate (47), as does the lectin-like receptor
Mincle (32). CD36, an unrelated scavenger receptor, has also
been implicated in mycobacterial stimulation of TNF release
by macrophages (33).
Uptake
Depending on its size and bulk, uptake of a microbial particle is
usually by phagocytosis, or modiﬁcations thereof, induced by
selected pathogens (4) (Fig. 2). Viruses can enter via endocyto-
sis, macropinocytosis, or fusion. Complex signaling pathways,
cytoskeleton remodeling, dynamic membrane movements,
ﬁssion and vesicular fusion, and relays of phosphoryla-
tion⁄dephosphorylation are set in train. Intravacuolar
processes such as acidiﬁcation and killing and digestion deter-
mine the outcome of infection. Cytoplasmic proteins enter the
nucleus and these transcription factors regulate gene expres-
sion, biosynthesis, and secretion of pro- and anti-inﬂamma-
tory molecules (proteins such as cytokines, chemokines,
Fig. 1. Schematic structures of selected macrophage receptors implicated in microbial recognition. Macrophages express a wide variety of recep-
tors which mediate recognition of microbial pathogens. Phagocytic surface receptors include non-opsonic receptors (e.g. C-type lectins and Scavenger
Receptors) as well as opsonic receptors (e.g. complement receptor and Fc receptors). Toll-like receptors (TLRs) are sensing receptors, some of which
are expressed on the surface (e.g. TLR4), while others are vacuolar (e.g. TLR9). Sensing receptors are also found in the cytoplasm, and these include
the NOD-like receptors (NLRs), RIG-like receptors (RLRs), and DNA sensors (e.g. AIM2). Other surface molecules regulate the response of myeloid
cells to unrelated agonists, for example the EGF-TM7 molecule EMR2, as well as TREM1⁄2 and CD200⁄CD200R. AIM2, absent in melanoma 2; CARD,
caspase recruitment and activation domain; CR3, complement receptor 3; DAP12, DNAX activation protein of 12 kDa; EGF-TM7, epidermal growth
factor seven transmembrane receptor; FccR, Fc gamma receptor; HIN200, Hin 200 domain; family; ITAM⁄ITIM; immunoreceptor tyrosine-based
activation⁄inhibition motif; MARCO, macrophage receptor with collagenous structure; NLRs, NOD-like receptors; PYD, pyrin domain; RLRs, RIG-like
receptors; SR-A, scavenger receptor A; Siglecs, sialic acid binding Ig-like lectins; TLRs, Toll-like receptors; TREM1, triggering receptor expressed on
myeloid cells-1.
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some of the features of both M1 and M2 m!. Regulatory m! express CD206 and 
the scavenger receptor CD163 and like M2 m!, they produce high levels of IL10 
but low levels of TNF! and IL12 (83). Despite this inhibitory phenotype, regulatory 
m! are avidly phagocytic and express class II MHC and costimulatory molecules, 
potentially allowing them to interact with T-lymphocytes (83). The exact conditions 
that lead to polarisation of m! into this regulatory phenotype remain to be fully 
elucidated. However, glucocorticoids, IL10 and TGF" have been implicated (84, 
85), as has phagocytosis of apoptotic cells, which may act by inducing TGF" (86). 
FcR-mediated signalling by immune complexes has also been proposed to cause 
induction of the regulatory phenotype in m!, usually acting in concert with TLR 
ligands (87). Furthermore, CCL2 has been shown to induce M2-like phenotype in 
human  monocytes  (88).  M!  exhibiting  a  regulatory/M2-like  m! p h e n o t y p e  h a v e  
been shown to be present in vivo in the placenta and the uterus, and appear to be 
the major m! type in tumours (50, 89, 90). Tumour associated m! (TAM) promote 
tumour growth through the production of growth factors such as VEGF and by 
inducing/maintaining  Treg  via  the  production  of  IL10  and  CCL22  (75,  91). 
Increased  CSF-1  and  CSF-1R  expression  correlates  with  poor  prognosis  in 
patients with certain cancers (92), and over expression of CSF-1 in mice leads to 
acceleration of tumour growth and metastasis (48), implying that m! can support 
tumour development and growth. 
  Thus  the  plastic  nature  of  tissue  m!  allows  them  to  adopt  different 
phenotypic and functional/activation states in order to perform functions that are 
tailored  to  provide  specific  functions  in  distinct  tissues  and  environments. 
Furthermore, it has been suggested that m! can move between these activation 
states, as is likely to be necessary to fulfil the various requirements at different 
stages  of  infection  or  in  distinct  anatomical  locations.  As  discussed  more  fully 
below, this is particularly true for intestinal m! that require many adaptations to 
allow them to exist in harmony with their antigen and microbe rich environment. 
1.3.4  Regulation of Macrophage Activation 
  As noted above, m! possess a plethora of receptors that allow them to 
sense  microbes  and  damaged  tissue.  These  include  TLR,  NLR,  retinoic  acid 
inducible-I (RIG-I)-like receptors, as well as the mannose receptor (CD206) and 
scavenger receptors such as CD36, MARCO and scavenger receptor A (SR-A).   34 
Furthermore, m! express Fc receptors and complement receptors that allow them 
to recognise and engulf opsonised particles.   
 
Figure 1.3: Macrophage Activation 
The  factors  that  induce  and  the  characteristics  that  define  classically  activated,  alternatively 
activated and regulatory macrophages. 
  The most studied family of receptors are the TLR. To date 10 TLR have 
been  identified  in  humans  and  13  in  mice,  and  between  them,  they  recognise 
many different PAMPs associated with bacteria, viruses, fungi and helminths, as 
well as endogenous ligands released by damaged cells (93). TLR have to dimerise 
to function and can be expressed on the cell surface or intracellularly. Surface 
TLR1  and  TLR2  heterodimerise  to  recognise  bacterial  triacylated  lipoproteins, 
while dimerisation of TLR2 with TLR6 allows recognition of bacterial diacylated 
lipoproteins. TLR4 and TLR5 form homodimers on the cell surface and recognise 
bacterial LPS and flagellin, respectively. TLR3, TLR7 and TLR9 are associated 
with  endosomal  compartments  and  recognise  viral  double  stranded  RNA,  viral 
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single  stranded  RNA  or  unmethylated  CpG-motifs  in  bacterial  and  viral  DNA, 
respectively (93).  
  Recognition of ligands by TLR occurs through their extracellular leucine rich 
repeat  (LRR)  elements  and  causes  a  conformational  change  to  occur,  thereby 
bringing their intracellular Toll/IL1 receptor (TIR) domains together.  For most TLR, 
the MyD88 adaptor molecule is recruited to the TIR domain, which in turn recruits 
IL1 receptor associated kinase (IRAK)4 (93).  IRAK4 causes phosphorylation of 
IRAK1,  which  then  binds  TNF  receptor  activated  factor  (TRAF)6.  The  IRAK1-
TRAF6  complex  then  dissociates  from  MyD88  and  activates  TGF!-activated 
kinase (TAK)1 and TAK1 binding protein (TAB)2. This leads to the phosphorylation 
of the inhibitory #B (IKK) complex which in turn phosphorylates I#B, causing the 
release of NF-#B from inhibition and the activation of IFN regulatory factors (IRF).  
NF-#B  then  translocates  to  the  nucleus  and  allows  the  transcription  of  pro-
inflammatory cytokines, chemokines and costimulatory molecules. TLR3 ligation 
does not employ the MyD88 pathway, but results in the recruitment of TIR-domain 
containing adaptor protein inducing IFN" (TRIF) that acts to induce the expression 
of  the  transcription  factor  IRF3,  leading  to  the  production  of  type  I  IFN.  TLR4 
signalling can signal via MyD88 or TRIF dependent routes, causing activation of 
the TRIF-related adaptor molecule (TRAM), which in turn leads to activation of 
IRF3 and NF-#B. Together these pathways allow TLR ligation to generate robust 
pro-inflammatory responses.   
  Uncontrolled, prolonged or excessive m! activation can be deleterious to 
the host due to the potential for m! to cause pathology and therefore multiple 
mechanisms  exist  to  ensure  m!  activity  is  regulated.  First,  there  are  in-built 
negative  feedback  loops  that  terminate  TLR  signalling.  For  example  LPS 
stimulation is known to cause the induction of MyD88s, a splice variant of the 
MyD88 protein that lacks the necessary domain to interact with IRAK4, thereby 
inhibiting  positive  TLR  signalling  (94).  Similarly,  IRAK-M  is  a  TLR-inducible 
molecule that inhibits the dissociation of IRAK1-IRAK4 complexes from MyD88, 
thereby preventing further signalling (95), while TOLLIP prevents phosphorylation 
of  IRAK  (96).  A20  is a   molecule  that  terminates  TLR  signalling  through  the 
removal  of  ubiquitin  from  TRAF6,  thereby  interfering  with  the  TLR  signalling 
pathway  (97).  That  A20  KO  mice  develop  IBD,  as  well  as  spontaneous 
inflammation  in  other  tissues,  demonstrates  that  regulation  of  TLR  by  this   36 
molecule  is  vital  (98).  Similarly,  the  single  immunoglobulin  IL1-receptor  related 
molecule (SIGIRR; also known as Tir8) is a decoy for TRAF6 and IRAK1, and 
SIGIRR-deficient mice are more susceptible to intestinal inflammation (99). More 
recently it has been shown that mircoRNAs (miRNAs) can regulate TLR function. 
miRNAs are small non-coding RNAs that complex with the RNA-induced silencing 
complex,  which  causes  posttranscriptional  pro-inflammatory  gene  repression 
(100). The best documented of these is miR-146, which is induced in m! by LPS 
(101)  and  targets  IRAK1,  IRAK2  and  TRAF6  mRNA  downstream o f  M y D 8 8 ,  
thereby  preventing  activation  and  nuclear  translocation  of  NF-kB  (101).  The 
importance of miR-146 regulation of TLR stimulation is evidenced by heightened 
m! responses to LPS and the development of a fatal spontaneous autoimmune 
disorder in miR-146 KO mice (102). 
  In  addition  to  regulation  of  TLR,  m!  express  a  multitude  of  inhibitory 
receptors that control their activation. Many of these inhibitory receptors are paired 
with structurally related receptors involved in activation, such as those belonging 
to  the  immunoglobulin  domain  superfamily  and  the  C-type  lectin  family  (103). 
Within the immunoglobulin superfamily, these include signal regulatory proteins 
(SIRP), triggering receptors expressed by myeloid cells (TREM) and the CD200 
receptor  (CD200R)  family.  SIRP!  is  an  inhibitory  receptor  expressed  by  most 
myeloid cells that interacts with the ubiquitously expressed molecule CD47 (104). 
This  interaction  allows  SIRP!  to  associate  with  the  phosphatases  SHP-1  and 
SHP-2  to  downregulate  pro-inflammatory  features  of  myeloid  cells.  In  contrast, 
SIRP"  is  associated  with  activation  through  its  interaction  with  the  adaptor 
molecule  DAP-12,  whereas  very  little  is  known  about  the  third  member  of  the 
family,  SIRP$ (104).  Similarly,  whereas  TREM-1  is  a  potent  amplifier  of  pro-
inflammatory responses in monocytes, m! and some granulocytes (105), TREM-2 
has been shown to attenuate m! activation induced by TLR ligation and thus m! 
from  TREM2  KO  mice  showed  enhanced  pro-inflammatory  cytokine  release  in 
response to TLR stimulation (106). 
  The  CD200R  family  is  more  complex.  There  are  currently  five  known 
members of the CD200R family (CD200R1-5 or CD200RLa-e), one of which has a 
well defined inhibitory role, namely CD200R1 (107). CD200R1 is expressed by 
m!, DC, mast cells, as well as some peripheral TH2 cells (108). There is currently 
only one identified ligand for the CD200R family, CD200 (formerly known as OX2),   37 
which is expressed by a variety of non-haematopoietic cells including neurons of 
the  central  nervous  system  (CNS),  keratinocytes,  placental  trophoblasts  and 
endothelial cells, as well as B cells, activated T cells, follicular DC and thymocytes 
(Fig1.4) (109). Importantly, this pattern of expression is largely conserved between 
rodents  and  humans.  The  other  CD200Rs  have  activating  functions  and  it  is 
controversial whether they bind CD200, or if they have distinct ligands (110, 111).   
 
Figure 1.4: Expression Pattern of CD200R1 and its ligand CD200 
 
  Although  originally  thought  to  be  a  costimulatory  molecule  due  to  its 
structural homology with CD80 and CD86 (112), it is now believed that the primary 
role of CD200 is in the regulation of myeloid cell activity through CD200R1 (113, 
114). The CD200-CD200R1 interaction delivers a unidirectional, negative signal to 
the CD200R1-bearing cell, whereas CD200 has a small cytoplasmic domain and 
so  delivers  no  signal  into  the  CD200
+  cell  (115).  CD200-deficient  mice  have 
expanded  populations  of  splenic  and  MLN  m!,  as  well  as  increased  microglial 
activation under steady state conditions (113). Excessive m! activation in CD200-
deficient mice is associated with accelerated disease in experimental autoimmune 
encephalomyelitis (EAE) and increased susceptibility to collagen-induced arthritis 
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(CIA).  CD200  KO  mice  show  more  intense  infiltration  of  the  retina  by  NO-
producing  m!  during  experimental  autoimmune  uveoretinitis  (EAU)  (113,  116, 
117). CD200-deficiency also renders mice resistant to UV-mediated induction of 
tolerance  in  the  skin  and  lack  of  CD200  expression  by  keratinocytes  leads  to 
autoimmune destruction of hair follicles (118). More recently, CD200R1-mediated 
regulation of m! has been reported in the lung, where alveolar m! from CD200 KO 
mice showed uncontrolled activation characterised by excessive pro-inflammatory 
cytokine production. During experimental influenza infection this leads to extensive 
tissue  pathology,  although  mice  also  show  higher  protection  against  the  virus 
(119). Control of m! activity in CD200 KO models can be restored using agonistic 
anti-CD200R1  antibodies  or  CD200-Fc  fusion  proteins,  directly  confirming  the 
importance of the CD200-CD200R1 axis in controlling m! behaviour (119, 120).  
  The cellular and molecular basis of the effects of the CD200-CD200R1 axis 
remain to be defined precisely. However, unlike most myeloid inhibitory receptors, 
CD200R1  does  not  possess  an  immunoreceptor  tyrosine-based  inhibitory  motif 
(ITIM) that could bind inhibitory enzymes directly (103). In mast cells it has been 
shown  that  after  binding  CD200,  CD200R1  is  phosphorylated  and  recruits  the 
adapter  molecules  Dok-1  and  Dok-2  (121).  This  in  turn  recruits  the  inhibitory 
molecules  SH2  domain  containing  inositol  phosphatase  (SHIP)  and  RasGAP, 
resulting  in  the  inhibition  of  transcription  factors  of  the  Ras/MAPK  pathway 
including  ERK,  JNK  and  P38  MAPK,  and  downregulation  of  pro-inflammatory 
signalling  cascades  (121).  The  role  of  Dok  proteins  in  the  inhibitory  effects  of 
CD200R1 is supported by the fact that Dok protein deficiency results in enhanced 
TNF! and NO production after LPS challenge of peritoneal m! (122). Thus its 
appears  that  the  CD200R1-CD200  axis  represents  a  novel  regulatory  pathway 
independent of ITIMs.   
  CD200R1  has  also  been  shown  to  be  involved  in  the  induction  of 
indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DC (pDC) in a type I IFN-
dependent manner (123). Expression of IDO by DC can promote the induction of 
regulatory T cells, although this pathway has not been examined in CD200R1-
bearing m!. In addition, regulation by CD200R1 may be triggered by the uptake of 
apoptotic cells, as these cells have been shown to upregulate CD200 (124) and 
thus loss of CD200 could lead to m! hyperactivity.     39 
  These findings have been backed up by a limited number of reports using 
CD200R1-deficient mice, in whom allograft rejection may be more rapid (125). In 
addition, splenocytes from these mice have heightened baseline pro-inflammatory 
cytokine  production  and  respond  more  aggressively  to  LPS  stimulation  (125). 
CD200R1  KO  alveolar  m!  also  have  heightened  pro-inflammatory  cytokine 
release  upon  stimulation  with  IFN$  (119).  However  it  has  been  suggested  by 
others that CD200R1-mediated regulation of m! is limited to activation via pro-
inflammatory  cytokines  such  as  IFN$  and  IL17,  and  that  TLR  ligands  override 
CD200R1 signals, thereby allowing m! to respond during infection (126). 
  Because of its ability to restrict m! activation, CD200R1 has also become a 
target of pathogens trying to evade the immune system and many viruses such as 
herpesviruses and poxviruses express homologues of CD200. For example the 
human herpesvirus K14 protein binds the human CD200R1 with similar affinity to 
CD200, causing down regulation of pro-inflammatory cytokine release (127). 
  Thus  there  is  substantial  evidence  that  CD200R1-mediated  down-
modulation of m! may be an important means of regulating m! function in vivo.  
However, there are no studies evaluating the role of this regulatory axis in the 
control  of  intestinal  m!  behaviour,  although  one  poorly  documented  report  has 
suggested that MP of the intestine express CD200R1 (119). Therefore examining 
the role of CD200R1 in the control of colonic m! activity was one of the aims of 
this thesis. 
1.4 The Gastrointestinal Tract 
  The gastrointestinal (GI) tract encompasses the stomach, small intestine, 
caecum, large intestine/colon and rectum. The primary role of the GI tract is to 
process  foodstuffs  and  allow  the  efficient  reabsorption  of  nutrients  and  water, 
processes  which  occur  in  the  small  and  large  intestines  respectively.  These 
physiologic functions demand that the barrier between the host and the external 
environment be accessible to dietary products. However such requirements create 
vulnerability  to  attack  from  pathogenic  organisms,  and  considering  most 
pathogens enter the body via mucosal surfaces and the surface of the GI tract is 
the largest mucosal surface in the body, this threat is very great indeed (128). In 
addition to food products and potentially pathogenic organisms, the GI tract also   40 
houses a vast community of commensal bacteria, ten times more abundant than 
the number of cells in the human body (129). To deal with this massive antigenic 
load, the intestine is home to the largest compartment of the immune system in the 
body and it is the job of the intestinal immune system to discriminate between 
pathogenic microbes and harmless antigens and mount the appropriate immune 
response to each. As discussed below, breakdown in this discrimination results in 
the development of inflammatory bowel disease (IBD) and coeliac disease, where 
immune responses are targeted against innocuous antigens in commensals and 
food proteins respectively (128). 
1.4.1  Protective Immunity versus Tolerance in the Intestine 
  That most humans do not suffer from chronic inflammatory conditions of the 
GI tract indicates that many mechanisms are present to ensure a balance between 
the  physiological  functions  of  the  intestine,  symbiosis  with  the  microbiota  and 
defence against pathogens. The immune system at the mucosal surface involves 
multiple layers of innate and adaptive immune mechanisms, as well as physical, 
biochemical and mechanical mechanisms that all maintain intestinal homeostasis. 
First,  the  anatomical  make-up  of  the  intestinal  mucosa  aids  host  protection. 
Despite being only one cell thick, the epithelial layer that exists along the entire 
length  of  the  GI  tract  provides  a  robust  physical  barrier  and  disruption  of  its 
integrity is associated with the development of IBD in mice and humans (130). 
However  the  epithelium  is  more  than  an  inert  barrier  and  is  able  to  initiate 
inflammatory responses by virtue of the expression of PRR such as TLR and NLR 
by enterocytes (131, 132). Most of the epithelial surface is also coated in a thick, 
viscous mucus layer that is maintained through mucin production by goblet cells, 
which  are  interspersed  throughout  the  intestinal  epithelium.  Goblet  cells  also 
produce  trefoil  peptides  which  contribute  to  both  barrier  function  and  mucosal 
repair (133). The mucus layer, together with anti-microbial peptides such as !-
defensins, cathelicidins and cryptidins from Paneth cells in the base of the crypts 
of Lieberkuhn collectively form the glycocalyx which traps and aids expulsion of 
invading microorganisms, a process aided by peristaltic movement. In addition, 
Paneth cells secrete degradative enzymes such as lysozyme and phospholipase 
A2 that can break down the structure of microorganisms (134). Consistent with the 
increasing bacterial burden, the quantity of mucus increases along the GI tract. 
Given that the production of mucins such as MUC2 is altered in human IBD (135)   41 
and  MUC2  KO  mice  lack  goblet  cells  and  develop  spontaneous  colitis  (136), 
mucus appears to be much more than a lubricant and essential for host protection.  
  Despite  the  presence  of  these  physical,  biochemical  and  mechanical 
barriers, some antigens will breach the epithelium and be exposed to cells of the 
immune system. The nature of the antigen determines the outcome of the immune 
response mounted. The intestine has a range of innate leucocytes present under 
steady  state  conditions,  including  mast  cells,  eosinophils,  NK  cells,  innate 
lymphoid cells (ILC) and the largest population of m! in the body. These various 
innate cells act as a first line of defence against pathogens, as well as producing 
immunoregulatory cytokines such as IL10, TGF! and IL22 that contribute to the 
maintenance  of  homeostasis  (137).  Initiation  of  specific  immune  responses 
requires the uptake of antigen by DC, which are located in organised lymphoid 
tissues such as Peyer's patches and isolated lymphoid follicles (ILF), as well as 
throughout  the  villous  lamina  propria  (LP).  These  DC  monitor  the  mucosa, 
capturing and constitutively transporting antigen to the draining mesenteric lymph 
nodes (MLN), where they present it to recirculating T cells. Recognition of cognate 
antigen on mucosal DC by T cells results in their expansion and differentiation and 
the acquisition of the gut homing molecules !4"7 integrin and CCR9, which allow 
these  T  cells  to  return  to  the  small  intestine  (138).  Presentation  of  innocuous 
antigen  such  as  dietary  components  or  commensal  bacteria  does  not  result  in 
protective immunity, but rather in the induction of a state of local and systemic 
immunological unresponsiveness known as oral tolerance. The exact mechanisms 
that  underpin  the  maintenance  of  oral  tolerance  remain  to  be  established  with 
certainty,  but  clonal  deletion  or  anergy  of  reactive  T  cells  may  be  involved.  In 
addition,  FoxP3
+  Tregs  are  induced,  which  migrate  back  to  gut  mucosa  and 
prevent  antigen-specific  responses  through  cell-cell  interactions  and 
immunoregulatory  cytokine  production  (139).  Some  of  these  Tregs  can  also 
regulate  systemic  immune  responses,  by  mechanisms  that  are  unclear.  The 
intestinal immune system is also capable of generating potent effector responses 
when  required  and  indeed  the  mucosa  contains  the  majority  of  the  body's 
lymphocytes, including CD4
+, CD8
+, $% T cells and IgA-producing plasma cells. 
Most of the T lymphocytes have an effector/memory phenotype and they are found 
in  both  the  epithelial  layer  and  the  LP  (128).  The  majority  of  intraepithelial 
lymphocytes (IEL) are CD8
+ T cells, but $% T cells are also present. Although the 
exact role of IEL is unclear, they have been shown to be directly cytotoxic (140)   42 
and play a protective role in T. gondii infection (141). However, IEL have also been 
shown to produce cytokines such as keratinocyte growth factor (KGF) (142) which 
may allow them to contribute to maintaining epithelial barrier integrity. In the LP, 
the majority of T cells are CD4
+, however there is also a sizable CD8
+ population. 
These  LP  lymphocytes  produce  high  levels  of  a  variety  of  cytokines,  including 
IFN$, IL17 and IL10 (143). Plasma cells secrete IgA which is transported from the 
mucosa to the luminal surface via the actions of the polymeric immunoglobulin 
receptor.  IgA  specific  for  bacteria  associates  with  the  glycocalyx  and  acts  to 
sequester  bacteria,  limiting  their  contact  with  the  epithelium  in  an  attempt  to 
prevent bacterial penetration (144). Given the presence of such a vast range of 
leucocytes under normal conditions, the intestine has been described as existing 
in a state of physiological inflammation (145), emphasising the delicate balance it 
needs to maintain to prevent tissue damage. 
1.4.2  The Commensal Microbiota 
  Virtually all the functions of the intestinal immune system are dependent on 
the presence of the local commensal microbiota. The intestine of most mammals 
is colonised by trillions of bacteria consisting of over 1000 species (144). These 
bacteria are essential for life, as they provide vitamins and certain amino acids not 
produced  by  mammals,  as  well  as  fermenting  otherwise  non-digestible 
components of the diet. The fermentation of dietary fibre by the microflora releases 
short chain fatty acids which are essential for epithelial cell renewal, as well as 
having anti-inflammatory properties (146). The commensal bacteria also play a 
role in innate defence by occupying environmental niches that could otherwise be 
colonised  by  pathogens.  Certain  commensals,  such  as  Bacteriodes 
thetaiotaomicron, stimulate anti-microbial peptide production by Paneth cells (132) 
and there is recent evidence suggesting that the ability of the immune system to 
produce effector cytokines such as IL17 is driven by specific components of the 
microbiota, including segmented filamentous bacteria (SFB) (147). It is no surprise 
therefore that broad-spectrum antibiotic treatment leads to increased susceptibility 
to  enteric  infection  due  to  the  ablation  of  commensal  microorganisms.  The 
intestinal microbiota also plays a fundamental role in influencing the development 
of the intestinal immune system, and germ free mice have poorly developed gut 
epithelium, lymphoid structures and virtually no intestinal leucocytes (144, 148). 
Mice that lack the cellular machinery to recognise bacteria and their derivatives,   43 
such as MyD88 KO mice, have disrupted epithelial barrier function, resulting in 
enhanced susceptibility to chemically induced colitis (149). However the current 
understanding of the composition of the commensal microbiota is poor, primarily 
due to the fact that over 90% of commensals are unculturable using conventional 
techniques. 
  Under normal conditions, the microbiota exists in symbiosis with the host 
and commensal bacteria that penetrate the epithelial layer are rapidly engulfed 
and eliminated by m! that are associated with the epithelium, and as discussed 
below,  this  happens  without  provoking  inflammation.  T  cell  responses  are 
generated to commensal bacteria, but these are dominated by IL10- and TGF!-
secreting Tregs. The involvement of Tregs in maintaining tolerance to commensal 
bacteria  is  supported  by  work  with  animal  models  of  IBD,  for  example  the 
development of colitis by transfer of colitogenic T cells which can be ameliorated 
by the co-transfer of Tregs (150). Similarly, IgA from plasma cells acts to prevent 
adhesion  to  and  penetration  of  the  epithelium  by  commensal  bacteria.  It  is 
important to note however, unlike food antigens, tolerance to commensal bacteria 
appears to be local, with the immune system outside of the gut oblivious of their 
presence.  
1.4.3  Inflammatory Bowel Disease   
  Crohn's disease and ulcerative colitis are chronic, relapsing and remitting 
inflammatory disorders that are increasingly common in developed countries, with 
prevalence rates of IBD reaching up to 396/100,000 inhabitants (151). Although 
many parallels can be drawn between Crohn's disease and ulcerative colitis, there 
are major differences in their clinical manifestations, immunological features and 
genetic basis. Crohn's disease can affect any area of the GI tract, although the 
terminal ileum is the most common site of pathology. The inflammation can be 
transmural and is non-continuous, characterised by the presence of granulomas 
with aggregates of activated m! (130). Crohn's disease is also associated with a 
TH1 or TH17 skewed immune response, with high levels of the pro-inflammatory 
cytokines  TNF!,  IFN$ a n d  I L 1 7   (130,  152).  In  contrast,  UC  is  associated  with 
superficial and continuous inflammation that is restricted to the colon (130). Its 
pathology  is  characterised  by  a  large  infiltrate  of  neutrophils  that  cause  micro-  44 
abscesses in intestinal crypts and is usually considered to be a TH2 skewed or 
antibody-mediated disease, associated with IL5, IL13 and TGF! (153). 
  Although the aetiology of IBD is still unclear, work from animal models of 
IBD,  along  with  human  studies,  has  demonstrated  that  IBD  involves  multiple 
environmental factors in genetically predisposed individuals (130). Although there 
is strong heritability, there is limited concordance between monozygotic twins and 
the  incidence  of  IBD  is  increasing  rapidly  in  countries  adopting  a  'Western' 
lifestyle, suggesting that factors such as diet, stress and hygiene could be involved 
(153).  The  so-called  'hygiene  hypothesis'  suggests  that  children  raised  in  an 
extremely  hygienic  environment  are  more  susceptible  to  IBD,  autoimmune 
disorders  and  allergy,  as  exposure  to  environmental  antigens  and  diverse 
microbial material appears essential for full development of the immune system 
(151). This hypothesis also proposes that the lack of helminths in the GI tract of 
the western man also contributes to the susceptibility to intestinal inflammation, as 
helminths are thought to help prevent excessive inflammatory responses (151). 
Indeed the incidence of IBD is significantly lower in developing countries where 
helminth  infection  is  commonplace.  Furthermore  recent  clinical  studies  have 
documented  that  treatment  of  IBD  patients  with  helminths  or  their  derivatives 
improves their clinical outcome (154).  
  However there is growing consensus that IBD is a result of inappropriate 
immune responses directed against the commensal microbiota. This is supported 
by the fact that most animal models of IBD are dependent on the presence of 
commensal microorganisms and so do not develop in mice reared in germ-free 
conditions and appear rapidly upon colonisation with normal commensal bacteria 
(155). Colitis can also be induced by the transfer of commensals present in the 
intestine of colitic mice (156) and antibiotic treatment is therapeutically beneficial in 
some  IBD  patients,  while  probiotic  treatment  has  been  shown  to  ameliorate 
intestinal  inflammation  (157).  Why  the  immune  system  reacts  against  host 
commensals in this way is still unclear and there remains a school of thought that 
considers there maybe a role for specific 'colitogenic' bacteria. It is well recognised 
that  the  composition  of  the  enteric  flora  changes  in  patients  with  IBD,  with  an 
unusual prevalence of entero-adherent E. coli and reduction in the numbers of 
Firmicutes and Bacteriodetes species, which dominate the bacterial landscape in 
healthy  individuals  (158).  Also  it  has  long  been  suggested  that  atypical   45 
Mycobacteria, such as Mycobacterium paratuberculosis might be involved (159). 
However no single species has ever been confirmed and 16S rRNA sequencing 
has  shown  that  dysbiosis  only  occurs  in  a  subset  of  IBD  patients  (158). 
Furthermore, it is usually very difficult to determine whether the changes seen in 
bacterial populations are primary effects, or are simply secondary to the presence 
of inflammation. 
  IBD is a polygenic disorder and in recent years the use of genome wide 
association  studies  (GWAS)  has  allowed  at  least  30  risk-conferring  loci  to  be 
identified, some of which are common to Crohn's disease and ulcerative colitis, but 
most  of  which  are  related  to  Crohn's  disease.  An  important  outcome  of  these 
studies is that they have confirmed the involvement of the immune system in IBD 
with  linkage  to  genes  such  as  IL10,  IL23  and  STAT3,  all  of  which  had  been 
suggested  as  candidate  genes  in  experimental  animals.  The  most  frequent 
association  with  Crohn's  disease  are  polymorphisms  in  receptors  involved  in 
bacterial recognition, the most important being NOD2. 30% of patients with small 
intestinal  Crohn's  disease  have  a  non-functional  polymorphism  in  NOD2  (160). 
Why polymorphisms in NOD2 contribute to intestinal inflammation is unclear and 
this  is  made  more  complex  by  the  fact  that  NOD2  KO  mice  do  not  develop 
spontaneous colitis (161). However, patients with Crohn's disease and NOD2 KO 
mice appear to produce less anti-microbial peptides such as !-defensins (162), 
supporting  the  idea  that  dysregulation  of  the  usual  immune  response  to 
commensal flora is central to the pathogenesis of IBD. Further candidate genes 
identified by GWAS include ATG16L1 and IRGM, which are involved in autophagy 
and strongly imply that defects in the innate immune system underlie susceptibility 
to IBD. Mice with KO of ATG16L1 in myeloid cells show increased susceptibility to 
DSS-induced colitis and m! from these mice show enhanced LPS responsiveness 
(160). Similarly m! from IRGM KO mice display reduced bacterial killing and as a 
result, these mice are more susceptible to a range of bacterial infections (163, 
164).  
  Much  of  this  work  emphasises  the  involvement  of  innate  immunity  in 
susceptibility  to  Crohn's  disease.  M!  are  known  to  be  major  components  of 
inflammation and their products have shown to be successful targets for treatment, 
such  as  TNF! a n d  I L 6  (165,  166).  Thus  there  is  considerable  interest  in  m! 
present in the intestine during homeostasis and disease.   46 
1.5 Intestinal Macrophages 
  Despite forming one of the largest reservoirs of m! in the body (167), the 
immunobiology  of  intestinal  m!  remains  poorly  understood,  partly  due  to  the 
difficulty in isolating these cells. M! are most abundant in the lamina propria, in 
close  association  with  the  epithelial  layer,  however  they  can  also  be  found  in 
deeper layers of the gut such as the submucosa and the muscularis mucosae 
(168). The presence of m! appears to be partly dependent on the presence of 
commensal bacteria, since germ-free mice have reduced numbers of intestinal m! 
(169).  In  addition,  the  number  of  m!  increases  progressively  from  the  almost 
sterile jejunum, to the colon where the commensal burden is the greatest (167). 
  Most  of  the  current  understanding  of  the  phenotype  and  function  of 
intestinal m! is derived from work on human biopsy tissue. These studies have 
shown that human small intestinal m! express CD13 and high levels of class II 
MHC (170, 171), while those from colon were found to have uniform expression of 
CD33, but low levels of CD11b and class II MHC (172). Both human small bowel 
and  colonic  m!  lack  the  expression  of  CD14,  the  LPS  co-receptor,  and  CD16 
(Fc$RIII), markers that are expressed by blood monocytes (12). Less has been 
published on mouse intestinal m! and as discussed below, the characterisation of 
these cells is now known to be more complex than originally believed, as their 
distinction from other myeloid cells requires careful attention. Nevertheless by the 
time  I  started  my  project,  several  consistent  features  of  these  cells  had b e e n  
established  using  conventional  markers.  Although  there  are  subtle  differences 
between mouse and man, and between the small and large intestines, there was 
consensus that intestinal m! are highly adapted to their antigen- and microbe-rich 
environment. 
  Human and mouse intestinal m! have been shown to be highly phagocytic, 
possess secondary lysosomes and are able to capture and kill bacteria without 
prior 'activation' (170, 171, 173). However, unlike m! found in other tissues and 
blood  monocytes,  intestinal  m!  do  not  produce  pro-inflammatory  cytokines 
following phagocytosis of particles or after stimulation with a range of bacterial 
products including LPS, Helicobacter pylori urease and heat-killed Staphylococcus 
aureus  (171).  This  unresponsiveness  of  intestinal  m!  extends  to  other  stimuli 
including the NOD2 ligand MDP, pro-inflammatory cytokines and even PMA (171,   47 
174).  In  addition,  human  intestinal  m!  show  no  respiratory  burst  activity  after 
stimulation  with  PMA  or  opsonised  zymosan  (175)  and  lack  iNOS  expression 
(176). Rather than producing pro-inflammatory cytokines, intestinal m! have been 
shown  to  produce  immunomodulatory  cytokines  such  as  IL10  and  TGF! b o t h  
constitutively and in response to stimulation with whole bacteria antigens (177-
179). Furthermore, despite expressing high levels of class II MHC, human small 
intestinal m! express only low levels of costimulatory molecules, again suggesting 
these cells are not classically 'activated' despite their appearance (170, 171). For 
these reasons, it is believed that one of the crucial roles of resident intestinal m! is 
to remove cellular debris and act as a non-inflammatory waste disposal unit for 
commensal bacteria that have breached the epithelial layer.  
  Resident intestinal m! perform other crucial homeostatic functions, such as 
contributing  to  the  maintenance  of  the  epithelial  barrier  integrity  by  COX2-
dependent  production  of  prostaglandin  (PG)E2,  which  induces  proliferation  of 
epithelial progenitors in the pericryptal niche (180, 181). Depletion of m! in MaFIA 
mice, in which the CSF-1R promoter drives expression of Fas in m!, results in 
increased epithelial cell injury and enhanced susceptibility to DSS colitis (182). 
Very recently, intestinal m! have been implicated in the maintenance of antigen-
specific  peripheral  tolerance  through  their  local  interactions  with  Treg.  Murine 
small intestinal m! have been shown to cause Treg differentiation in vitro in the 
presence of exogenous TGF" (178) and in vivo studies now show that intestinal 
m! contribute to the terminal differentiation and maintenance of regulatory T cells 
in the LP (139, 183). These effects are dependent on IL10 production by the m! 
and are absent in CX3CR1 KO mice, in whom oral tolerance to protein antigens 
does not develop (139). F4/80 KO mice also fail to develop oral tolerance due to a 
defect in CD8
+ regulatory T cell function (184). Thus intestinal m! possess several 
functional adaptations that allow capture of any bacteria breaching the epithelial 
monolayer without provoking overt inflammation, but also promote the generation 
and  expansion  of  Treg  that  control  specific  immune  responses  against  such 
antigens. 
  As noted above, the exact phenotypic characteristics of resident intestinal 
m! in mice have become controversial. Although it has been clear for many years 
that these cells express F4/80 and are highly phagocytic (185, 186), they also 
express high levels of CD11b and class II MHC (186, 187), which are features of   48 
many classical DC. Most work in the gut had classified DC and m! on the basis of 
CD11c expression and had not combined this with other markers such as F4/80 
and CD103. Around the time I began my project, it was becoming increasingly 
clear that some, if not all, tissue m! express CD11c to some degree (188). In 
addition, several studies had used CD11b alone to identify intestinal m! (177), and 
as I will show, this is a marker expressed by a number of myeloid cells in the 
mucosa.  Work  at  this  time  in  the  Pabst  and  Agace  labs  proposed  a  new 
nomenclature for the discrimination of individual intestinal MP populations, based 
on the mutually exclusive expression of CD103 (!e integrin) and CX3CR1, the 
chemokine receptor for CX3CL1 (also known as fractalkine or neurotactin) (189). 
Both CD103
+ and CX3CR1
+ MP express class II MHC and can express CD11c, 
but  they  possess  phenotypic,  functional  and  developmental  differences. 
CD103
+CD11c
+MHCII
+  MP  migrate  in  intestinal  afferent  lymph  in  a  CCR7 
dependent  manner  to  the  draining  LN,  where  they  interact  with  and  cause 
differentiation of naïve T cells (138, 189). These are the only cells that can present 
intestinally-derived  antigen  and  are  the  endowed  with  the  ability  to  induce  gut 
homing receptors such as CCR9 and !4"7 on T cells, which allows them to transit 
back to the intestinal mucosa (138, 190). This requires the conversion of dietary 
vitamin A into retinoic acid (RA) by the CD103
+ MP and this also allows them to 
induce  the  differentiation  of  naïve  T  cells  into  antigen-specific  FoxP3
+  Treg,  a 
process that is also dependent on TGF! (191, 192). In terms of phenotype and 
function, CD103
+ MP appear to be a specialised population of bona fide DC.  
  CX3CR1
+  MP  first  aroused  attention  when  they  were  found  to  extend 
transepithelial  dendrites  (TED)  into  the  intestinal  lumen  to  sense  and  perhaps 
sample intestinal contents (193, 194). This property, together with the expression 
of CD11c
 and class II MHC, resulted in these being classified as DC. However, 
using a combination of approaches including intra-vital microscopy, Schulz et al. 
(189)  demonstrated  that  the  intestinal  afferent  lymph  was  essentially  devoid  of 
CX3CR1
+ MP, suggesting that CX3CR1
+ MP are non-migratory, tissue resident 
cells. Consistently, the vast majority of CX3CR1
+ MP express high levels of m! 
markers such as F4/80, CD11b and CD115 (189, 195), as well as CD68 (169). 
That CD103
+ and CX3CR1
+ LP MP are distinct populations is supported by their 
distinct  developmental  origins.  Whilst  CD103
+  MP  are  derived  from  the  DC-
committed pre-cDC that requires flt3L and/or CSF-2 for development (189, 195), 
CX3CR1
+  cells  are  dependent  on  CSF-1  and  CSF-2  and  are  replenished  by   49 
monocytes  (28,  189,  195,  196).  Further  evidence  for  the  CX3CR1
+ p o p u l a t i o n  
belonging to the m! lineage is that they are significantly reduced in CSF1R KO 
mice (195) and that administration of an anti-CD115 antibody resulted in depletion 
of intestinal m! (197). 
  These emerging studies indicated that many of the previous reports on 'DC' 
and 'm!' in the mucosa needed to be reinterpreted using appropriate combinations 
of markers to allow precise assessment of function. This was particularly important 
for m!, as these had often been misclassified as DC and had not been examined 
for m! behaviour directly. Also it was unclear whether the CX3CR1
+ fraction was a 
uniform population, or if it contained multiple cell types. 
1.5.1  CX3CL1 and Its Receptor 
  CX3CR1  is  a  receptor  that  recognises  the  chemokine  CX3CL1.  
Chemokines are small chemotactic cytokines that act through G-protein coupled 
seven  transmembrane  receptors  and  are  best  known  for  their  ability  to  cause 
directed  migration  of  leucocytes  and  other  cells.  They  are  grouped  into  four 
families  (CXC,  CC,  XC,  CX3C)  based  on  their  structure,  in  particular  the 
positioning of a conserved tetra-cysteine motif (198). Chemokines are produced by 
a variety of cells including leucocytes, epithelial, endothelial and stromal cells, and 
the  vast  majority  are  secreted  as  soluble  proteins,  although  they  are  often 
immobilised on extracellular matrix proteoglycans to form chemotactic gradients 
(198).   
  One exception to this is CX3CL1, which is produced as a transmembrane 
molecule,  with  the  chemokine  domain  anchored  to  the  membrane  through  a 
mucin-like stalk (199). However following proteolytic cleavage by disintegrin-like 
metalloproteinase (ADAM)-10 or 17, CX3CL1 can also exist in soluble form (200, 
201). In the intestine, CX3CL1 has been shown to be produced by epithelial cells 
(202) and more recently by goblet cells (203). However, vascular endothelial cells, 
smooth muscle and neurons, as well as DC and m! have been shown to produce 
CX3CL1 elsewhere (204-208). To date, CX3CR1 is the only identified receptor for 
CX3CL1 and it is expressed by multiple cell types. As noted above, CX3CR1 is 
expressed by early progenitors of the MPS and the level of CX3CR1 expression 
has  been  used  in  conjunction  with  Ly6C  to  define  'inflammatory'  and  'resident'   50 
monocytes (12). In addition to intestinal m!, m! in the CNS (microglia) and skin 
(Langerhan's  cells)  express  CX3CR1  at  high  levels  (55,  60).  In  contrast, 
peritoneal,  splenic  and  liver-resident  Kupffer  cells  do  not  express  CX3CR1, 
suggesting that its expression may be tissue-specific. Some T cells, NK cells and 
plasmacytoid DC can also express CX3CR1, albeit at lower levels than monocytes 
and m! (209-211).    
  The  exact  role  of  CX3CR1  in  the  MPS  remains  to  be  established  with 
certainty  and  the  relative  roles  of  its  membrane  bound  and  soluble  forms  are 
unclear.  Membrane  tethered  CX3CL1  has  been  shown  to  mediate  integrin-
independent  cell  adhesion  through  interactions  with  CX3CR1  (212) a n d  
interestingly, CX3CR1 has been suggested to be necessary for TED formation in 
the  gut,  although  this  is  controversial  (193,  203,  213).  Recently  it  has  been 
proposed that the CX3CR1-CX3CL1 axis may also be involved in cell survival. In 
particular,  CX3CR1  appears  to  play  a  role  in  the  survival  of  Ly6C
lowCX3CR1
+ 
monocytes, as these cells are reduced in CX3CR1-deficient (CX3CR1
gfp/gfp) mice 
(214). That this is due to reduced survival is supported by the fact that introduction 
of the apoptosis inhibitor Bcl2 rescued the phenotype (214). Similarly, exogenous 
CX3CL1 prevents Fas-induced cell death of in vitro cultured microglia (215) and 
CX3CL1 has been shown to promote survival of human intestinal epithelial cells in 
vitro (216). CX3CL1 has also been shown to modulate the function of mature m!, 
although there is conflicting evidence on whether these effects are anti- or pro-
inflammatory.  For  example,  CX3CL1  has  been  shown  to  attenuate  pro-
inflammatory m! responses in vitro (217), but disruption of the CX3CR1-CX3CL1 
axis  in  CX3CR1
gfp/gfp  mice  may  protect  mice  from  the  development  of 
atherosclerosis and experimental colitis (169, 218, 219).  
1.5.2  Mechanisms Governing Macrophage Unresponsiveness 
  How intestinal m! can exist in a state of 'inflammatory anergy' when in such 
close proximity to vast quantities of immunostimulatory material is unclear. Several 
mechanisms  have  been  proposed,  with  no  clear  answer  being  offered.  Human 
resident small intestinal m! lack receptors involved in m! activation, including the 
LPS co-receptor CD14 (170), TREM-1 (220), complement receptors (CR) 3 and 4, 
as well as the Fc receptors for IgA and IgG (CD89 and CD64 respectively) (170). 
Although it was originally reported that they also failed to express TLR (221, 222),   51 
evidence is emerging that human intestinal m! may express a full range of TLR 
(179) and this needs to be explored more fully. However, it seems more likely that 
the  TLR  unresponsiveness  in  intestinal  m!  may  reflect  one  or  more  of  the 
mechanisms  that  have  been  shown  to  inhibit  the  TLR  signalling  cascade,  as 
described above. Indeed intestinal m! have markedly downregulated expression 
of  MyD88,  TRAF6,  TRIF,  IRAK1  and  IRAK4  adaptor  molecules  compared  with 
blood monocytes, resulting in a failure to phosphorylate and translocate NF-#Bp65 
to the nucleus (179).  
  The control of intestinal m! activity is likely to be a multi-factorial process 
involving  many  mechanisms,  one  of  which  is  conditioning  of  m!  by  local 
environmental factors. IL10 is an obvious candidate for this, as intestinal m! from 
IL10-deficient mice have heightened responsiveness to a range of TLR ligands, 
producing  pro-inflammatory  cytokines  such  as  TNF!,  IL12  and  IL23  which 
facilitate the generation of pathogenic TH1 and TH17 cells (177, 178, 223) (Platt, A. 
personal communication).  Furthermore, blockade of the IL10R has been shown to 
result in a loss of unresponsiveness by intestinal MP (224) and IL10R2 KO mice 
develop  spontaneous  colitis  (225).  In  addition,  IL10  KO  mice  or  mice  with  a 
myeloid  cell-specific  deletion  of  the  IL10R  signalling  molecule  STAT3,  also 
develop  colitis  (226,  227)  and  polymorphisms  in  the  IL10R  predispose  to  IBD 
development (228). IL10 is a well-known inhibitor of NF-#B activation in m! and 
this may involve induction of factors such as I#BNS and Bcl-3, which inhibit the 
binding  of  NF-#B  to  DNA  (223,  229,  230).  These  inhibitory  factors  have  been 
identified in gut resident m!, but it is not known whether m! themselves are the 
source of IL10. Aside from IL10, the LP is also a rich source TGF!, one of the 
most  potent  anti-inflammatory  cytokines  which  has  a  well  established  ability  to 
cause  downregulation  of  the  pro-inflammatory  actions  of  m!  (231).  TGF!  is 
produced by leucocytes such as Treg, as well as by epithelial and stromal cells 
(179), and has been shown to attract monocytes to the mucosa together with IL8 
(232).  Furthermore,  human  IBD  is  associated  with  upregulated  expression  of 
Smad7, leading to defective TGF!R signalling (233).  
  Other local soluble factors have been shown to have effects on mucosal 
'DC'  and  it  is  possible  that  they  may  also  have  the  potential  to  influence  m! 
behaviour. These include vasoactive intestinal peptide (VIP) (234), RA (235), and 
PGE2 (236), all of which are available in the resting mucosa. Also ligands for the   52 
nuclear receptor PPAR$ are abundant in the resting mucosa and these have been 
shown to control pro-inflammatory cytokine production by myeloid cells (237). As a 
result,  mice  with  a  m!-specific  deletion  of  PPAR$  show  heightened  pro-
inflammatory m! activity and increased susceptibility to DSS-induced colitis (238). 
Thus many overlapping mechanisms may exist to ensure gut m! are maintained in 
this TLR-hyporesponsive state. 
1.5.3  Intestinal Macrophages During Inflammation 
  It  is  well  established  that  during  inflammation,  the  composition  of  the 
intestinal m! compartment alters markedly. In humans, the CD14
neg resident m! 
pool becomes outnumbered by CD14
+ m! (239-242), which are believed to derive 
from blood monocytes (243). These CD14
+ m! express higher levels of TLR2 and 
TLR4, costimulatory molecules and inflammatory chemokine receptors CCR1 and 
CCR2  (221,  242).  Furthermore,  they  express  TREM-1  which  may  potentiate 
activation (220, 244). In addition, whereas resident intestinal m! have been shown 
to produce TGF! and IL10 (177, 179, 242), the inflammatory CD14
+ cells produce 
high levels of IL12, IL23, TNF!, and IL6 following stimulation with the commensal 
bacterium Enterococcuss faecalis (242) and show greater respiratory burst activity 
(175). As in humans, many models of colitis are associated with the accumulation 
of m! in the inflamed mouse intestine (245-250). Similar inflammatory m! are seen 
during intestinal infection with T. gondii (25). However, these cells were frequently 
interpreted as being 'inflammatory DC', because they expressed class II MHC and 
CD11c (250). Therefore the exact relationship between these pro-inflammatory m! 
and  those  found  in  the  healthy  mucosa  remain  unclear.  Gaining  a  better 
understanding  of  the  relationship  between  these  cells  is  an  important  practical 
issue,  as  it  could  provide  insight  into  possible  new  therapies  for  inflammatory 
diseases such as IBD. 
  Work  carried  out  in  our  lab  immediately  before  I  started  suggested  that 
resident and inflammatory m! in mice could be distinguished on the basis of TLR 
and CCR2 expression (222). These studies suggested that in the normal colon, 
most F4/80
+ m! lacked expression of TLR2, CCR2 and class II MHC and were 
also unresponsive to TLR stimulation. During DSS colitis, there was infiltration by 
TLR2
+CCR2
+MHCII
+/neg TNF!-producing, TLR responsive m!, a few of which were 
present in the steady state colon. These findings were interpreted in the light of the   53 
current paradigm of monocyte heterogeneity, and it was proposed that the resident 
and  inflammatory  m!  represented  unrelated  progeny  of  distinct  populations  of 
blood monocytes (222). However this was not shown directly and as I discussed 
above, it has never actually been shown that the so-called 'resident' population of 
Ly6C
lowCX3CR1
+ monocytes could migrate into the healthy intestine. Indeed the 
only  studies  of  monocyte  transfer  have  suggested  that  Ly6C
high  inflammatory 
monocytes can migrate to the resting gut (28, 196), although these studies used 
intense depletion regimes to provide empty niches in the host and the resulting 
progeny were interpreted as inflammatory DC. Thus at the point of starting my 
project, no work had used wide combinations of markers to compare the nature 
and origins of precisely defined resident and inflammatory m! and therefore this 
was one of the aims of my project. 
1.6 Thesis Aims 
  It  is  clear  that  intestinal  m!  can  play  essential  roles  in  both  tissue 
homeostasis and inflammation. However, to date, the definition of intestinal m! 
has been stifled by increasing confusion generated by the use of overlapping m! 
and  DC  markers  such  as  F4/80  and  CD11c.  As  a  result,  the  exact  nature  of 
intestinal m! in healthy mouse colon has remained unclear. In particular, it was not 
known how m! in the steady state and inflamed intestine might be related to each 
other and their origins had not been defined properly. 
  The  main  aims  of  this  thesis  therefore,  were  to  establish  protocols  that 
allowed  the  comprehensive  phenotypic  characterisation  of  colonic  m!  under 
steady  state  conditions  using  multi-parameter  flow  cytometry  and  recently 
described  markers  of  MP.  Having  established  the  composition  of  the  m! 
compartment during steady state conditions, I aimed to define the changes that 
occurred  during  inflammation  using  the  DSS-induced  model  of  acute  colitis.  If 
distinct  populations  were  identified  under  these  conditions,  I  intended  to 
characterise them functionally and examine their origin to address whether they 
represented independent populations, or if they were related to each other.  
  Chapter  3  of  this  thesis  introduces  the  phenotypic  heterogeneity  of  the 
colonic MP compartment under normal physiological conditions and describes how 
individual m! subsets can be distinguished on the basis of CX3CR1.  This chapter   54 
then  goes  on  to  detail  the  dramatic  changes  in  these  populations  during 
experimental colitis. Chapter 4 sets out to examine the origin of the different m! 
and  explores  the  relationship  between  these  subsets  under  steady  state 
conditions, using a combination of adoptive transfer experiments. Chapter 5 then 
examines the functional characteristics of the colonic m! subsets in resting and 
inflamed colon. The aim of Chapter 6 was to explore the role of recruited/elicited 
m! in the pathology of experimental colitis and finally, in Chapter 7, I investigated 
the potential mechanisms underlying the characteristic TLR unresponsiveness of 
resident  colonic  m!,  including  an  in  depth  study  of  the  role  of  the  CD200-
CD200R1 axis.   55 
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2  Chapter 2                                    
Materials and Methods   56 
2.1 Mice 
  All mice were maintained under specific pathogen free (SPF) conditions at 
the Central Research Facility (CRF) or Veterinary Research Facility (VRF) at the 
University of Glasgow and were used between 6 and 12 weeks of age, unless 
specified otherwise. Table 2.1 details the mouse strains used throughout these 
studies. Unless stated otherwise, all strains were on the C57/BL6 background and 
were bred in house. All procedures were carried out in accordance with UK Home 
Office regulations.   
Table 2.1: Details of Mouse Strains 
Strain  Source 
C57BL/6 (B6; CD45.2
+)  Harlan Olac (Bicester, Oxfordshire) 
C57BL/6.SJL (CD45.1
+; Ly5.1
+)  Kindly  provided  by  Prof.  William  Agace  (Lund  University, 
Sweden). 
C57BL/6 (CD45.1
+/CD45.2
+)  Generated by crossing C57BL/6 mice with C57BL/6.SJL  
CX3CR1
gfp/gfp  
(B6.129P-CX3CR1
tm1Litt/J) 
Kindly  provided  by  Prof. W i l l i a m  A g a c e  ( L u n d  U n i v e r s i t y ,  
Sweden) (209). 
CX3CR1
gfp/gfp mice do not exhibit any developmental defects. 
All GFP
+ cells in blood of CX3CR1
+/gfp mice are stained with 
a  CX3CL1-Fc  fusion  protein  and  all  CX3CL1-Fc
+ c e l l s  
express  GFP,  confirming  GFP  expression  accurately 
represents  CX3CR1  expression. C X 3 CL1-Fc  did  not  bind 
GFP
+ c e l l s  f r o m  C X 3 C R 1
gfp/gfp m i c e ,  confirming  that  these 
mice lack CX3CR1 and that there is no alternative receptor 
for CX3CL1. 
However  due  to  the  extended  half-life  of  eGFP  protein 
(>24hrs),  not  all  GFP
+ c e l l s  i n  C X 3 C R 1
+/gfp m i c e  w o u l d  
necessarily be expected to be CX3CR1
+. 
CX3CR1
+/gfp (CD45.2
+)  Generated by crossing CX3CR1
gfp/gfp with C57BL/6 mice. 
CX3CR1
+/gfp (CD45.1
+/CD45.2
+)  Generated by crossing CX3CR1
gfp/gfp with C57BL/6.SJL. 
CCR2 null  Kindly provided by Dr Robert Nibbs (University of Glasgow).  
Obtained originally from Jackson Laboratories (Maine, USA) 
CD200R1 null  Kindly  provided  by  Prof. T r a c y  H u s s e l l  ( I m p e r i a l  C o l l e g e ,  
London) (125). 
CD200R1  null  mice  do  not  exhibit  any  developmental 
defects. These mice lack exons 2, 3 and 4 of the CD200R1 
gene, which encode the extracellular domain of CD200R1. 
CD200 null  Kindly provided by Prof. Andrew Dick (University of Bristol) 
(113). 
CD11c-DTR-GFP  Kindly  provided  by  Prof. P a u l  G a r s i d e  ( U n i v e r s i t y  o f  
Glasgow) (251). 
Vert-X  
(C57BL/6 IL10eGFP) 
Kindly  provided  by  Dr  Kevin  Couper  (London  School  of 
Hygiene and Tropical Medicine) (252).   57 
 
2.2  Isolation of Peritoneal Macrophages 
  To  obtain  resting  peritoneal  m!,  CO2-euthanased  mice  were  injected 
intraperitoneally  (i.p.)  with  8-10ml  of  ice-cold  PBS  (Gibco,  Life  Technologies, 
Paisley,  Scotland)  containing  1mM  EDTA  (Sigma-Aldrich,  Poole,  UK)  and  the 
peritoneal cavity massaged. Peritoneal exudate cells (PEC) were then harvested 
by lavage. 
2.3  Isolation of Colonic Lamina Propria cells 
  To obtain leucocytes from the colonic LP, I used an established laboratory 
protocol.  The  large  intestines  of  mice  were  excised  and  soaked  in  PBS.  After 
removing  all  excess  fat  and  faeces,  the  intestines  were  opened  longitudinally, 
washed in Hank’s balanced salt solution (HBSS; Gibco) 2% FCS, and cut into 
0.5cm sections. The tissue was then shaken vigorously in 10 ml HBSS 2% FCS, 
and the supernatant was discarded. To remove the epithelial layer, 10 ml fresh 
calcium  and  magnesium-free  (CMF)  HBSS  containing  2mM  EDTA  was  then 
added, the tube placed in a shaking water bath (or shaking incubator) for 15mins 
at  37
oC,  before  being  shaken  vigorously  and  the  supernatant  discarded.  The 
intestinal tissue was washed by adding 10ml fresh CMF HBSS, shaking the tube 
vigorously  and  discarding  the  supernatant.  After  a  second  incubation  in  CMF 
HBSS/2mM EDTA, the wash step was repeated and the remaining tissue was 
digested with pre-warmed complete RPMI 1640 (RPMI 1640, 2mM L-glutamine, 
100µg/ml penicillin, 100µg/ml streptomycin, 1.25µg/ml Fungizone, and 10% foetal 
calf  serum  (FCS)  (all  Gibco)  containing  1.25mg/ml  collagenase  D  (Roche 
Diagnostics  GmbH,  Mannheim,  Germany),  0.85mg/ml  collagenase  V  (Sigma-
Aldrich), 1mg/ml dispase (Gibco), and 30U/ml DNase (Roche) for 30-45 minutes in 
a shaking water bath (or shaking incubator) at 37
°C. To aid successful digestion, 
the tube was shaken vigorously every 5-10 minutes until complete digestion of the 
tissue. The resulting cell suspension was passed through a 40µm cell strainer (BD 
Falcon) and then washed twice in complete RPMI to ensure complete removal of 
residual enzymes.  Cells were counted and kept on ice until use.   58 
2.4  Generation of Bone Marrow Derived Macrophages 
  BM was flushed out of the femurs and tibias of adult mice in RPMI 1640.  
The BM cells were passed through Nitex mesh (Cadisch and Sons, London, UK) 
and counted. To generate macrophages 1ml of cells were added into 90cm Petri 
dishes  (Sterilin,  UK)  at  3x10
6  cells/ml  with  8ml  complete  medium  (20%  FCS), 
containing  1mM  sodium  pyruvate  (Gibco),  and  20%  supernatant  from  L929 
fibroblasts as a source of CSF-1 at 37
oC in 5% CO2. After 3 days, the medium was 
supplemented with 5ml complete medium and 20% CSF-1.  On day 6/7 of culture, 
non-adherent cells were removed by washing with RPMI 1640 and the adherent 
cells were then collected by adding ice cold PBS/1mM EDTA for 5 minutes and 
then displacing them with cell scrapers (Costar). The purity of the harvested bone 
marrow-derived  m!  (BMM)  was  assessed  by  flow  cytometry  and  was  typically 
>90% F4/80
 positive.  
2.5 Isolation of Alveolar and Lung Macrophages 
  Resting alveolar m! were obtained from terminally anaesthetised mice by 
bronchoalveolar  lavage  (BAL)  with  0.8ml  (x2)  ice-cold  PBS/1mM  EDTA  via  an 
intra-tracheal cannula. For lung m!, lungs were removed from CO2-euthanased 
mice, washed in 2% FCS HBSS and cut into small pieces. Lung tissue was then 
incubated for 1hr with 0.5mg/ml collagenase IV (Sigma-Aldrich) in complete RPMI 
in a shaking incubator at 37
oC. Residual tissue was mashed through a 40µm cell 
strainer  and  washed  twice  in  complete  RPMI  to  ensure  removal  of  residual 
enzymes. 
2.6 Processing of Whole Blood 
  Heparinised blood was incubated on ice with ammonium chloride solution 
(0.8%  NH4Cl/0.1mM  EDTA;  Stem  Cell  Technologies,  Grenoble,  France)  for  10 
minutes to lyse red blood cells (RBC). Cells were washed twice in PBS and kept 
on ice until use. 
2.7  In vitro Stimulation of BMM and Purified Monocytes 
  BMM were plated out at 1x10
6 cells/ml and whole colonic lamina propria 
(CLP) digest cell suspensions were plated at 2x10
6 cells per well in 1ml, in ultra 
low adherence, 24-well tissue culture plates (Costar). Cells were incubated either   59 
in  medium  alone,  or  with  1µg/ml  lipopolysaccharide  (LPS)  from  Salmonella 
typhimurium  (Sigma-Aldrich),  1µg/ml  bacterial  lipoprotein  (BLP;  Pam3CSK4) 
(Invivogen), and/or 100U/ml recombinant mouse interferon (IFN)$ (BioSource) at 
37
oC in 5% CO2. In some experiments BMM were pre-incubated with 2.5µg/ml 
CD200-Fc  fusion  protein  (R&D  Systems)  for  1hr  before  stimulation  with  LPS 
and/or IFN$. FACS-purified colonic or BM Ly6C
high monocytes were cultured with 
50ng/ml  recombinant  CX3CL1  (R&D  Systems),  10ng/ml  recombinant  human 
TGF! (Peprotech) or 20% supernatant from L929 fibroblasts as a source of CSF-
1, at 37
oC in 5% CO2. 
2.8  Flow Cytometry and Antibodies 
2.8.1  Surface Staining 
  2-3x10
6  cells  were  added t o  1 2 x 7 5 m m   polystyrene  tubes  (BD  Falcon), 
washed in ice cold FACS buffer (PBS containing calcium and magnesium + 4% 
FCS) and then incubated at 4°C with anti-CD16/CD32 ('Fc Block') to reduce non-
specific binding via Fc receptors. Cells were washed once with ice cold FACS 
buffer  and  then  incubated  with  the  relevant  primary  antibodies  (as  detailed  in 
Table 2.2) for 20-30 minutes at 4°C protected from light. Cells were then washed 
three times in ice cold FACS buffer and if required, incubated for a further 10-15 
minutes with fluorochrome-conjugated streptavidin (SAv). Cells were washed once 
more in ice cold FACS buffer and analysed using a FACSCalibur, FACSAria I or 
LSRII flow cytometer (all BD Biosciences). Dead cells were excluded from analysis 
by adding 10µl 7-aminoactinomycin D (7-AAD; BD Biosciences) to each sample 
immediately before acquisition. Appropriate isotype controls were included in all 
experiments. As detailed in Table 2.2, isotype controls were purchased from the 
manufacturer  of  the  appropriate  antibodies.  All  data  generated  were  analysed 
using FlowJo software (Tree Star Inc, OR, USA). 
2.8.2  Detection of Intracellular Cytokines by Flow Cytometry 
  When staining for intracellular cytokines, the staining protocol was adapted 
slightly to be compatible with the fixable dead cell exclusion dyes used. 2x10
6 cells 
were incubated with or without TLR ligands for 4.5hrs in the presence of 1µM 
monensin  and  10µg/ml  Brefeldin  A  (both  Sigma-Aldrich)  to  prevent  cytokine 
secretion in 5ml polystyrene tubes. Cells were washed in PBS and then incubated   60 
with LIVE/DEAD
® fixable violet or aqua dead cell stain kits (Molecular Probes; Life 
Technologies) as per the manufacturer's guidelines, for 20-30 minutes protected 
from light.  Cells were then washed in ice cold PBS, incubated with purified anti-
CD16/CD32 and stained with the appropriate antibodies for cell surface antigens 
as described above, before being washed three times in PBS. Cells were then 
fixed using 4% paraformaldhyde (PFA; Thermo Scientific) in PBS for 10 minutes at 
room temperature and then washed in ice cold PBS. Cells were permeabilised 
using 'PermWash' (PBS containing 0.1% saponin/0.1% sodium azide/0.1% BSA 
(all Sigma-Aldrich)/0.2% FCS) before a further incubation with anti-CD16/CD32 to 
block  intracellular  Fc  receptors.    Cells  were  then  resuspended  in  'PermStain' 
(PBS/0.1%  saponin/0.1%  sodium  azide/0.1%  BSA/1%  FCS)  together  with  the 
appropriate fluorochrome-conjugated cytokine-specific antibodies for 20 minutes 
protected from light.  Cells were then washed with 'PermWash', resuspended in 
FACS buffer and analysed by flow cytometry.  
2.8.3  Detection of CCR2 Chemokine Receptor by Flow Cytometry 
  To  examine  the  presence  of  the  chemokine  receptor  CCR2,  a  specific 
monoclonal  antibody  (MC-21)  was  used  (a  kind  gift  from  Prof.  M.  Mack, 
Department for Internal Medicine, University of Regensburg, Germany). Cells were 
first incubated with PBS/2% FCS/10% mouse serum (Biosera) for 1 hour at 4°C to 
reduce non-specific binding, before being washed three times with ice cold FACS 
buffer. Cells were then stained with 5µg/ml MC-21 or purified rat IgG2b (as an 
isotype control) at 4°C for a further hour. Cells were washed three times in FACS 
buffer and stained with a biotinylated polyclonal anti-rat IgG (BD Biosciences) for 
30 minutes at 4°C before being washed as before. Cells were then incubated with 
SAv-QDot 605 (Molecular Probes) for 15 minutes at 4°C protected from light and 
then washed again. Other surface markers were then stained for as described 
above, except that the incubation step with anti-CD16/CD32 was omitted. CCR2 
KO cells were used as the negative control for all CCR2 staining. 
2.9  Purification of Tissue Macrophages by FACS 
  To obtain purified macrophage populations, colonic lamina propria cells and 
PEC were prepared as for flow cytomtery in sterile conditions, as described above. 
Cells  were  then  sorted  using  a  FACSAria  I  and  the  purity  of  sorted  cells  was 
routinely between 91-98%. Colonic LP myeloid cell subsets were sorted on the   61 
basis of CD11b, CX3CR1-GFP, Ly6C, class II MHC, F4/80 and CD11c expression 
by live-gated cells (see Figure 3.8). Peritoneal m! were sorted as CD45
+ 7-AAD
neg 
F4/80
high  CD11b
+  SiglecF
neg.  Colonic  and  peritoneal  eosinophils  were  sorted  as 
CD45
+ 7-AAD
neg F4/80
low MHCII
neg SiglecF
+. 
2.10  Assessment of Phagocytosis 
  To measure the phagocytic activity of colonic LP m!, LP leucocytes were 
isolated  from  CX3CR1
+/gfp  mice  and  3x10
6  cells  stained  for  flow  cytometry  as 
above  and  phagocytosis  was  assessed  according  to  the  manufacturer's 
guidelines.  Briefly,  cells  were  incubated  with  20µl  pHrodo  E.  coli  bioparticles 
(Molecular Probes) for 15mins at 37°C or at 4°C as a control, washed in Buffer C 
and analysed by flow cytometry.  
2.11  Induction of DSS Colitis 
  To induce acute colitis, I used a well established protocol whereby mice 
received  2%  dextran  sodium  sulphate  (DSS)  salt  (reagent  grade;  MW  36,000-
50,000 kDa; MP Biomedicals, Ohio), ad libitum in sterile drinking water for up to 8 
days. In some experiments mice were fed DSS for 4 days and then returned to 
normal drinking water in order to assess the 'recovery' phase of disease. Mice 
were  monitored  daily  for  weight  change,  rectal  bleeding  and  diarrhoea  and  a 
clinical score generated (Table 2.3). Mice that lost >20% of their initial bodyweight 
were sacrificed immediately in accordance with Home Office regulations. Water 
intake was measured daily for each group and the volume of water consumed per 
mouse was estimated by dividing the total volume of water consumed per cage by 
the number of animals in the cage. At each time point, the colons were removed 
and measured to assess the extent of colon shortening. In some experiments, 
sections of colon were fixed in 10% formalin, processed and stained with H&E for 
histological  analysis  by  the  Veterinary  Biosciences  unit  within  the  School  of 
Veterinary Medicine (University of Glasgow). 
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Table  2.2:  List  of  Monoclonal  Antibodies  and  Streptavidin  Conjugates  used  for  Flow 
Cytometry.  
Primary antibodies were conjugated to either FITC, PE, PerCP-Cy5.5, PE-Cy7, APC, APC-Cy7, 
AlexaFluor 700, BD Horizon V450, V500, or were biotinylated and detected using fluorochrome-
conjugated streptavidin. 
 
Antibody  Clone  Isotype  Source 
CD3  17A2  Rat IgG2b  BD Biosciences 
CD4  RM4-5  Rat IgG2a  BD Biosciences 
CD8  53-6.7  Rat IgG2a  BD Biosciences 
CD11b  M1/70  Rat IgG2b  BD Biosciences 
CD11c  HL3  Hamster IgG1  BD Biosciences 
CD14  Sa2-8  Rat IgG2a  eBioscience 
CD16/32  2.4G2  Rat IgG2b  BD Biosciences 
CD19  1D3  Rat IgG2a  BD Biosciences 
CD31   MEC 13.3  Rat IgG2a  BD Biosciences 
CD40  3/23  Rat IgG2a  BD Biosciences 
CD45  30-F11  Rat IgG2b  BD Biosciences 
CD45.1  A20  Mouse IgG2a  BD Biosciences 
CD45.2  104  Mouse IgG2a  BD Biosciences 
CD45R (B220)  RA3-6B2  Rat IgG2a  BD Biosciences 
CD80  16-10A1  Hamster IgG1  BD Biosciences 
CD86  GL1  Rat IgG2a  BD Biosciences 
CD103  M290  Rat IgG2a  BD Biosciences 
CD103  2E7  Hamster IgG  eBioscience 
CD115  AFS98  Rat IgG2a  eBioscience 
CD117  2B8  Rat IgG2b  BD Biosciences 
CD135  A2F10.1  Rat IgG2a  BD Biosciences 
CD172a  P84  Rat IgG1  BD Biosciences 
CD193  83103  Rat IgG2a  BD Biosciences 
CD200  OX-90  Rat IgG2a  AbD Serotec 
CD200R  OX-110  Rat IgG2a  AbD Serotec 
CD206  MR5D3  Rat IgG2a  Biolegend 
BrdU      BD Biosciences 
F4/80  BM8  Rat IgG2a  eBioscience 
IL-10  JES5-16E3  Rat IgG2b  BD Biosciences 
Ki-67  B56  Mouse IgG1  BD Biosciences 
Ly6C  AL-21  Rat IgM  BD Biosciences 
Ly6G  1A8  Rat IgG2a  BD Biosciences 
MHC II (IA-IE)  M5/114.15.2  Rat IgG2b  eBioscience 
SiglecF  E50-2440  Rat IgG2a  BD Biosciences 
TLR2  6C2  Rat IgG2b  eBioscience 
TLR4  MTS510  Rat IgG2a  eBioscience 
TNF!   MP-6XT22  Rat IgG1  BD Biosciences 
       
Streptavidin QDot 605      Molecular Probes 
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Table 2.3: Clinical Disease Score criteria used during DSS-induced colitis studies 
Score  Weight Loss  Rectal Bleeding  Stool 
0  0%  None  Well-formed pellet 
1  5-9.9%  Blood around anus  Pasty soft pellets 
2  10-14.9%  Bleeding  Faeces around anus 
3  15-19.9%  Gross Bleeding  Diarrhoea 
4  >20%  N/A  N/A 
 
2.12  Measure of Cell Turnover by BrdU Incorporation 
  For  short  term  studies,  mice  were  injected  i.p.  with  1mg  5-bromo-2'-
deoxyuridine (BrdU; BD Biosciences) and then sacrificed at different time points 
thereafter. The incorporation of BrdU by isolated cells was assessed using the BD 
BrdU Flow Kit (BD Biosciences). Cells were treated as for intracellular staining, 
except that after fixation with 4% PFA, the cells were treated as per the Flow Kit 
instructions.   
  For long term BrdU administration, mice were injected once i.p. with 1mg 
BrdU and then received 0.8mg/ml BrdU in their drinking water for a maximum of 8 
days.  The  BrdU-supplemented  water  was  protected  from  light  and  replenished 
daily.   
2.13  Adoptive Transfer of Purified Monocytes 
  Bone  marrow  was  flushed  from  the  tibiae  and  femurs  of  CX3CR1
+/gfp 
CD45.2
+ or CX3CR1
+/gfp CD45.1
+/CD45.2
+ mice and the cells were incubated with 
ammonium chloride solution for 10 minutes on ice to lyse red blood cells (RBC).  
The remaining cells were stained for CD11b, CD117 (c-kit), Ly6G and Ly6C to 
allow  discrimination  between  Ly6C
high  monocytes  (CD11b
+CD117
negLy6G
neg 
Ly6C
highCX3CR1
int)  and  Ly6C
low  monocytes  (CD11b
+  CD117
negLy6G
negLy6C
low 
CX3CR1
+)  and  the  subsets  were  sorted  using  a  FACSAria  I  cell  sorter  into 
complete  RPMI  1640.  The  purity  of  these  monocyte  populations  was  routinely 
>97%.  Sorted  monocytes  were  washed  twice  in  sterile  PBS  and  then  2x10
6 
Ly6C
high  or  0.5-1x10
6 L y 6 C
low  monocytes  were  transferred  intravenously,  in  a 
volume of 0.1ml into resting or colitic congenic recipient mice, the genotype of   64 
which  varied  between  experiments.  Recipient  mice  were  examined  for  the 
presence of donor cells at different time points after monocyte infusion.     
2.14  Competitive Adoptive Transfer of BM cells 
  To study the relative ability of CCR2-deficient and WT BM monocytes to 
migrate to the intestine, a 1:1 mix of total BM cells from C57Bl/6.SJL (CD45.1
+) 
and CCR2KO (CD45.2
+) mice was labelled with 5µM CellTrace™ Far Red DDAO-
SE (Molecular Probes) in HBSS at RT for 5 minutes.  Following labelling, the cells 
were washed twice with PBS/5% FCS and 12 x 10
6 labelled cells in 0.2ml of PBS 
were injected i.v. into C57BL/6 (CD45.2
+) mice that had received 2% DSS in their 
drinking water for 5 days to induce colonic inflammation, or into control mice that 
had  received  normal  drinking  water.  Following  cell  transfer,  recipient  mice 
continued to receive DSS or normal drinking water for a further 24hrs, after which 
cells  were  harvested  from  the  spleens  and  colons  of  the  recipient  mice  and 
analysed for the presence of donor (Far Red DDAO-SE
+) cells. The ratio of WT 
(CD45.1
+) versus CCR2KO (CD45.2
+) cells was then assessed in each tissue.  
2.15  Transfer of Monocytes into Mice Depleted of    
   CD11c
+ cells 
  To deplete CD11c-expressing cells, CD11c-DTR-GFP mice were injected 
with  4ng/g  bodyweight  diphtheria  toxin  (DT;  Sigma-Aldrich)  and  24hrs  after 
treatment, mice received 2x10
6 Ly6C
high purified BM monocytes from CX3CR1
+/gfp 
CD45.1
+/CD45.2
+ mice and were assessed for the presence of donor cells 24hrs 
or 4 days after transfer. 
2.16   Generation of BM Chimeric Mice 
  8 week old female C57Bl/6 (CD45.2
+) mice were irradiated with a total dose 
of 11 Gy 2 hrs apart.  Mice then received 1x10
7 BM cells from CD45.1
+/CD45.2
+ 
C57Bl/6 mice and were left for 8 weeks to allow BM engraftment. BM chimeric 
mice were generated by Dr. K.M. Lee, University of Glasgow. 
2.17   Administration of Growth Factors In Vivo 
  To assess DC expansion CX3CR1
+/gfp mice were injected i.p. with 10µg 
human recombinant CHO-derived flt3L (a kind gift of Amgen Corp, Seattle, USA)   65 
in 0.2ml sterile PBS for 8 consecutive days to achieve maximal cell expansion, as 
previously optimised in the Mowat lab. To assess the role for CSF-1, 20,000U of 
recombinant CSF-1 (a kind gift of Dr. David Sester, Roslin Institute, Edinburgh) 
was injected i.p. in 0.2ml sterile PBS for 4 consecutive days, as this has been 
shown previously to expand tissue macrophage numbers (49). The extent of cell 
expansion  was  assessed  by  comparing  cell  numbers  with  non-injected  resting 
CX3CR1
+/gfp mice. 
2.18  Cytospins 
  Aliquots of FACS-purified cells (0.5-1x10
5 cells) were spun onto Polysine
TM 
glass microscope slides (VWR International) at 300 RPM for 6 minutes using a 
cyto-centrifuge (Shandon, Runcorn, UK). Cells were then fixed in acetone for 10 
minutes, allowed to air dry and then stained using the Rapid-Romanowsky staining 
kit  (Raymond  A.  Lamb,  Eastbourne,  UK).  Slides  were  washed  thoroughly  in 
distilled water, allowed to air dry and then mounted in DPX mountant (BDH, UK) 
under glass.  Stained cells were assessed for morphology using an Olympus BX41 
microscope. 
2.19  RNA Extraction 
  Single cell suspensions (FACS-sorted cells or BMM) were washed twice 
with PBS, spun down and the supernatant discarded.  RNA was then isolated 
using the RNeasy Micro or Mini Kit (Qiagen) (depending on cell number) according 
to the manufacturer’s guidelines. Contaminating genomic DNA was removed on-
column during RNA isolation with the RNase-free DNase Set (Qiagen) according 
to  the  manufacturer’s  instructions.  The  RNA  was  quantified  using  a 
spectrophotometer (Amersham Biosciences) and then stored at –20
°C until use. 
2.20  cDNA Synthesis from RNA 
  cDNA was reverse transcribed from DNase-treated RNA using Superscript 
II  Reverse  Transcriptase  (RT)  (Invitrogen)  according  to  the  manufacturer’s 
instructions.  Briefly,  13ng  of  RNA,  1"l  Oligo(dT)12-18  (500"g/ml;  Invitrogen),  1"l 
dNTP  mix  (25mM  each;  Invitrogen),  and  nuclease-free  water  (Ambion)  were 
added to a nuclease-free microcentrifuge tube (ABgene, Surrey, UK) in a total 
volume of 12"l. The mixture was heated at 65
0C for 5 minutes, and then quick-  66 
chilled on ice. 4"l 5X First-Strand Buffer (Invitrogen), 2"l 0.1M DTT (Invitrogen), 
and 1"l RNaseOUT (40 units/ml; Invitrogen) were added and incubated at 42
0C for 
2 minutes. 1"l (200 units) Superscript II RT was then added and the RNA was 
reverse transcribed at 42
0C for 50 minutes. Superscript II RT was then inactivated 
by heating at 70
0C for 15 minutes. cDNA was diluted 1:10 and then stored at -
20
0C  until  use.  Negative  control  samples  were  incubated  in  the  absence  of 
Superscript II, and cDNA was stored at –20
0C until use.    
2.21  Quantitative/Real Time PCR 
  Gene expression was assayed by quantitative reverse transcription PCR 
(qRT-PCR)  using  Brilliant  III  Ultra  Fast  SYBR  qPCR  master  mix  (Agilient 
Technologies) on the 7900HT Fast system (Applied Biosystems) using the primers 
as  detailed  in  Table  2.4.  cDNA  samples  were  assayed  in  triplicate  and  gene 
expression levels were normalised to Cyclophilin A (CPA). The mean relative gene 
expression  was  calculated  using  the  2
-#C(t) m e t h o d .   All  qRT-PCR  experiments 
were carried out by Charlotte Scott. 
2.22  Statistical Analysis 
  Results are presented as means + 1 standard deviation and groups were 
compared using a Student’s t test, Mann Whitney test or for multiple groups, a 
one-way  ANOVA  followed  by  a  Bonferroni  post  test  using  Prism  Software 
(GraphPad  Software,  Inc.).  Values  of  less  than  p<0.05  were  considered  to 
statistically significant. 
 
 
 
 
 
  
 
Table 2.4:  Primers used in qRT-PCR 
!
Gene  Sense  Anti-sense  Reference 
Cyclophilin A  GTG GTC TTT GGG AAG GTG AA  TTA CAG GAC ATT GCG AGC AG  (317) 
Cx3cr1  TGT CCA CCT CCT TCC CTG AA  TCG CCC AAA TAA CAG GCC  (30) 
Cd163  CCT TGG AAA CAG AGA CAG GC  TCC ACA CGT CCA GAA CAG TC  (317) 
Cd206  TGT GGT GAG CTG AAA GGT GA  CAG GTG TGG GCT CAG GTA GT  (317) 
Tgfbr2  ACA TTA CTC TGG AGA CGG TTT GC  AGC GGC ATC TTC CAG AGT GA  n/a 
Arginase-1  CAG AAG AAT GGA AGA GTC AG  CAG ATA TGC AGG GAG TCA CC  (318) 
Ccr2  ATC CAC GGC ATA CTA TCA ACA TC  CAA GGC TCA CCA TCA TCG TAG  (317) 
Il6  CCA GTT GCC TTC TTG GGA CT  GGT CTG TTG GGA GTG GTA TCC  (317) 
inos  GCC ACC AAC AAT GGC AAC A  GCC ACC AAC AAT GGC AAC A  (222) 
Il10  GCT CTT ACT GAC TGG CAT GAG  CGC AGC TCT AGG AGC ATG TG  (317) 
Tnfa  ACC CTC ACACTC AGA TCA TCT TC  TGG TGGTTT GCT ACG ACG T  (319) 
Vegf  CCT TCG TCC TCT CCT TAC CC  AAG CCA CTC ACA CAC ACA GC  (317) 
Tlr1  TGG ACA CCC CTA CAG AAA CGT  AAT TTG GTT TAG TCA TTG TTG TAT GGC C  (320) 
Tlr2  CTG GAG CAT CCG AAT TGC A  CAT CCT CTG AGA TTT GAC GCT TT  (320) 
Tlr3  CCA GAA GAA TCT AAT CAA ATT AGA TTT GTC  TTT TGC TAA GAG CAG TTC TTG GAG  (320) 
Tlr4  GGC AAC TTG GAC CTG AGG AG  CAT GGG CTC TCG GTC CAT AG  (320) 
Tlr5  CAC TCC CTC GGA GAA CCC A  GGC CTT GAA AAA CAT CCC AAC  (320) 
Tlr6  AAA GTC CCT CTG GGA TAG CCT CT  TGC TTC CGA CTA TTA AGG CCA  (320) 
Tlr7  ACA GAA ATC CCT GAG GGC ATT  CAG ATG GTT CAG CCT ACG GAA G  (320) 
Tlr9  GGG CCC ATT GTG ATG AAC C  CTT GGT CTG CAC CTC CAA CA  (320)   68 
!
!
!
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3.1  Introduction 
  As discussed in Chapter 1, the precise characterisation of individual MP 
populations in the intestine has been stifled by the realisation that markers such as 
F4/80 and CD11c, previously thought to be specific for m! and DC respectively, 
are inadequate for the identification of discrete populations when used in isolation. 
The  position  has  been  made  more  complex  by  the  use  of  different  isolation 
techniques, for example the use or not of density gradients to purify mononuclear 
cells.  As a result, when I began my project, it was becoming increasingly apparent 
that  many  myeloid  cell  populations  in  the  intestine  had  been  misclassified, 
meaning  there  was  confusion  over  their  exact  roles  in  homeostasis,  protective 
immunity and pathology.  
  Studies carried out by the Mowat laboratory prior to my arrival had been 
limited to 4 colour flow cytometry and had concluded that the colonic LP housed 
two discrete F4/80
+ m! populations based on the presence or absence of surface 
TLR2 expression (222). The F4/80
+TLR2
neg subset was shown to form the majority 
population  (~70%  of  F4/80
+  cells)  within  the  steady  state  colonic  LP  and  was 
characterised  by  lack  of  class  II  MHC  and  CCR2  expression,  as  well  as 
unresponsiveness to TLR stimulation. In contrast, the F4/80
+TLR2
+ subset which 
made up ~30% of F4/80
+ cells in the normal mucosa expressed high levels of 
class  II  MHC,  responded  to  TLR  ligation  and  came  to  dominate  during 
inflammation,  being  recruited  in  a  CCR2-dependent  manner.  Because  of  these 
phenotypic  differences  and  the  changes  in  abundance  of  the  respective 
populations  during  inflammation,  it  was  concluded  that  the  F4/80
+TLR2
neg a n d  
F4/80
+TLR2
+ subsets represented 'resident' and 'pro-inflammatory' m! populations 
respectively.  The  presence  of  these  two  m!  subsets  with  distinct  functional 
properties  was  thought  to  help  explain  the  fact  that  intestinal F 4 / 8 0
+ m !  are 
essential  for  the  maintenance  of  mucosal  homeostasis  and  yet  can  also  drive 
intestinal inflammation.  
  However when multi-parameter flow cytometry became available to us soon 
after I began work, it became apparent that the mucosal populations were much 
more complex and thus these initial conclusions about m! in the colon needed 
revisited. Thus in this first chapter I set out to re-examine the phenotype of the   70 
myeloid cell compartment present in the steady state colon and investigated how 
these populations changed during experimental colitis. 
3.2 Preliminary Identification of Macrophages in Steady 
State Colon 
  The previous studies in the laboratory identifying m! subsets using 4-colour 
flow cytometry had had to be restricted to F4/80, TLR2, 7-AAD (to exclude dead 
cells)  and  one  other  marker  of  e.g.  activation.  My  first  experiments  were  also 
limited to 4-colours, but when I added the pan-leucocyte marker, CD45 to exclude 
non-haematopoietic  cells,  I  made  the  surprising  discovery  that  many  of  the 
F4/80
+TLR2
neg cells were not CD45
+ (Fig. 3.1A and B). Furthermore, most of the 
cells in the CD45
+ fraction of this TLR2
neg population had a high SSC profile more 
like  granulocytes  than  myeloid  cells  (Fig.  3.1B).  There  were  also  significant 
numbers of these cells which appeared to be cell debris or aggregates, as shown 
when I gated for doublets (Fig. 3.1C). 
  I therefore devised an improved gating strategy in which single cells were 
first identified within whole LP digests using forward (FSC) and side scatter (SSC) 
parameters  (Fig.  3.2A),  and  then  live  leucocytes  were  identified  by  gating  on 
CD45
+ 7-AAD
neg cells. This gating strategy resulted in far superior separation of 
F4/80
+ populations (Fig. 3.2B) and revealed that the frequency of F4/80
+TLR2
neg 
versus F4/80
+TLR2
+ populations was altered considerably, with F4/80
+TLR2
+ cells 
now dominating over the F4/80
+TLR2
neg subset even in healthy colon. 
  At this point two major developments occurred which allowed me to exploit 
this revised gating strategy more fully. First, I was able to make use of 10-colour 
flow cytometry and secondly, CX3CR1
+/gfp mice became available.  As I discussed 
previously,  not  long  after  I  started  my  project  it  had  been  proposed  that  the 
mutually  exclusive  expression  of  CD103  and  the  chemokine  receptor  CX3CR1 
could be used to identify DC and m! respectively in the intestine (189). Therefore 
having access to CX3CR1
+/gfp mice, in which one of the genes encoding CX3CR1 
has been replaced with the green fluorescent protein (gfp) (209), allowed me to 
examine the TLR2
neg and TLR2
+ populations of the F4/80
+ cells from the colon in 
more  detail.  This  analysis  confirmed  my  earlier  conclusions  that  most  of  the 
TLR2
neg subset were not m!, as they had a high SSC profile and lacked CX3CR1 
expression  (Fig.  3.2C  and  D).  In  contrast,  all  F4/80
+TLR2
+  cells  expressed   71 
CX3CR1,  although  the  levels  varied,  suggesting  that  this  population  might  be 
heterogeneous (Fig. 3.2D). 
  Thus  together  these  data  reveal  that  most  of  the  F4/80
+  cells  originally 
thought to be m! are either non-haematopoietic cells or not m!, and that TLR2 
cannot be used to distinguish m! subsets in the colon. In addition, they indicate 
that CX3CR1 expression is more informative for the identification of individual MP 
populations.   
3.3 CX3CR1 Expression Defines 3 Populations of CD11b
+ Cells 
  Having established some fundamental parameters that appeared to allow 
clearer  definition  of  MP  in  the  colonic  mucosa,  I  went  on  to  use  these  gating 
strategies and multi-colour flow cytometry to characterise these cells more fully in 
CX3CR1
+/gfp mice. First I used CD11b expression to identify the entire myeloid 
compartment of the CD45
+7-AAD
neg cells in the mucosa and analysed CX3CR1-
GFP  expression.  This  revealed  three  distinct  populations  of  CD11b
+  cells: 
CX3CR1
neg,  CX3CR1
int a n d  C X 3 C R 1
high  that  constituted  5.04±1.02%,  6.1±1.6% 
and 15.7±1.7% of the CD45
+ fraction of all viable cells in resting mice, respectively 
(Fig. 3.3A and B). To explore the composition of each of these populations in more 
detail, I first examined their FSC and SSC profiles (Fig. 3.3C). The CX3CR1
neg 
population was heterogeneous in terms of FSC and SSC, with the majority of cells 
displaying  high  SSC  characteristics  akin  to  that  of  granulocytes,  whereas  the 
remainder of cells had low FSC and SSC profiles. The CX3CR1
int and CX3CR1
high 
populations  had  profiles  typical  of  myeloid  cells,  although  the  CX3CR1
high 
population had higher FSC, indicating they were larger. I next went onto assess 
the expression of F4/80, CD11c, class II MHC, CD103 and Ly6C on these cells, as 
markers of putative m!, DC and monocytes.   
3.3.1  CX3CR1
neg Cells 
  Initial  analysis  of  this  population  showed  that  most  CX3CR1
neg  cells 
expressed F4/80, albeit at lower levels than those on the CX3CR1
high cells and 
more comparable to CX3CR1
int cells (Fig. 3.4A).  The vast majority of CX3CR1
neg 
cells  lacked  expression  of  class  II  MHC,  but  expressed  intermediate  levels o f  
CD11c and Ly6C (Fig. 3.4A). Further examination of these markers in combination 
revealed that two distinct populations could be defined by their SSC profile and   72 
CD11c  expression  (Fig.  3.5A).  SSC
highCD11c
low-int  cells  lacked  class  II  MHC 
expression, whereas the minor SSC
low population expressed high levels of CD11c 
and  class  II  MHC.  This  suggests  that  these  CX3CR1
negSSC
low  cells  may  be 
CD11b
+ DC, an idea supported by the fact that 20-30% of them co-expressed 
CD103 (Fig. 3.5B). However the vast majority of CD103
+ DC in the colon failed to 
express CD11b or CX3CR1 (not shown). 
  Because of the high SSC profile of the CD11c
low-int cells and because recent 
studies have identified F4/80
low eosinophils in the normal small intestine (253), I 
examined the SSC
highCD11c
low population for the expression of SiglecF, a sialic 
acid-binding  immunoglobulin  lectin  reported  to  be  expressed  exclusively  by 
eosinophils  (254).  This  revealed  that  over  90%  of  the  SSC
highCD11c
low-int 
population  expressed  SiglecF  (Fig.  3.5C).  Surprisingly,  colonic  LP  SiglecF
+ 
eosinophils failed to express the CCL11 (eotaxin) receptor CCR3 to any significant 
level (Fig. 3.5D), in contrast to what has been reported for eosinophils in the BM, 
small  intestine  and  lung  (253).  The  remainder  of  the  SSC
highCD11c
low-int  cells 
appeared to be neutrophils, as determined by intermediate levels of Ly6C and 
uniformly  high  expression  of  the  neutrophil-specific  marker  Ly6G  (Fig.  3.5E). 
These neutrophils were extremely rare in the steady state intestine, constituting 
less than 0.5% of the total CD45
+ live fraction of cells and indicating the colonic LP 
populations were not contaminated significantly by blood. 
  To confirm that intestinal SiglecF
+ cells were eosinophils, I FACS-purified 
them to >90% purity and assessed their morphological appearance (Fig. 3.6A and 
B). Similar to the small population of F4/80
lowSiglecF
+ eosinophils FACS-purified 
from  the  resting  peritoneal  cavity,  intestinal  SiglecF
+  cells  exhibited  typical 
eosinophil  characteristics  such  as  ring-shaped  nuclei  and  the  presence  of 
eosinophilic granules (Fig. 3.6B and C). 
  Together  these  phenotypic  analyses  demonstrated  that  the  CD11b
+ 
CX3CR1
neg  population  comprises:  (1)  F4/80
lowSiglecF
+  eosinophils,  (2)  a  small 
population of CD11c
+MHCII
high putative DC and (3) a small population of Ly6C
int 
(Ly6G
+) neutrophils.     73 
3.3.2  CX3CR1
high Cells 
  The  CX3CR1
high  compartment  of  CD11b
+  cells  was  a  homogeneous 
population that uniformly expressed F4/80 and class II MHC at high levels, but 
lacked expression of CD103 or Ly6C (Fig. 3.4C and 3.7). This would have made 
up most of the F4/80
+TLR2
+ subset found using the former gating strategy (Fig. 
3.2). Significantly, this population expressed CX3CR1 at levels much higher than 
any  other  myeloid  cells  I  examined,  including  resident  peritoneal  m!,  CSF-1 
generated  BM  m!  or  either  population  of  Ly6C
highCX3CR1
+  'inflammatory'  or 
Ly6C
lowCX3CR1
'high' 'resident' blood monocytes (Fig. 3.9A and B). The majority of 
CX3CR1
high cells also expressed low to intermediate levels of CD11c, a property 
that led to them being misclassified as DC in previous studies (195, 196). However 
the  level  of  CD11c  expression  I  found  was  extremely  variable  between 
experiments,  being  dependent  upon  the  clone  of  antibody  used  and  even  the 
fluorochrome to which it was conjugated. Analysis of FACS-purified CX3CR1
high 
cells (purity Fig. 3.8) showed that they possessed the morphological features of 
mature m!, including a large 'foamy' appearance and the presence of cytoplasmic 
vacuoles (Fig. 3.7B). In future experiments, they will be referred to as Population 4 
(Table 3.1 and see below). 
3.3.3  CX3CR1
int Cells  
  In contrast to the CX3CR1
high population, the CX3CR1
int fraction of CD11b
+ 
cells  was  heterogeneous  in  terms  of  F4/80,  class  II  MHC,  CD11c  and  Ly6C 
expression (Fig. 3.4B). By examining all these markers in combination, I found that 
the CX3CR1
int fraction contained at least four populations of cells (Fig. 3.7A). For 
simplicity when referring to the subsets in the remainder of this thesis, these are 
numbered according to the scheme outlined in Table 3.1.  
  First I divided the CX3CR1
int compartment on the basis of F4/80 and CD11c 
expression.  Although  the  exact  proportions  of  these  subsets  varied  between 
experiments, approximately two thirds of them usually expressed F4/80 and low to 
intermediate  levels  of  CD11c.  The  remaining  third  (named  P5)  expressed  high 
levels  of  CD11c,  but  generally  lacked  F4/80  expression  and  also  uniformly 
expressed high levels of class II MHC (Fig. 3.7A). In contrast, the F4/80
+ fraction 
of CX3CR1
int cells could be further subdivided on the basis of Ly6C and class II 
MHC expression to give three populations: Ly6C
highMHCII
neg (P1), Ly6C
+MHCII
+   74 
cells (P2) and Ly6C
negMHCII
+ (P3). Although P1, P2, P3 and P5 all expressed 
'intermediate'  levels  of  CX3CR1,  the  exact  level  of  expression  varied  between 
these  populations.  P5  expressed  the  lowest  level  of  CX3CR1,  whereas  P1-P3 
expressed CX3CR1 at a level comparable to blood monocytes (Fig. 3.9B). FACS-
purified  P1  and  P3  possessed  distinct  morphological  features.  Whereas  P3 
contained prominent cytoplasmic vacuoles similar to CX3CR1
high cells, P1 cells 
were much smaller and monocytic in appearance, which would be consistent with 
a  surface  phenotype  that  is  identical  to  blood  monocytes  (CD11b
+Ly6C
high 
MHCII
negCX3CR1
int) (Fig. 3.7B). Due poor cell yield I was unable to assess the 
morphological characteristics of P2 and P5.  
  Due  to  their  phenotypic  appearance  (F4/80
negCD11c
+),  I  next  set  out  to 
assess whether the cells in P5 were a population of CX3CR1
+ DC by assessing 
their responsiveness to the growth factor flt3L in vivo.  As expected, administration 
of  flt3L  to  mice  for  8  consecutive  days  expanded  the  numbers  of  archetypal 
mucosal CD103
+ DC (Fig. 3.10A-C). However it had little or no effect on cells in 
P1-P4.  Although  P1  and  P2  were  increased  in  number,  the  difference  from 
untreated mice was not significant. In contrast, flt3L treatment resulted in a 5.9-fold 
increase in the number of P5 cells (CD11c
+Ly6C
negMHCII
+CX3CR1
neg) similar to 
that seen with the CD103
+ DC population (Fig. 3.10A-C). These results confirm 
that the F4/80
+ and CD11c
+ populations within the Ly6C
negMHCII
+ fraction of the 
CX3CR1
int compartment are distinct and that the latter population represent bona 
fide DC.   
3.4 Lamina Propria Myeloid Cells During Inflammation 
  It is well established that the composition of the intestinal MP pool changes 
dramatically during inflammation in both mouse and man (222, 242). However, the 
use of inappropriate markers has meant that many of the populations have not 
been documented accurately. Therefore as a first step to exploring the biology of 
the  CX3CR1
+  subsets  I  had  defined  in  the  normal  colon,  I  used  my  newly 
established gating strategies to examine how these cells changed in acute colitis 
induced by feeding dextran sodium sulphate (DSS).   75 
3.4.1 Induction of Intestinal Inflammation 
  I  first  compared  disease  progression  in  CX3CR1
+/gfp  mice  and  wild  type 
(WT)  C57  Bl/6  mice,  to  ensure  that  lack  of  one  CX3CR1  allele  did  not  alter 
susceptibility to DSS-induced colitis. WT C57 Bl/6 mice began to lose weight after 
5-6 days of administering 2% DSS in their drinking water and this continued to 
progress over the remainder of the study (Fig. 3.11A). This was accompanied by 
rectal bleeding and diarrhoea that worsened over time, leading to a progressive 
increase in the clinical disease score (detailed in Table 2.3 in the Materials and 
Methods). There were no differences in weight loss or in the clinical features of 
disease  in  CX3CR1
+/gfp  mice  (Fig.3.11B).  In  addition,  comparable  colon 
shortening,  a  further  index  of  pathology  in  this  model,  was  seen  in  B6  and 
CX3CR1
+/gfp  mice  (Fig.  3.11C).  C57BL/6  mice  and  CX3CR1
+/gfp  consumed 
equivalent amounts of DSS-containing water over the 9 days (Figure 3.11D).   
3.4.2 Effects of Inflammation on the Mucosal Myeloid 
Compartment  
  I next examined the changes in CD11b
+ populations during experimental 
colitis in CX3CR1
+/gfp mice.  Initial examination revealed that there was a massive 
increase in the total CD11b
+ compartment in colitic animals compared with resting 
mice (Fig. 3.12). Whereas the total CD11b
+ population constituted 23.3±6.1% of 
the CD45
+7-AAD
neg fraction of cells in resting mice, this increased significantly to 
40.1±6.6% and 51.1±5.1% on d4 and d6 of colitis respectively (Fig. 3.12A and B).  
This increase in proportion was matched by a significant increase in the absolute 
number of CD11b
+ cells from 2.75x10
5 ± 0.4 per colon in steady state to 6.2x10
5 ± 
2.1 and 12.1x10
5 ± 2.4 per colon on d4 and d6 of colitis respectively (Fig. 3.12C). 
Thus,  there  is  at  least  a  4-fold  increase  in  the  total  myeloid  compartment  in 
established colitis.   
  I next examined the composition of the CD11b
+ fraction using CX3CR1 to 
define the populations I had found in steady state LP. The induction of colitis had 
very dramatic effects on the composition of these populations found in the colon, 
with  large  increases  in  the  proportions  and  numbers  of  both  CX3CR1
neg a n d  
CX3CR1
int cells (Fig. 3.13A-C). As discussed above, the steady state CX3CR1
neg 
population  contains  SiglecF
+  eosinophils,  as  well  as  small  populations  of 
CD11c
+MHCII
+ DC and Ly6G
+ neutrophils. Administration of DSS resulted in an   76 
intense  influx  of  both  populations  of  granulocytes  (Fig.  3.14A  and  B),  with  the 
absolute number of Ly6C
int (Ly6G
+) neutrophils increasing from 0.18x10
4 ± 0.05 
per colon during resting conditions to 2.3x10
4 ± 2.5 per colon on d4 of colitis and 
to 13.5x10
4 ± 6.6 per colon on d6 (Fig. 3.14C). This equated to a 75-fold increase 
in the number of neutrophils between d0 (resting) and d6. The number of SiglecF
+ 
eosinophils  increased  over  6-fold  from  3.3x10
4  ±  0.7  per  colon  during  resting 
conditions to 20.2x10
4 ± 7.4 per colon on d6 of colitis (Fig. 3.14D).  In contrast, the 
absolute number of CX3CR1
neg CD11b
+ DC did not change significantly during 
colitis, suggesting that this population is generally unaffected by the presence of 
inflammation (Fig. 3.14E).
 
  The  CX3CR1
int  compartment  showed  even  greater  expansion  than  the 
CX3CR1
neg  population.  Whereas  the  various  CX3CR1
int  populations  constituted 
6.1±0.7% of the CD45
+7-AAD
neg fraction during resting conditions, this increased 
significantly to 22.1±7.6% on d4 of colitis and further yet to 28.2±7.4% on d6 of 
colitis (Fig. 3.13A-C). This proportional increase was due to true expansion of this 
compartment as the absolute number of CX3CR1
int cells increased 9.2-fold from 
7.3x10
4 ± 1.8 per colon under normal physiological conditions to 66.8x10
4 ± 23.5 
on d6 of colitis (Fig. 3.13C). 
  Next, I examined the individual populations within the CX3CR1
int (P1, P2, 
P3 and P5) at different stages of colitis. DSS administration led to a statistically 
significant  expansion  in  Ly6C
high M H C
neg  cells  (P1),  which  increased  from 
14.5±2.9%  of  the  CX3CR1
int  population  from  during  resting  conditions  to 
26.1±4.6% and 32.4±5.4% on d4 and d6 of colitis respectively (Fig. 3.15A and B).  
This  translated  to  a  25-fold  increase  in  absolute  numbers  of  P1  cells  between 
resting and d6 of colitis (Fig. 3.15C). The proportion of Ly6C
+MHCII
+ cells (P2) 
within  the  CX3CR1
int p o p u l a t i o n  a l so  increased  markedly  between  resting  and 
colitic mice (Fig. 3.15D), with a 14-fold increase in their number from 1.4x10
4 ± 0.6 
per colon during steady state conditions to 20.01x10
4 ± 8.2 at d6 of colitis (Fig. 
3.15E). 
  Despite  a  significant  decrease  in  the  proportion  of  the  CX3CR1
int 
compartment  occupied  by  the  Ly6C
negMHCII
+  populations  (P3  and  P5),  these 
populations increased in terms of absolute numbers during colitis, although this 
increase  was  not  as  dramatic  as  that  of  P1  and  P2  cells  (Fig.  3.16A).  The   77 
F4/80
+MHCII
+Ly6C
neg cells in P3 increased only 5-fold between resting conditions 
and d6 of colitis from 2.1x10
4 ± 0.5 to 10.04x10
4 ± 3.8 per colon respectively (Fig. 
3.16B).  In  addition,  their  expansion  appeared  to  lag  behind  that  of  P1  and  P2 
which  occurred  earlier  in  disease.  Although  there  was  a  statistically  significant 
increase in the number of the DC-like CD11c
+MHCII
+Ly6C
negF4/80
neg cells in P5 
between resting conditions and d6 of colitis (2.2x10
4 ±0.9 versus 6.1x10
4 ±2.1 per 
colon, respectively), this only represented a 2.9-fold increase and their proportions 
fell markedly in comparison to the other CX3CR1
int cells (Fig. 3.16C).  
  In contrast to the CX3CR1
neg and CX3CR1
int populations, the CX3CR1
high 
population did not increase in abundance during colitis (Fig. 3.13). Indeed their 
proportion amongst the total viable CD45
+ population decreased progressively as 
colitis  developed  (12.03±4.7%  versus  3.0±1.1%  in  resting  and  d6  colitic 
respectively; Fig. 3.13A and B). Although these differences did not translate into a 
statistically significant decrease in absolute number, there was a 2-fold decrease 
in the number of CX3CR1
high cells retrieved from the resting versus the colitic LP 
by d6 (13.3x10
4 ± 2.0 versus 6.7x10
4 ± 1.9, respectively; Fig. 3.13C). Despite the 
massive  disruption  in  the  intestinal  architecture  and  the  infiltration  of  many 
inflammatory  cells,  the  phenotype  of  CX3CR1
high  resident  m!  did  not  change 
during colitis, and they all remained F4/80
high MHCII
high Ly6C
neg (Fig. 3.17A and B). 
3.5 Summary 
  In this chapter I set out to optimise a protocol for the characterisation of 
myeloid  cells  in  the  mouse  colon  using  multi-parameter  flow  cytometry,  as  my 
initial studies established that 4-colour flow cytometry using classical markers was 
inadequate for this.  By using CX3CR1-GFP mice, I was able to define individual 
myeloid cell subsets very precisely and this revealed unsuspected heterogeneity 
within the intestinal CD11b
+ compartment under steady state and inflammatory 
conditions.  This  population  comprised  CX3CR1
neg,  CX3CR1
int a n d  C X 3 C R 1
high 
cells. T h e  C X 3 C R 1
neg  compartment  contained  eosinophils,  CD11b
+ D C  a n d  a  
small population of neutrophils. The CX3CR1
high cells resembled tissue resident 
m! phenotypically and morphologically and dominated the CD11b
+ compartment 
of the resting colonic mucosa. A smaller but distinct population of CX3CR1
int cells 
was also present within the steady state mucosa and included multiple 'subsets' of 
myeloid  cells,  including  Ly6C
highMHCII
neg  cells  (P1),  Ly6C
+MHCII
+  cells  (P2),   78 
Ly6C
negMHCII
+ F4/80
+ cells (P3) and Ly6C
negMHCII
+ F4/80
negCD11c
high cells (P5).  
Both  the  CX3CR1
int a n d  C X 3 C R 1
neg  populations  expanded  dramatically  during 
experimental colitis, dwarfing the CX3CR1
high population. This was largely due to a 
massive  increase  in  the  number  of  Ly6C
highMHC
neg  (P1)  and  Ly6C
+MHC
+  (P2) 
cells.  Thus  the  colonic  LP  seems  to  house  populations  of  'resident'  and  'pro-
inflammatory' m! identified by differential levels of CX3CR1 expression and this 
may go some way to explain how intestinal m! can play such distinct roles in 
homeostasis and inflammation. 
  In the next chapter I next set out to assess whether these CX3CR1-defined 
compartments  represented  independent  subsets  or  if  a  relationship  existed 
between  them  by  examining  the  precursor-subset  relationship  between  distinct 
blood monocytes and CX3CR1
int and CX3CR1
high LP cells.  
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Table 3.1: Summary of CX3CR1
+ Mononuclear Phagocytes in Steady State LP 
 
Surface Phenotype 
 
Population 
CX3CR1  F4/80  CD11c  Ly6C  MHC II  CD103 
Proposed Cell 
Type 
1  ++  +  -  ++  -  -  Monocyte-like  
2  ++  ++  +  +  +  -  ? 
3  +++  ++  +  -  ++  -  ? 
4  ++++  +++  +  -  ++  -  Resident M!  
5  +  -  ++  -  ++  -  DC 
Expression of surface markers and putative lineage of P1-P5 subsets of CD11b
+ cells found in 
resting colon based on CX3CR1 expression (see text for details). 
 
Table 3.2: Changes in CX3CR1
+ Populations During Inflammation 
 
Cell Number (x10
4)  Population 
Steady state  d6 Colitis 
Fold Increase 
Total CD11b
+  27.4±4.0  121.0±24.0  4.4 
P1 (Ly6C
highMHCII
negCX3CR1
int)  1.03±0.2  24.8±3.0  24.1 
P2 (Ly6C
+MHCII
+CX3CR1
int)  1.4±0.6  20.01±8.2  14.4 
P3 (F4/80
+MHCII
+CX3CR1
int)  2.1±0.5  10.04±3.8  4.8 
P4 (F4/80
+MHCII
+CX3CR1
high)  13.3±2.0  6.7±1.9  0.5 
P5 (CD11c
+MHCII
+CX3CR1
int)  2.2±0.9  6.1±2.1  2.9 
Total colonic CD11b
+ cells and CX3CR1-defined myeloid subsets were enumerated in steady state 
and in mice that had received DSS for 6 days.  Results are the means + 1SD for 4 mice/group.  
The right-hand column indicates the fold-increase in each population during colitis over steady 
state conditions. 
 
 
 
 
 
 Figure 3.1: Original Gating Strategy for Identification of Colonic Macrophage Subsets 
Colonic LP cells were isolated from WT mice and analysed for the expression of F4/80, TLR2 and 
CD45 by flow cytometry. A. Representative dot plots showing the original gating strategy using 
TLR2 to define subsets in which live (7-AADneg) cells were assed for the expression of F4/80 and 
TLR2.  B.  Expression  of  CD45  and  SSC  profile  of TLR2+  (black  dots)  and TLR2neg  (red  dots) 
‘macrophage’ subsets. C. FSC-Area (FSC-A) versus FSC-Height (FSC-H) of TLR2+ (black dots) 
and TLR2neg (red dots) subsets. The gate shown identifies single cells and allows exclusion of 
doublets. Results are representative of at least 10 individual experiments.  
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80 Figure 3.2: Refined Gating Strategy for Analysis of Colonic Myeloid Cells 
Colonic LP cells were isolated from CX3CR1+/gfp mice and analysed for the expression of CD45, 
F4/80, TLR2 and CX3CR1-GFP by flow cytometry. A. Representative dot plots demonstrate the 
refined gating strategy that involves the exclusion of ‘doublets’ and the selection of CD45+ 7-
AADneg (live haematopoietic cells). B. Expression of F4/80 and TLR2 on live leucocytes. C. FSC 
and SSC profiles of F4/80+TLR2neg and F4/80 +TLR2+ populations, highlighting the difference in 
size  and  granularity  of  these  populations.  D.  Expression  of  CX3CR1  by  F4/80+TLR2neg a n d  
F4/80+TLR2+ populations. Results are representative of at least 10 individual experiments.  
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 Figure 3.3: Colonic Myeloid Cell Populations Defined by CX3CR1 Expression 
Colonic LP cells were isolated from resting CX3CR1+/gfp mice and CD11b+ populations identified 
on the basis of CX3CR1-GFP expression by flow cytometry. A. Representative dot plot of CD11b 
staining and CX3CR1-GFP expression by CD45+ live LP cells and (B) the relative frequencies of 
CX3CR1neg, CX3CR1int and CX3CR1high CD11b+ cells as determined by flow cytometry. C. FSC 
and SSC profiles of each of the CX3CR1-defined populations. Results are representative of at 
least 10 individual experiments. 
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82 Figure 3.4: Phenotypic Characterisation of Colonic Myeloid Cells Identified by 
Levels of CX3CR1 Expression 
Colonic  LP  cells  were  isolated  from  CX3CR1+/gfp  mice  and  subpopulations  of  CD11b+  cells 
identified on the basis of CX3CR1-GFP expression by flow cytometry. Expression of F4/80, class 
II MHC, CD11c, CD103 and Ly6C by CX3CR1neg (A), CX3CR1int (B) and CX3CR1high CD11b+ (C) 
cells.  Shaded  histograms  represent  staining  with  the  appropriate  isotype  control.  Results  are 
representative of 3 individual experiments. 
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 Figure 3.5: CD11b+ CX3CR1neg SSChigh cells in the Colonic Mucosa are Eosinophils and 
Neutrophils 
Colonic  LP  cells  were  isolated  from  CX3CR1+/gfp  mice  and  the  CD11b+CX3CR1neg  fraction 
amongst live gated CD45+ cells was analysed for the expression of CD11c and SSC properties by 
flow cytometry. Representative dot plot of SSC versus CD11c expression (A) and the expression 
of class II MHC by SSChighCD11cint (granulocytes - red) and SSClowCD11chigh cells (DC – blue) (B). 
C.  Expression  of  Ly6C  and  SiglecF  on  SSChighCD11cint  cells  identifies  SiglecF+  putative 
eosinophils and Ly6Cint cells. Expression of CCR3 by SiglecF+ eosinophils (D) and expression of 
Ly6G by Ly6Cint cells (E), confirming these as neutrophils. Shaded histograms represent staining 
with the appropriate isotype control. Results are representative of at least 3 individual experiments.  
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 Figure 3.6: SiglecF+ Cells in the Colonic Mucosa Are Eosinophils 
A. Colonic LP cells were isolated from WT mice and colonic eosinophils were identified amongst 
live-gated CD45+ F4/80low MHCIIneg cells on the basis of SiglecF+ SSChigh and purified by FACS. B. 
Frequency of SiglecF+ eosinophils amongst live-gated CD45+ cells (left panel) and the post-sort 
purity  of  FACS-purified  intestinal  eosinophils  (right  panel).  C.  Cytospins  of  purified  SiglecF+ 
intestinal  cells  were  fixed  and  stained  for  morphological  assessment  and  compared  to  FACS-
purified F4/80lowSiglecF+ peritoneal cells (final magnification x400). Both had characteristic ring 
shaped nuclei and eosinophilic cytoplasmic staining. Results are representative of 2 individual 
experiments.  
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85 Figure 3.7: Heterogeneity within the CX3CR1+ Populations of Colonic Myeloid Cells 
Colonic  LP  cells  were  isolated  from  resting  CX3CR1+/gfp  mice  and  live-gated  CD45+ C D 1 1 b + 
populations  characterised  on  the  basis  of  CX3CR1-GFP  expression  by  flow  cytometry.  A. 
Representative  dot  plots  of  F4/80,  CD11c,  Ly6C  and  MHC  II  expression  by  CX3CR1int a n d  
CX3CR1high CD11b+ cells, revealing a number of populations. As summarised in Table 3.1, these 
are  CX3CR1intLy6C+MHCnegF4/80low  (P1),  CX3CR1intLy6C+MHC+F4/80+  (P2),  CX3CR1intLy6Cneg 
MHC+F4/80+  (P3),  CX3CR1highLy6CnegMHC+F4/80high  (P4)  and  CX3CR1intLy6CnegMHC+F4/80lneg 
CD11c+ (P5). Results are representative of at least 10 individual experiments. B. Morphological 
analysis of cytospins of FACS purified CX3CR1intLy6Chigh MHCneg (P1), CX3CR1intLy6CnegMHC+ 
(P3) and CX3CR1high cells (P4) (final magnification x400). Results are representative of a single 
experiment.   
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P4 Figure 3.8: Post-sort Purity of FACS-purified CX3CR1+ Populations of Colonic Myeloid 
Cells 
Colonic LP cells were isolated from resting CX3CR1+/gfp mice and populations 1-4 were identified 
amongst live-gated CD45+ CD11b+ cells on the basis of CX3CR1-GFP, Ly6C, class II MHC, F4/80 
and CD11c expression and purified by FACS.  Representative plots of the post-sort purity of each 
population (1-4). Results are representative of at least 5 individual experiments.  
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87 Figure 3.9: CX3CR1 Expression by Different Myeloid Cell Populations 
A. Comparison of CX3CR1-GFP levels by CSF-1 generated BM m! (F4/80+MHCIIneg), resident 
peritoneal m! (F4/80highMHCIIneg) and total colonic m! (F4/80+MHCIIhigh) from resting CX3CR1+/gfp 
mice.  B.  Histogram  showing  CX3CR1-GFP  levels  of  colonic  LP  populations  1-5  versus 
‘resident’  (CD11b+Ly6ClowCX3CR1+)  and  ‘inflammatory’  (CD11b+Ly6ChighCX3CR1int)  blood 
monocytes. Results are representative of 2 individual experiments.  
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 Figure 3.10: Effects of In Vivo Administration of Flt3L on Colonic CX3CR1+ Subsets 
CX3CR1+/gfp  mice  received  flt3L  for  8  consecutive  days  and  the  absolute  numbers  of  cells  in 
populations 1-5 of CX3CR1 expressing colonic LP leucocytes were enumerated and compared 
with those in untreated CX3CR1+/gfp mice. A. Representative F4/80 and CD11c expression by live-
gated  CD45+CD11b+CX3CR1intLy6CnegMHCII+  cells  from  untreated  mice  (left  panel)  or  mice 
receiving flt3L (right panel) to identify P3 and P5. B. The absolute numbers of P1-P4 cells from 
untreated or flt3L treated mice.  C. The absolute numbers of P5 cells and CD103+ DC (live gated 
CD11c+MHCII+CD103+)  from  untreated  or  flt3L  treated  mice.  Data  are  representative  of  two 
individual experiments with 3 mice per group.  (*** p<0.0001; Student’s t test) 
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P3 
P5 Figure 3.11: Development of Acute Experimental Colitis is Comparable in CX3CR1+/
gfp and WT Mice 
WT or CX3CR1+/gfp mice received 2% DSS-supplemented drinking water for 9 days and their 
bodyweights (A) and clinical disease scores (B) were recorded daily.   Results are presented as 
the mean ± 1 SD for 4 (WT) and 5 (CX3CR1+/gfp) mice for a single experiment. On day 9 mice 
were culled and their colons measured compared in comparison with resting mice (d0) (C). D. 
Water consumption (ml) per mouse on each day of colitis.   
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90 Figure 3.12: Accumulation of Myeloid Cells During Acute Experimental Colitis 
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and colonic LP CD11b+ cells 
were enumerated at different time points.  A. Representative CD11b staining by live-gated (CD45+ 
7-AADneg) colonic LP cells obtained from resting (left panel), d4 colitic (middle panel) and d6 colitic 
(right panel) mice.  The proportions (B) and absolute numbers (C) of CD11b+ cells at d4 and d6 of 
colitis compared with steady state levels. Results are the mean + 1 SD for 4 mice at each time 
point and are representative of 3 individual experiments.  (* p<0.05, ** p<0.01, *** p<0.001; One-
way ANOVA with Bonferroni’s post tests) 
B 
A 
C 
FSC 
C
D
1
1
b
  22.9  49.7  57.7 
Resting  d4 DSS  d6 DSS 
Resting d4 d6
0
4
8
12
16 **
***
N
u
m
b
e
r
 
C
D
1
1
b
+
 
c
e
l
l
s
 
p
e
r
 
c
o
l
o
n
 
(
x
1
0
5
)
Resting d4 d6
0
20
40
60
**
***
%
 
C
D
1
1
b
+
 
o
f
 
C
D
4
5
+
 
L
i
v
e
91 Figure 3.13: Changes in Colonic LP CX3CR1-defined Populations During DSS Colitis 
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and the CX3CR1-defined 
populations were enumerated at d4 and d6 of colitis.   A. Representative CD11b staining and 
CX3CR1-GFP expression by live-gated (CD45+7-AADneg) colonic LP cells obtained from resting 
(left panel), d4 colitic (middle panel) and d6 colitic (right panel) mice.   The proportions (B) and 
absolute numbers (C) of CX3CR1neg, CX3CR1int and CX3CR1high cells at d4 and d6 of colitis 
compared with steady state levels. Results are the mean + 1 SD for 4 mice at each time point and 
are  representative  of  3  individual  experiments.    (*  p<0.05,  **  p<0.01,  ***  p<0.001;  One-way 
ANOVA with Bonferroni’s post tests) 
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92 Figure 3.14: Expansion of Mucosal CX3CR1neg Myeloid Cell Numbers During Colitis 
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and the composition of the 
colonic  LP  CD11b+  CX3CR1neg  compartment  was  examined  at  d4  and  d6  of  colitis.    A. 
Representative  MHC  II  expression  by  live-gated  CD45+ C D 1 1 b +  CX3CR1neg LP  cells  obtained 
from  resting  (left  panel),  d4  colitic  (middle  panel)  and  d6  colitic  (right  panel)  mice.    B. 
Representative Ly6C and SiglecF expression by SSChigh granulocytic cells at each time point. The 
absolute number of Ly6Cint neutrophils (C), SiglecF+ eosinophils (D) or CD11b+ DC (E) at d4 and 
d6 of colitis compared with resting mice. Results are the mean + 1 SD for 4 mice at each time 
point and are representative of 3 individual experiments.  (* p<0.05, ** p<0.01, *** p<0.001; One-
way ANOVA with Bonferroni’s post tests) 
A 
SiglecF 
L
y
6
C
  6.3  15.6  35.8 
91.5  81.6  59.6 
MHC II 
S
S
C
 
Resting  d4 DSS  d6 DSS 
82 
12.4 
89.5 
15.6 
95.2 
0.97 
Resting d4 d6
0.00
0.25
0.50
0.75
1.00
N
u
m
b
e
r
 
C
X
3
C
R
1
n
e
g
M
H
C
I
I
+
 
D
C
p
e
r
 
c
o
l
o
n
 
(
x
1
0
4
)
Resting d4 d6
0
5
10
15
20
25
30
35
**
*
N
u
m
b
e
r
 
C
X
3
C
R
1
n
e
g
L
y
6
C
i
n
t
n
e
u
t
r
o
p
h
i
l
s
 
p
e
r
 
c
o
l
o
n
 
(
x
1
0
4
)
Resting d4 d6
0
5
10
15
20
25
30
35
**
*
N
u
m
b
e
r
 
C
X
3
C
R
1
n
e
g
S
i
g
l
e
c
F
+
e
o
s
i
n
o
p
h
i
l
s
 
p
e
r
 
c
o
l
o
n
 
(
x
1
0
4
)
Gated: CD45+7-AADneg CD11b+ CX3CR1neg 
B 
C  E  CX3CR1neg DC  CX3CR1neg Ly6Cint 
neutrophils 
CX3CR1neg SiglecF+ 
eosinophils 
Resting  d4 DSS  d6 DSS 
D 
DC 
Granulocytes 
93 Figure 3.15: Expansion of Mucosal CX3CR1int Myeloid Cell Numbers During Colitis 
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and the cellular composition 
of the colonic LP CX3CR1int compartment was examined by flow cytometry at d4 and d6 of colitis. 
A. Representative Ly6C and class II MHC expression by live-gated CD45+ CD1 1b + CX3CR1int 
cells  obtained  from  resting  mice  or  d4  or  d6  colitic  mice.   The  proportion  (B)  and  absolute 
numbers (C) of P1 (Ly6ChighMHCIIneg) cells per colon at each time point. The proportion (D) and 
absolute numbers (E) of P2 (Ly6C+MHCII+)   cells per colon at each time point. Results are the 
mean + 1 SD for 4 mice at each time point and are representative of 3 individual experiments.      
(* p<0.05, ** p<0.01, *** p<0.001; One-way ANOVA with Bonferroni’s post tests) 
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94 Figure 3.16: Expansion of Mucosal CX3CR1int Myeloid Cell Numbers During Colitis 
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and the cellular composition 
of the colonic LP CX3CR1int compartment was examined by flow cytometry at d4 and d6 of colitis. 
A. Representative Ly6C and class II MHC expression by live-gated CD45+ CD1 1b + CX3CR1int 
cells obtained from resting mice or d4 or d6 colitic mice.  The proportions (of CX3CR1int cells) and 
absolute numbers of P3 (F4/80+ Ly6Cneg MHCII+) (B) and P5 (CD11c+Ly6CnegMHCII+) (C) at each 
time point. Results are the mean + 1 SD for 4 mice at each time point and are representative of 3 
individual experiments. (* p<0.05, ** p<0.01, *** p<0.001; One-way ANOVA with Bonferroni’s post 
tests) 
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95 Figure 3.17: Effects of Acute Colitis on Colonic CX3CR1high Cells  
CX3CR1+/gfp mice received 2% DSS in their drinking water for 6 days and the cellular composition 
of the colonic LP CX3CR1high compartment was examined by flow cytometry at d4 and d6 of 
colitis. Representative Ly6C and class II MHC expression (A) and F4/80 and CD11c expression 
(B)  by  live-gated  CD45+  CX3CR1high C D 1 1 b +  colonic  LP  leucocytes  at  d4  and  d6  of  colitis 
compared with CX3CR1high CD11b+ LP leucocytes from resting mice. Results are representative of 
3 individual experiments.  
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4.1  Introduction 
  In the previous chapter, I showed that the m! populations of the colon were 
unexpectedly  heterogeneous  comprising  two  main  groups  that  differed  in  the 
expression of CX3CR1. Those with high levels of CX3CR1 dominated the resting 
mucosa, whereas CX3CR1
int cells expanded during colitis. In this chapter, I set out 
to examine the relationship between these cells and their origins. It is generally 
accepted that monocytes are the precursors of most tissue m!. However, this is 
complicated by the fact that the monocyte pool may itself be heterogeneous, with 
a  paradigm  having  arisen  that  distinct  blood  monocyte  populations  replenish 
'resident'  and  'inflammatory'  m!  in  tissues  (12).  According  to  this  idea, 
Ly6C
lowCX3CR1
+ monocytes are believed to migrate to peripheral tissues under 
normal  physiological  conditions  and  repopulate  tissue  resident  m!,  whereas 
Ly6C
highCX3CR1
int monocytes give rise to pro-inflammatory m! in many models of 
inflammation  (12,  22,  25).  A  number  of  studies  have  shown  that  Ly6C
high 
monocytes can repopulate mouse intestine in the absence of overt inflammation 
and  my  initial  studies  identified  for  the  first  time  a  putative  group  of  Ly6C
high 
monocyte-like cells in the resting colon. However this work is difficult to interpret 
because the primary focus was on populations of cells that were defined as 'DC' 
because they were CD11c
+.  As I showed in the previous chapter, most CD11c
+ 
cells in the resting colon appear to be m! and multiple markers are needed to 
distinguish individual MP subsets in the intestine (28, 196). In particular, none of 
the previous work used levels of CX3CR1 expression to define MP subsets.  As a 
result, the origin of resident intestinal m! is not clear and in this chapter, I set out 
to  investigate  directly  whether  monocytes  could  replenish  CX3CR1
int a n d  
CX3CR1
high MP in the resting intestine and to obtain an idea of how these might 
be related.  To do this I used a combination of adoptive transfer and BrdU labelling 
studies. 
4.2  Recruitment of Monocytes to the Resting Intestine 
  I first examined whether Ly6C
high ('inflammatory') and Ly6C
low ('resident') 
monocytes  could  migrate  to  the  intestine  of  unmanipulated  CX3CR1
+/gfp  mice.  
Ly6C
high (CX3CR1
int) or Ly6C
low (CX3CR1
+) monocytes were purified from the BM 
of CX3CR1
+/gfp (CD45.2
+) mice (Fig. 4.1) and transferred into resting CX3CR1
+/gfp 
mice  (CD45.1
+/CD45.2
+)  (Fig.  4.2A)  and  the  recipient  LP  assessed  for  the   99 
presence o f  d o n o r   cells  after  24hrs  (Fig.  4.2B).  At  the  time  of  transfer,  donor 
Ly6C
high monocytes expressed high levels of Ly6C and CD115, but only low levels 
of F4/80
 and lacked expression of CD11c or class II MHC (Fig. 4.1A-C).  On the 
other hand, the transferred Ly6C
low donor monocytes expressed higher levels of 
CX3CR1 and F4/80 than Ly6C
high monocytes, as well as some class II MHC and 
CD11c, but lower levels of CD115 (Fig. 4.1C).  24 hrs after transfer of Ly6C
high 
monocytes into resting mice, very few donor cells could be found in the recipient 
colon, but these were detectable above the background of non-transferred mice 
and  the  majority  had  altered  their  phenotype  from  Ly6C
highMHCII
negF4/80
low t o  
Ly6C
negMHCII
+F4/80
+ and had also upregulated their level of CX3CR1 expression 
(Fig.  4.2C  and  D).  In  contrast,  I  could  not  detect  a  clear  population  CD45.1
+ 
CD45.2
neg donor cells above background in the colon of mice that had received 
Ly6C
low monocytes (Fig. 4.2C and D). Similarly, donor cells in the bloodstream 
were difficult to detect above background staining (Fig. 4.3). 
4.3 Monocyte Recruitment to the Colon Following Diphtheria 
Toxin-Mediated Mononuclear Phagocyte Depletion 
  This preliminary evidence suggested that Ly6C
high monocytes might migrate 
to  the  resting  mucosa  and  give  rise  to  both  CX3CR1
int a n d  C X 3 C R 1
high m !.  
However this experiment was unsatisfactory is several ways. Not only were the 
numbers of donor cells obtained very low and so difficult to analyse, but the use of 
CX3CR1
+/gfp mice as both monocyte donors and as recipients meant that donor 
cells could only be identified on the basis of lacking CD45.1 expression.  This 
proved difficult due to background staining in the PBS control group.   
  Thus,  I  next  took  advantage  of  a  strategy  which  allowed  depletion  of 
resident LP m! in recipient mice in an attempt to enhance the visualisation of 
monocyte  recruitment. T h e  C D 1 1 c -DTR  mouse  has  been  used  extensively  for 
such studies, as they express the human diphtheria toxin receptor under control of 
the CD11c promoter and administration of diphtheria toxin (DT) results in depletion 
of CD11c
+ MP in the intestine without causing significant inflammation (196, 251). 
First  I  characterised  the  effects  of  DT  on  the  LP  MP  subsets  I  had  defined  in 
Chapter 3 by examining the LP CD11b
+ compartment 24hrs after administering 
DT. Due to the lack of CX3CR1-GFP in these mice and the unavailability of a 
reliable  anti-CX3CR1  antibody,  I  had  to  develop  an  alternative  gating  strategy 
which  allowed  me  to  define  LP  myeloid  cell  populations  equivalent  to  those  in   100 
CX3CR1
+/gfp mice (Figure 4.4). First, total CD11b
+ cells were identified from within 
the  CD45
+  live  fraction  of  cells  and  SSC
high  cells  were  gated  out  to  exclude 
eosinophils and any neutrophils. This approach revealed very similar populations 
to those described in Chapter 3, with Ly6C
highMHCII
neg cells (equivalent to P1) and 
Ly6C
+MHCII
+  cells  (equivalent  to  P2)  being  readily  identifiable.  However  the 
F4/80
+MHCII
+Ly6C
negCD11c
neg contained both P3 and P4 subsets, since CX3CR1 
expression is the only distinguishing feature between these subsets (Fig. 4.4A and 
B). In addition, the CD11c
+MHCII
+ Ly6C
negF4/80
neg population is not identical to 
that defined previously as P5, as it will also include additional CD11b
+ DC which 
would  be  CX3CR1
neg  and  thus  usually  excluded  from  the  CX3CR1
int  P5. 
Nevertheless,  with  these  provisos,  it  seemed  possible  to  define  generally 
equivalent  populations  of  MP.  To  confirm  this,  I  applied  the  alternative  gating 
strategy  to  CX3CR1
+/gfp  mice.  This  showed  that  all  Ly6C
highMHCII
neg  cells  and 
Ly6C
+MHCII
+ cells expressed intermediate levels of CX3CR1, whereas the vast 
majority of the F4/80
+MHCII
high cells were identified as CX3CR1
high (Fig. 4.4B). I 
therefore  used  this  strategy  in  all  subsequent  analysis  using  non-CX3CR1
+/gfp 
mice.   
  Administration  of  DT  resulted  in  depletion  of  the  majority  (>85%)  of 
F4/80
+MHCII
+ m! (equivalent to P3+P4), but had little effect on P1 and P2 (Fig. 
4.5A). Interestingly, DT treatment depleted all F4/80
+ m! regardless of their levels 
of CD11c expression and these appeared to be depleted to a greater extent than 
the  CD11c
+F4/80
neg  cells  assumed  to  be  DC  (Fig.  4.5B).  Although  somewhat 
surprising,  this  showed  that  the  CD11c-DTR  system  could  be  used  to  deplete 
resident gut m! and importantly, as P1 and P2 were relatively unchanged, it does 
not seem to affect monocyte recruitment. Therefore I went on to examine the fate 
of  adoptively  transferred  Ly6C
high  BM  monocytes  from  CD45.1
+/CD45.2
+ 
CX3CR1
+/gfp  mice  in  CD11c-DTR  mice
  (CD45.2
+)  that  had  received  DT  24hrs 
previously (Fig. 4.6A). 
   Using this approach, donor cells were easily identifiable on the basis of both 
GFP
 and CD45.1
 expression and were clearly distinct from endogenous CD11c
+ 
cells in the CD11c-DTR recipient mice which expressed GFP under the CD11c 
promoter (Fig. 4.6B). 24hrs after transfer, essentially all donor cells were within the 
CX3CR1
int compartment and expressed variable levels of Ly6C and class II MHC, 
and low levels of F4/80 (Fig. 4.6B and C). However by 96hrs, the vast majority of   101 
donor-derived cells were within the CX3CR1
high fraction and their phenotype had 
changed dramatically. They now lacked Ly6C expression, expressed high levels of 
class II MHC and F4/80 and had increased in size, as determined by an increase 
in  their  FSC  profile  (Fig.  4.6B  and  C).  These  changes  were  specific  to  the 
intestine,  as  donor  cells  that  remained  in  the  bloodstream  did  not  display 
increased  expression  of  F4/80  and  upregulation  of  class  II  MHC  was  only 
moderate (Fig. 4.7A and B). In addition, although Ly6C expression was reduced 
on these circulating donor cells, this was not to the same extent as donor cells in 
the gut. This conversion from the Ly6C
high to Ly6C
low phenotype has been reported 
previously for blood monocytes (29). In parallel, the level of CX3CR1-GFP was 
moderately increased on circulating donor cells at 96hrs (Fig. 4.7A), but again this 
never reached the level expressed by donor m! in the LP. 
  Taken  together  these  results  indicate  that  Ly6C
high  'inflammatory' 
monocytes can replenish CX3CR1
high tissue resident m! following MP cell ablation 
and  suggest  that  this  process  seems  to  involve  the  differentiation  of  Ly6C
high 
monocytes within the mucosa, arriving first as Ly6C
highMHCII
negF4/80
lowCX3CR1
int 
cells  and  subsequently  maturing  into  F4/80
highCX3CR1
high  cells.  This  is 
accompanied by a loss of Ly6C expression, upregulation of class II MHC and an 
increase in size. 
4.4 Analysis of Monocyte Recruitment in CCR2-deficient Mice 
  Although  the  CD11c-DTR  model  is  reported  to  cause  no  significant 
inflammation, the level of resident cell depletion was rather extensive, meaning 
that monocyte behaviour under these circumstances may not truly represent m! 
replenishment during steady state conditions. Thus, to try to mimic steady state 
conditions  more  accurately  I  made  use  of  CCR2-deficient  mice  which  have  a 
dramatic reduction in the frequency of circulating Ly6C
high monocytes (Fig. 4.8A 
and B) due to their high levels of CCR2 (Fig. 4.8C) and the indispensible role of 
CCR2 in BM egress (22).   
  Although CCR2-deficient and WT mice had similar proportions of CD11b
+ 
cells amongst live leucocytes in the colon (Fig. 4.9A and B),  the  absolute  number 
of CD11b
+ cells per colon was significantly lower in CCR2-deficient mice (1.3x10
5 
±  0.2  versus  2.1x10
5  ±  0.4  per  colon  for  CCR2  KO  and  WT  respectively;  Fig.   102 
4.9C).  Within  the  CD11b
+  fraction,  SiglecF
+  (SSC
high)  eosinophils  constituted  a 
larger  proportion  of  CD11b
+  cells  in  CCR2  KO  mice  compared  with  their  WT 
counterparts (32.9±1.0% versus 17.9±3.9%, respectively), although the absolute 
numbers of SiglecF
+ eosinophils were comparable (Fig. 4.10A-C). Similarly, the 
proportions and absolute numbers of Ly6C
intLy6G
+ neutrophils were similar in the 
two strains (Fig. 4.10D and E). 
  Using  the  alternative  gating  strategy  outlined  above  for  non-CX3CR1
gfp 
mice, it was clear that the Ly6C
highMHCII
neg population of SiglecF
negCD11b
+ cells 
(P1) was essentially absent from the colon of CCR2 KO mice (Fig. 4.11A and B).  
There was a similar, but less dramatic reduction in the proportion and absolute 
number of Ly6C
+MHC
+ cells (P2) in CCR2-deficient mice compared with their WT 
counterparts (Fig. 4.11A, D and E). In contrast, the numbers of F4/80
+ class II 
MHC
+ m! were only reduced by approximately 50% in CCR2 KO mice (3.4x10
4 
±0.8 versus 7.0x10
4 ±1.2 per colon, respectively; Fig. 4.12A and B). Interestingly, 
the CD11b
+ DC population (which included the CX3CR1
int DC population as well 
as  CD11b
+CD103
+CX3CR1
neg  DC)  was  also  significantly  reduced  in  CCR2  KO 
mice compared with WT mice (Fig. 4.12D).   
  Antibody  staining  confirmed  CCR2  expression  on  the  Ly6C
high  class  II 
MHC
neg  P1  cells  that  were  absent  in  CCR2  KO  mice.  Unfortunately  it  proved 
impossible  to  determine  whether  the  P2,  P3+4  or  the  CD11b
+  DC  expressed 
CCR2 due to the high background staining of these populations in KO mice (Fig. 
4.12).  
  Having  established  that  CCR2  KO  mice  have  partial  depletion  of 
mononuclear  phagocytes  in  their  colon,  I  next  used  them  as  recipients  of 
adoptively transferred BM monocytes (Fig. 4.13A). Consistent with the results from 
the CD11c-DTR model, donor Ly6C
high monocytes could be found in the colon of 
unmanipulated CCR2 KO recipients within 24hrs of transfer, at which time all were 
CX3CR1
int and around 50% had acquired class II MHC (Fig. 4.13B and C).  By 
48hrs,  almost  90%  of  donor  cells  had  upregulated  class  II  MHC  and  this  was 
accompanied by the loss of Ly6C expression (Fig. 4.13B and C), as well as a 
moderate  increase  in  CX3CR1  expression  (Fig.  4.13D).  As  in  CD11c-DTR 
recipients,  by  96hrs  after  transfer  virtually  all  donor  cells  had  acquired  class  II 
MHC, upregulated F4/80 and now expressed high levels of CX3CR1 (Fig. 4.13D).    103 
Again this phenotypic switch was accompanied by an increase in cell size (FSC) 
(Fig. 4.13D). In a separate experiment, Ly6C
high monocytes were transferred into 
CCR2 KO mice and the presence of donor cells was examined after 7 days.  This 
showed that GFP
+ CD45.1
+/CD45.2
+ cells were still present in the LP of recipient 
CCR2 KO mice after one week, implying that Ly6C
high monocytes can generate 
relatively long-lived CX3CR1
high tissue m! (Fig. 4.14A). At this time point, the vast 
majority (>93%) of donor cells expressed F4/80 and did not seem to have entered 
the F4/80
negCD11c
+ compartment of putative DC (Fig. 4.14B). In addition, all donor 
cells  had  identical  FSC  profiles  to  endogenous  CD11b
+SSC
lowMHC
+  cells, 
indicating that they had matured fully (Fig. 4.14C).   
  Donor cells were also easily identifiable in the bloodstream of CCR2 KO 
recipient mice at all time points as donor monocytes constituted a much greater 
proportion of the total circulating monocyte pool compared with when CD11c-DTR 
mice were used as recipients (Fig. 4.15A). Analysis of donor cells showed that 
although  donor  Ly6C
highCX3CR1
int  monocytes  converted  into  Ly6C
lowCX3CR1
+ 
monocytes  by  48hrs,  these  cells  lacked  class  II  MHC  and  did  not  adopt  the 
CX3CR1
high phenotype seen in the LP (Fig. 4.15B and C). Therefore it is clear that 
donor cells within the LP preparations are not mere blood contaminants.    
  To  examine  whether  differentiation  of  Ly6C
high  'inflammatory'  monocytes 
into CX3CR1
high tissue m! occurred in other mucosal tissues, I examined the lung 
parenchyma of CCR2 KO recipient mice for the presence of donor cells 96hrs after 
transfer. Although donor cells could be identified within the lung preparation, these 
cells were phenotypically indistinguishable from donor cells in the bloodstream and 
because  the  lungs  were  not  perfused,  these  cells  most  likely  reflected  blood 
contaminants (Fig. 4.16A and B). Importantly, unlike in the colon, no CX3CR1
high 
CD45.1
+ cells could be identified in the lung, again emphasising the gut specific 
nature of Ly6C
high monocyte maturation (Fig. 4.16C).  
  In  all  the  adoptive  transfer  experiments  detailed  above,  I  noted  that  the 
phenotype of circulating donor cells changed with time from Ly6C
high (CX3CR1
int) 
to  Ly6C
low  (CX3CR1
+)  monocytes,  a  phenomenon  that  has  been  reported 
previously (29). Therefore it is possible that the Ly6C
high donor cells could first 
convert into Ly6C
low monocytes in the circulation or BM and provide a second 
wave of precursors of colonic m! at later times. My attempt to transfer Ly6C
low   104 
monocytes into resting WT mice had been complicated by the low numbers of 
donor cells I could find in the colon and by the fact that the 24hr time point I used 
in that experiment would not be sufficient to allow full conversion into resident m!. 
Therefore  I  decided  to  repeat  the  transfer  of  Ly6C
low  monocytes  using  CCR2-
deficient mice as recipients. However as before, donor-derived Ly6C
low monocytes 
could not be found in the LP of recipient mice 96hrs after transfer, despite forming 
a clear population in the circulation at this time (Fig. 4.17A-C).  Therefore, it seems 
unlikely  that  Ly6C
low  monocytes  derived  from  donor  Ly6C
high  monocytes 
repopulate the gut m! pool.  
  Taken together these adoptive transfer experiments demonstrate that so-
called  'inflammatory'  monocytes  appear  to  enter  the  intestinal  mucosa  and 
undergo  a  step-wise  differentiation  process  into  CX3CR1
high m !  through  a 
CX3CR1
int intermediary stage. In contrast, Ly6C
low monocytes play little or no role 
in  the  homeostasis  of  the  intestinal  m!  compartment  during  steady  state 
conditions.   
4.5 Population Dynamics of Intestinal Macrophages In Situ 
  The  adoptive  transfer  studies  suggested  that  newly  arrived  Ly6C
high 
monocytes might be able to mature into CX3CR1
high resident m! through a series 
of  transitional  stages.  I  next  examined  whether  I  could  find  evidence  for  a 
relationship  between  these  subsets  in  situ.  To  do  this,  I  first  used  BrdU 
incorporation  in  vivo  to  track  the  turnover  and  kinetics  of  the  CX3CR1-defined 
populations I had defined phenotypically. 
  Mice were injected intraperitoneally with a single dose of BrdU and 3hrs 
later approximately 25% of the Ly6C
high monocytes in the BM were labelled (Fig. 
4.18A  and  B),  consistent  with  them  being  derived  from  actively  dividing  pro-
monocytes (11). In contrast, no Ly6C
high blood monocytes were labelled at this 
time (Fig. 4.18C and D), consistent with their known non-cycling status (11, 12).  
Similarly,  after  3hrs,  no  BrdU
+  cells  were  present  in  any  of  the  LP  CX3CR1
+ 
populations (Fig. 4.19A-D).  12hrs after the single pulse of BrdU, around 60% of 
Ly6C
high monocytes in the BM were BrdU
+, as were 35% of Ly6C
high monocytes in 
blood, confirming exit from the BM within this period. There were still very few 
BrdU
+ cells within the CX3CR1
+ populations in the colon at this time, with P2, P3   105 
and P4 cells showing no uptake over background staining. However, 4.7±1.6% 
BrdU
+ cells were detectable in P1 (Fig. 4.19A), suggesting that within the 12hr 
time frame, Ly6C
high monocytes had left the BM and migrated to the gut via the 
bloodstream.   
  These  results  support  my  earlier  conclusions  that  the  Ly6C
highMHCII
neg 
CX3CR1
int cells I identified in P1 are closely related to blood monocytes and are 
the  earliest  stage  of  colonic  m! d e v e l o p m e n t .   To  examine  the  kinetics  of t h e  
intestinal  m!  subsets  in  more  detail,  I  used  a  long-term  BrdU  administration 
protocol, in which mice received a single intraperitoneal injection of BrdU followed 
by BrdU in their drinking water for 6 consecutive days, before being returned to 
normal drinking water.     
  After  4  days  of  continual  BrdU  administration,  over  75%  of  the 
Ly6C
highMHCII
negCX3CR1
int cells (P1) in the colon were BrdU
+, as were Ly6C
high 
monocytes in blood, again supporting the close relationship between these cells 
(Fig. 4.20A). A similar frequency of BrdU
+ cells was seen among Ly6C
high colonic 
monocytes  after  6  days  of  BrdU  administration,  indicating  these  were  maximal 
levels (Fig. 4.20B). When BrdU was withdrawn, the frequency of BrdU
+ cells within 
P1 and amongst blood monocytes fell rapidly to baseline by 4 days (Fig. 4.20B). 
The  colonic  Ly6C
+MHCII
+CX3CR1
int  cells  in  P2  also  contained  high  levels  of 
BrdU
+ cells (~50% BrdU
+) which were maximal after 4 days of administration, but 
in this case, the peak of BrdU uptake was maintained for 2 days after removal of 
BrdU, before decaying rapidly thereafter. The frequency of BrdU-labelled cells in 
the Ly6C
negMHCII
+CX3CR1
int population (P3) lagged behind that in P1 and P2, 
only  reaching  its  peak  2  days  after  cessation  of  BrdU  administration  and  then 
falling  rapidly  in  parallel  (Fig.  4.20B). I n  comparison,  the  proportion  of  BrdU
+ 
CX3CR1
high m! increased much more gradually during BrdU administration and 
unlike  the  other  subsets,  this  level  was  maintained  until  at  least  4  days  after 
withdrawal of BrdU. Notably, although the proportion of BrdU
+ cells in P4 at each 
time  point  was  significantly  lower  than  those  in  P1-3,  the  absolute  number  of 
BrdU
+CX3CR1
high cells was significantly higher, suggesting that BrdU
+ cells were 
accumulating in this compartment (Fig. 4.20C).  
  Together  these  data  support  the  idea  that  the  different  populations  of 
CX3CR1
int  cells  identified  in  resting  colon  are  short-lived  intermediaries  that   106 
represent  progressive  and  in  situ  differentiation  of  a  recently  derived  Ly6C
high 
monocyte, whose fate is to become a CX3CR1
high resident m!. 
4.6 Effects of CSF-1 on Colonic Macrophage Development In 
Vivo 
  To  explore  this  further,  I  examined  the  effects  of  CSF-1  in  vivo,  as  this 
cytokine  in  known  to  drive  differentiation  of  mature  m!  from  monocytes  (41). 
CX3CR1
+/gfp mice were injected i.p. with rhCSF-1 for 4 consecutive days and the 
proportions  and  absolute  numbers  of  the  colonic  CX3CR1
+  populations  were 
enumerated (Fig. 4.21). Treatment with CSF-1 did not cause as dramatic effects 
on the number of LP myeloid populations as flt3L did for DC which was carried out 
in parallel (Chapter 3). However there was a significant increase in the absolute 
numbers of CX3CR1
high m! and this was paralleled, by a modest decrease in the 
numbers of cells in P1 and P2 (Fig. 4.21B-F). The relatively higher responsiveness 
of  CX3CR1
high  cells  to  CSF-1  correlated  with  them  having  the  highest  level  of 
expression  of  the  CSF-1R  (CD115)  amongst  the  colonic  m!  subsets,  as 
determined by qRT-PCR (Fig. 4.21G). While these results need to be confirmed, 
they  would  be  consistent  with  the  idea  that  CSF-1  responsive  monocytes  can 
differentiate into CX3CR1
high m! in the colonic mucosa under the control of CSF-1.  
4.7 Differentiation of Monocytes In Vitro 
  Next,  I  attempted  to  investigate  whether  Ly6C
high  monocytes  could  be 
persuaded to differentiate into the equivalent of mucosal CX3CR1
high m! in vitro as 
this would allow me to explore the factors that might be involved. To this end, LP 
Ly6C
highMHCII
neg cells in P1 were FACS-purified from resting CX3CR1
+/gfp mice 
and I examined whether their phenotype changed after 24hrs culture in vitro.  As 
shown in Figure 4.22A, these cells upregulated class II MHC after culture, but 
remained  Ly6C
+CX3CR1
int  and  so  were  similar  to  P2  cells.  Due  to  the  poor 
viability of the purified LP monocytes in culture, I was unable to study later time 
points to examine whether further differentiation might occur in vitro.  
  I then tried to overcome these difficulties by using Ly6C
high monocytes from 
BM.  FACS-purified BM monocytes cultured alone did not upregulate class II MHC 
or CX3CR1, nor did they upregulate CX3CR1 when cultured with rTGF!, CSF-1 or 
CX3CL1  (FKN)  (Fig.  4.22B),  all  factors  abundant  in  the  normal  mucosa  which   107 
have been reported to influence m! differentiation (179, 202, 255). Due to these 
negative  results  and  the  technical  difficulties  associated  with  culturing  purified 
colonic cell in vitro, I decided not to pursue this approach further. 
4.8 Examining for the Presence of Radio-resistant Intestinal 
Macrophages 
  Thus far, my experiments have concentrated on the idea that colonic m! 
are  derived  from  BM  monocytes.  However,  there  is  growing  evidence  that  all 
organs have a population of m! derived directly from embryonic precursors that 
seed  the  tissues  prior  to  the  establishment  of  the  circulatory  system  and  are 
maintained  through  in  situ  proliferation  rather  than  being  replenished  by 
monocytes (256). Such non-BM derived m! include Langerhans cells in skin and 
microglia  in  the  CNS  (57,  60),  and  interestingly  they  appear  to  be  relatively 
unaffected by CCR2-deficiency (257), unlike some resident colonic m!. 
  An  opportunity  arose  for  me  to  address  the  possible  presence  of  BM 
independent,  radioresistant  m!  using  CD45.1/CD45.2  !  CD45.2  BM  chimeric 
mice generated by another research group within the department.  Consistent with 
them being derived from BM monocytes, colonic Ly6C
highMHCII
neg cells in these 
mice were entirely of donor origin (CD45.1
+/CD45.2
+), as were all the cells in P2 
and  the  CD11b
+  DC  (Fig.  4.23).  In  contrast,  5-7%  of  the  F4/80
+MHCII
high 
population of m! were of host origin in both mice 8 weeks after irradiation and 
these cells were phenotypically indistinguishable from the donor derived cells in 
this population (Fig. 4.23B and 4.24). 
  Whilst  the  results  of  this  experiment  need  to  be  confirmed  with  larger 
experimental groups at different time points following irradiation and reconstitution, 
they would appear to indicate that although there is a population of truly resident 
m! in the colonic mucosa, they form a much smaller population than that in other 
tissues such as the skin and brain. This underlines my earlier conclusions that the 
gut m! pool is mostly replenished from blood monocytes.  
4.9 Summary 
  In this chapter I explored the in vivo origins of CX3CR1
int and CX3CR1
high 
LP  populations  to  assess  whether  they  represent  discrete  populations  of  pro-  108 
inflammatory  and  resident  m!.  Using  a  combination  of  adoptive  transfer 
experiments and BrdU incorporation studies, I was able to show that rather than 
representing  independent  subsets  of  m!,  the  CX3CR1
int a n d  C X 3 C R 1
high 
compartments  appear  to  represent  cells  at  different  stages  of  an  in  situ 
differentiation  continuum  of  Ly6C
high  monocytes  into  tissue  m!.  BM  chimera 
studies  also  confirmed  the  monocyte  origin  of  the  vast  majority  of  colonic  m!.  
Together  these  studies  indicate  that  the  maintenance  of  the  intestinal  m! 
compartment  during  steady  state  conditions  is  not  compatible  with  the  current 
monocyte  paradigm  which  proposes  that  distinct  blood  monocytes  repopulate 
independent m! populations, since Ly6C
low 'resident' monocytes were unable to 
repopulate the mucosa.  Instead these data show that under normal physiological 
conditions  so-called  'inflammatory'  Ly6C
high  monocytes  constitutively  enter  the 
colonic mucosa and subsequently undergo a differentiation/maturation programme 
to become resident CX3CR1
high m!. Unfortunately I was unable to replicate this 
differentiation process in vitro, but in the next chapter, I went on to examine the 
functional implications of the transitional process I had uncovered. 
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Figure 4.1: Purification of Bone Marrow Monocytes 
BM  cells  were  isolated  from  CX3CR1+/gfp  (CD45.1+/CD45.2+  or  CD45.1neg/CD45.2+)  mice  and 
single cells analysed for the expression of CD11b, Ly6G, CD117 (c-kit), Ly6C and CX3CR1-GFP 
by flow cytometry.  A. CD11b+ cells were selected and Ly6G+ and CD117+ cells were gated out to 
exclude  neutrophils  and  early  haematopoietic  progenitors,  respectively.  B. C D 1 1 b +Ly6Gneg 
CD117neg  cells  were  then  examined  for  Ly6C  and  CX3CR1  expression  to  allow  sorting  of 
Ly6ChighCX3CR1int  ‘inflammatory’  and  Ly6ClowCX3CR1+  ‘resident’ monocytes.  C.  Expression  of 
F4/80,  class  II  MHC,  CD11c  and  CD115  on  Ly6Chigh ( upper  panel)  and  Ly6Clow ( lower  panel) 
monocytes. Representative of at more than 10 individual experiments. 
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 Figure 4.2: Adoptive Transfer of Bone Marrow Monocytes into Resting Mice 
A.  2x106  purified  Ly6Chigh  BM  monocytes  or  1x106  Ly6Clow  BM  monocytes  from  CX3CR1+/gfp 
CD45.2+  mice  were  transferred  into  unmanipulated C D 4 5 . 1 +/CD45.2+  CX3CR1+/gfp  mice.  B. 
Representative dot plots of CD45.1 and CD45.2 expression on live-gated CD45+ CD11b+ cells in 
the colon of recipients given PBS (left panel), Ly6Clow monocytes (middle panel) and Ly6Chigh 
monocytes  (right  panel)  24hrs  after  transfer.  Expression  of  F4/80  and  class  II  MHC  (C)  and 
CX3CR1-GFP  (D)  by  CD45.1negCD45.2+  cells  from  different  recipients.  1  experiment  with  2 
recipient mice per group. 
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Figure 4.3: Adoptively Transferred BM Monocytes in Bloodstream of Resting Mice 
A. 2x106 purified Ly6Chigh BM monocytes or 1x106 Ly6Clow BM monocytes from CX3CR1+/gfp 
CD45.2+  mice  were  transferred  into  unmanipulated C D 4 5 . 1 +/CD45.2+  CX3CR1+/gfp  mice.  B. 
Representative dot plots of CD45.1 and CD45.2 expression on live-gated CD45+ CD11b+ cells in 
the blood of recipients given PBS (left panel), Ly6Clow monocytes (middle panel) and Ly6Chigh 
monocytes (right panel) 24hrs after transfer. 1 experiment with 2 recipient mice per group. 
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Figure 4.4: Alternative Gating Strategy for Identifying Colonic MP Subsets in Non-
CX3CR1-GFP Mice 
Colonic LP cells were isolated from C57Bl/6 mice and live-gated CD45+ cells analysed for the 
expression of CD11b, F4/80, Ly6C, MHC class II and CD11c by flow cytometry.  A. SSChigh cells 
were gated out to exclude granulocytes (eosinophils and neutrophils) and the expression of Ly6C 
and class II MHC determined on SSClow cells.  Ly6CnegMHCII+ cells were then assessed for the 
expression of F4/80 and CD11c. B. Expression of CX3CR1-GFP by the indicated populations 
obtained by applying the alternative gating strategy to CX3CR1+/gfp mice.  
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Gated: Live CD45+ Figure 4.5: Ablation of Colonic MP Cells in CD11c-DTR Mice 
CD11c-DTR mice were injected with DT (4ng/g bodyweight) or not and 24hr later colonic LP cells 
were isolated. A. Representative dot plots of Ly6C and class II MHC expression by live-gated 
CD45+ CD1 1b + SSClow cells. B.   Representative dot plots of F4/80 and CD11c expression by 
Ly6CnegMHCII+  cells,  highlighting  the  depletion  of  both  F4/80+  macrophages  and  CD11c+ DC. 
Representative of 2 individual experiments. 
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B Figure 4.6: Accumulation of Transferred BM Monocytes in Colon of Depleted  
CD11c-DTR Mice 
A.  CD11c-DTR  (CD45.2+)  mice  were  injected  with  DT  and  24hr  later  received  2x106  purified 
Ly6Chigh BM monocytes from CD45.1+/CD45.2+ CX3CR1+/gfp mice. B. Representative dot plots of 
CD45.1 and GFP expression by live-gated CD45+ CD11b+ LP cells in the recipients given PBS 
(left panel), or receiving BM monocytes 24hr (middle panel) and 96hr before (right panel).   C. 
Expression of Ly6C, class II MHC, F4/80 and FSC on donor-derived CD45.1+GFP+ cells at 24hrs 
(red line) and 96hr (blue lines). Shaded histograms represent staining with appropriate isotype 
controls. CD45.1negGFP+ cells in (B) represent endogenous CD11c+ cells from the CD11c-DTR-
GFP mice. 1 experiment with 2 recipient mice per group. 
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Figure 4.7: Presence of Transferred BM Monocytes in Blood of Depleted CD11c-DTR 
Mice 
CD11c-DTR (CD45.2+) mice were injected with DT and 24hr later received 2x106 purified Ly6Chigh 
BM monocytes from CD45.1+/CD45.2+ CX3CR1+/gfp mice. A. Representative dot plots of CD45.1 
and GFP expression by live-gated CD45+ CD11b+ blood leucocytes in the recipients given PBS 
(left panel), or receiving BM monocytes 24hr (middle panel) and 96hr before (right panel).   B. 
Expression of Ly6C, class II MHC, F4/80 and FSC on donor-derived CD45.1+GFP+ cells at 24hrs 
(red line) and 96hr (blue lines). Shaded histograms represent staining with appropriate isotype 
controls. CD45.1negGFP+ cells in (B) represent endogenous CD11c+ cells from the CD11c-DTR-
GFP mice. 1 experiment with 2 recipient mice per group. 
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 Figure 4.8: Circulating Ly6Chigh Monocytes in CCR2 KO Mice 
Whole blood was obtained from resting WT or CCR2 KO mice and red blood cells lysed. The 
remaining cells were analysed for the expression of CD11b, Ly6C and CD115 by flow cytometry. 
A. Representative dot plots of Ly6C and CD115 expression by WT and CCR2 KO live-gated 
CD45+ CD11b+ blood leucocytes and (B) the mean frequency of Ly6Chigh blood monocytes within 
the CD11b+ cell fraction. C. Expression of CCR2 by Ly6Chigh blood monocytes from WT and 
CCR2 KO mice as determined by flow cytometry. Results shown are the means + 1SD for 3-4 
mice/group and are representative of 2 individual experiments. (*** p<0.001 Student’s t test) 
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 Figure 4.9: CD11b+ Myeloid Cell Compartment in Colon of CCR2 KO Mice 
Colonic LP cells were isolated from resting WT or CCR2 KO mice and live-gated CD45+ cells 
were analysed for the expression of CD11b by flow cytometry.   A. Representative dot plots of 
CD11b  expression  on  WT  and  CCR2  KO  LP  cells.  B.  The  mean  proportion  of  CD11b+  cells 
amongst live CD45+ cells. C. The absolute number of CD11b+ live cells per colon. Results shown 
are the means + 1SD for 3-4 mice/group and are representative of 3 individual experiments.         
(* p<0.05 Student’s t test) 
B  C 
A 
FSC 
C
D
1
1
b
 
WT CCR2 KO
0
10
20
30
40
%
 
C
D
1
1
b
+
 
o
f
 
C
D
4
5
+
 
v
i
a
b
l
e
 
c
e
l
l
s
WT CCR2 KO
0.0
0.5
1.0
1.5
2.0
2.5
*
A
b
s
o
l
u
t
e
 
n
u
m
b
e
r
 
o
f
 
C
D
1
1
b
+
 
l
i
v
e
c
e
l
l
s
 
p
e
r
 
c
o
l
o
n
 
(
x
1
0
5
)
WT  CCR2 KO 
16.9  18.4 
Gated: Live CD45+  
117 Figure 4.10: Eosinophils and Neutrophils in the Colon of CCR2 KO Mice 
Colonic LP cells were isolated from resting WT or CCR2 KO mice and live-gated CD45+ CD11b+ 
cells analysed for the presence of SiglecF+ eosinophils and Ly6Cint(Ly6G+) neutrophils by flow 
cytometry. A. Representative dot plots of SiglecF expression on WT and CCR2 KO CD11b+ LP 
cells and FSC and SSC profile of SiglecF+ and SiglecFneg cells. The percentage (B) and absolute 
numbers (C) of SiglecF+ eosinophils per colon. The percentage (D) and absolute numbers (E) of 
neutrophils  per  colon.  Results  shown  are  the  means  +  1SD  for  3-4  mice/group  and  are 
representative of 3 individual experiments. (** p<0.01 Student’s t test) 
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)Figure 4.11: Intestinal Myeloid Compartment in CCR2 KO Mice 
Colonic LP cells were isolated from resting WT or CCR2 KO mice and live-gated CD45+ CD11b+ 
SiglecFnegLy6Gneg  cells  were  analysed  for  the  expression  of  Ly6C  and  class  II  MHC  by  flow 
cytometry. A. Representative dot plots of Ly6C and class II MHC expression on WT and CCR2 
KO CD11b+ LP cells. The percentage (B) and absolute number (C) of live Ly6C+MHC IIneg cells 
(P1) and the percentage (D) and absolute number (E) of Ly6C+MHC II+ (P2) cells per colon. 
Results shown are the means + 1SD for 3-4 mice/group and are representative of 3 individual 
experiments. (* p<0.05, ** p<0.01, *** p<0.001 Student’s t test) 
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Figure 4.12: Intestinal Myeloid Compartment in CCR2 KO Mice 
A. Colonic LP cells were isolated from resting WT or CCR2 KO mice and live-gated CD45+ 
CD11b+ SiglecFnegLy6Gneg cells were analysed for the expression of Ly6C and class II MHC and 
then Ly6CnegMHCII+ cells analysed for the expression of F4/80. The absolute numbers of (B) 
F4/80+MHCII+ (P3+P4) cells and (C) F4/80negMHCII+ cells (CD11b+DC) per colon. D. Histograms 
show the expression of CCR2 by the indicated populations obtained from resting CX3CR1+/gfp 
(black line) or CCR2 KO (red line) mice.  Shaded histograms represent staining with the isotype 
control. Results shown are the means + 1SD for 3-4 mice/group and are representative of 3 
individual experiments. (* p<0.05, ** p<0.01, *** p<0.001 Student’s t test) 
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Figure 4.13: Accumulation of Transferred BM Monocytes in Colon of CCR2 KO Mice 
A.  CCR2  KO  (CD45.2+)  mice  received  2x106  purified  Ly6Chigh  BM  monocytes  from  CD45.1+/
CD45.2+ CX3CR1+/gfp mice. B. Representative dot plots of CD45.1 and GFP expression by live-
gated CD45+ CD11b+ LP cells in the recipients given PBS, or receiving BM monocytes 24hrs, 
48hrs and 96hrs before.   C. Expression of Ly6C and class II MHC by live-gated CD45+CD11b
+SSClow cells from WT mice or by CD45.1+GFP+ donor cells at the indicated time points after 
transfer. D. Expression of F4/80, CD11c, CX3CR1-GFP and FSC on donor-derived CD45.1+GFP+ 
cells at 24hrs (red line), 48hrs (blue line) and 96hrs (black line). Representative of 2 experiments 
with 2 recipient mice per group. 
121 Figure 4.14: Ly6Chigh Monocytes Give Rise to Long-lived CX3CR1high Macrophages in 
CCR2 KO Colon 
CCR2 KO (CD45.2+) mice received 2x106 purified Ly6Chigh BM monocytes from CD45.1+/CD45.2+ 
CX3CR1+/gfp mice and the presence of donor cells was analysed after 7 days. A. Representative 
dot plots of CD45.1 and GFP expression by live-gated CD45+ CD1 1b + LP cells in the recipients 
receiving  PBS  or  BM  monocytes  7  days  before.  B.  Expression  of  F4/80  and  CD11c  by           
CD11b+SSClowMHCII+ recipient cells (left panel) compared with donor-derived CD45.1+GFP+ cells 
(right panel). C. FSC profile of CD11b+SSClowMHCII+ recipient cells (grey) compared with donor-
derived  CD45.1+GFP+  cells  (black).  Representative  of  2  experiments  with  2  recipient  mice  per 
group.  
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 Figure 4.15:Presence of Adoptively Transferred Ly6Chigh Monocytes in Blood of CCR2 
KO mice 
CCR2 KO (CD45.2+) mice received 2x106 purified Ly6Chigh BM monocytes from CD45.1+/CD45.2+ 
CX3CR1+/gfp mice and the presence of donor cells in the blood was analysed 24hrs, 48hrs and 
96hrs later. A. The proportion of donor-derived cells (CX3CR1-GFP+) amongst Ly6Chigh monocytes 
24hrs  after  transfer  into  DT-treated  CD11c-DTR  mice  or  unmanipulated  CCR2  KO  mice.  B. 
Representative  dot  plots  of  CD45.1  and  GFP  expression  by  live-gated  CD45+  CD11b+  blood 
leucocytes in the CCR2 KO recipients receiving PBS or BM monocytes 24hrs, 48hrs and 96hrs 
before.  C. Expression of Ly6C and class II MHC by CD45.1+GFP+ donor cells at the indicated time 
points after transfer. Representative of 2 experiments with 2 recipient mice per group. 
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123 Figure 4.16: Comparison of Fate of Donor Derived Monocytes in Different Tissues of 
CCR2 KO Mice 
CCR2 KO (CD45.2+) mice received 2x106 purified Ly6Chigh BM monocytes from CD45.1+/CD45.2+ 
CX3CR1+/gfp mice and the presence of donor cells in the blood, lung parenchyma and colonic LP 
was analysed 96hrs later. A. Representative dot plots of CD45.1 and CX3CR1-GFP expression by 
live-gated CD45+ CD11b+ cells from each tissue from recipients receiving PBS or BM monocytes 
96hrs before.   B. Expression of Ly6C and MHC II on donor-derived CD45.1+CX3CR1+ cells. C. 
Comparison of CX3CR1-GFP levels of donor cells retrieved from each tissue. 1 experiment with 2 
mice per group. 
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124 Figure 4.17: Adoptive Transfer of Ly6Clow Monocytes into Resting CCR2 KO Mice 
A.  CCR2  KO  (CD45.2+)  mice  received  1x106  purified  Ly6Clow  BM  monocytes  from  CD45.1+/
CD45.2+ CX3CR1+/gfp mice and the presence of donor cells in the blood and colonic LP assessed 
96hrs  later.  Representative  dot  plots  of  CD45.1  and  CX3CR1-GFP  expression  by  live-gated 
CD45+ CD11b+ (B) blood leucocytes and (C) colonic LP cells in the recipients receiving PBS or 
BM monocytes 96hrs before. 1 experiment with 1 mouse per group. 
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Figure 4.18: Short Term BrdU Incorporation by Bone Marrow and Blood Monocytes 
CX3CR1+/gfp mice received 1mg BrdU by i.p. injection and the incorporation of BrdU by BM and 
blood monocytes was examined after 3 and 12hrs by flow cytometry.   A. Representative BrdU 
staining  on  live-gated  CD45+CD11b+Ly6ChighCX3CR1int  BM  monocytes  at  the  indicated  time 
points. B. The mean frequency of BrdU+ cells within the CD11b+Ly6ChighCX3CR1int BM monocyte 
population  at  3  and  12  hrs.  C.  Representative  BrdU  staining  on  live-gated  CD45+CD11b
+Ly6ChighCX3CR1int  blood  monocytes  at  the  indicated  time  points.  D. The  mean  frequency  of 
BrdU+ cells within the CD11b+Ly6ChighCX3CR1int blood monocytes population at 3 and 12 hrs.  
Background staining was determined by comparison of the BrdU staining of non-injected control 
cells. Representative of 2 individual experiments with 4 mice/group. (* p<0.05, ** p<0.01, *** 
p<0.001 Student’s t test) 
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Figure 4.19: Short Term BrdU Incorporation by Colonic Macrophage Subsets 
CX3CR1+/gfp mice received 1mg BrdU by i.p. injection and the incorporation of BrdU by live-gated 
CD45+  colonic  LP  CX3CR1+  subsets  (P1  to  P4)  was  examined  after  3  and  12hrs  by  flow 
cytometry. Representative BrdU staining and the mean frequency of BrdU+ cells within (A) P1, (B) 
P2, (C) P3 and (D) P4 at 3 and 12hrs compared with non-injected controls (con). Background 
staining was determined by the comparison of BrdU staining of non-injected control cells. Results 
are representative of 2 individual experiments and show the means + 1SD for 4 mice/group.  
(** p<0.01 Student’s t test) 
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127 Figure 4.20: Long Term BrdU Incorporation by Colonic Macrophage Subsets 
CX3CR1+/gfp mice received 1mg BrdU by i.p. injection, followed by 0.8mg/ml BrdU in their drinking 
water for six days and the incorporation of BrdU by CX3CR1+ populations (P1-P4) in the colon was 
examined  by flow cytometry.  A. Representative BrdU staining by colonic m! subsets and Ly6Chigh 
blood monocytes at d4 of BrdU administration. B. The mean frequency of BrdU+ cells within P1, 
P2, P3 and P4 at the indicated time points. C. Absolute number of BrdU+ cells within P1 to P4 after 
4 days of continuous BrdU administration. Results shown are the means ± 1SD for 3 mice/group 
and are representative of a single experiment. (* p<0.05 one-way ANOVA followed by Bonferoni’s 
multi-comparison post-test)  
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128 Figure 4.21: Effects of CSF-1 Administration on Colonic Macrophage Subsets 
CX3CR1+/gfp mice received 20,000 units/day of recombinant human CSF-1 i.p. for 4 consecutive 
days and the numbers of colonic m! determined by flow cytometry. A. Representative dot plots of 
CD11b and CX3CR1-GFP expression by live-gated CD45+ cells from the colon of resting (left 
panel) and CSF-1 treated (right panel) mice. B-F. The absolute numbers of P1-P5 after CSF-1 
treatment compared with resting CX3CR1+/gfp mice (data from Figure 3.9). Results shown are the 
mean number of cells per colon ± 1SD and are representative of a single experiment. (* p<0.05, 
Student’s t test) G. Levels of mRNA expression by P1-P4 for CD115 (CSF-1R) were analysed by 
qRT-PCR. Results shown are mean expression relative to Cyclophilin A using the 2-䂴C(t) method.  
The mean was obtained from two independent experiments using cells pooled from eleven/twelve 
mice. Primer sequences detailed in Table 2.4.  
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Figure 4.22: Effects of Culture of Colonic and BM Monocytes In Vitro 
A. Colonic Ly6ChighMHCIInegCX3CR1int (P1) cells and Ly6Chigh BM monocytes were FACS-purified 
from resting CX3CR1+/gfp mice and cultured overnight in medium and the levels of class II MHC 
and CX3CR1-GFP were examined by flow cytometry after 24hrs. B. FACS-purified Ly6Chigh BM 
monocytes  were  cultured  overnight  in  10ng/ml  TGF",  50ng/ml  CX3CL1  (FKN)  or  20%  L929 
fibroblast  cell  line  supernatant  (CSF-1)  and  the  level  of  CX3CR1-GFP  was  assessed  by  flow 
cytometry. Representative of 2 individual experiments. 
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 Figure 4.23: Radio-resistant Macrophages in the Colonic Mucosa 
C57BL/6  mice  (CD45.2)  were  irradiated  and  reconstituted  with  1x107  total  BM  cells  from 
CD45.1+/CD45.2+ C57BL/6 mice by intravenous infusion and 8 weeks later colonic LP myeloid 
cell subsets were examined for expression of CD45.1 and CD45.2. A. Representative dot plots 
showing the gating strategy adopted. B. Total live-gated cells were examined for the proportion of 
cells of host (CD45.2) and donor (CD45.1/CD45.2) origin within the P1, P2, P3+4 and CD11b+ 
DC populations.  Plots show the staining from each mouse examined compared with staining with 
the isotype control for CD45.1. Representative of 1 individual experiment with 2 mice. 
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131 Figure 4.24: Radio-resistant Macrophages in the Colonic Mucosa are Phenotypically 
Indistinguishable from BM-derived Resident Colonic Macrophages 
C57BL/6 mice (CD45.2) were irradiated and reconstituted with 1x107 total BM cells from CD45.1+/
CD45.2+ C57BL/6 mice by intravenous infusion and 8 weeks later live-gated colonic LP cells were 
examined by flow cytometry. Host-derived (CD45.2; red) cells were analysed for expression of 
F4/80, class II MHC and CD11c, and overlaid on the donor-derived cells (CD45.1/CD45.2; grey). 
Representative of 1 individual experiment with 2 mice. 
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5.1  Introduction 
  Like  most  tissue  m!,  intestinal  m!  are  highly  specialised  to  meet  the 
requirements  of  their  local  environment.  Previous  studies  have  shown t h a t  
intestinal  m!  display  selective  functional  inertia,  whereby  they  are  avidly 
phagocytic and express class II MHC, but phagocytosis or TLR stimulation does 
not lead to the production of pro-inflammatory mediators (171, 179). The extended 
and  more  rigorous  phenotypic  analysis  I  developed  in  the  preceding  chapters 
revealed  unsuspected  heterogeneity  amongst  the  resident  m! p o p u l a t i o n  i n  
healthy  mouse  colon.  Some  of  the  populations  of  cells  I  defined  had  the 
characteristics  of  blood  monocytes  and  their  immediate  descendants. 
Furthermore,  in  contrast  to  current  ideas  of  monocyte  heterogeneity,  I 
demonstrated  that  under  physiological  conditions,  'inflammatory'  Ly6C
high 
monocytes  can  replenish  the  entire  resident m !  population  through  an  in  situ 
differentiation process, involving the loss of Ly6C and the upregulation of class II 
MHC, CD11c, F4/80 and CX3CR1. As these results could suggest the presence of 
pro-inflammatory  cells  in  the  steady  state  colon,  in  this  chapter  I  set  out  to 
investigate whether changes in functional capacity accompanied the differentiation 
process implied by phenotypic characterisation.   
5.2  Baseline Cytokine Production by LP Myeloid Subsets 
  First,  I  examined  the  ability  of  the  CX3CR1-defined  subsets o f  M P  t o  
produce TNF! and IL10 as representative pro- and anti-inflammatory cytokines 
respectively. To do this, I established a method for intracellular cytokine staining 
that was sufficiently reproducible and sensitive for use with intestinal cells. This 
involved adapting standard protocols for the detection of intracellular cytokines in 
an attempt to prevent the colonic m! from adhering to the culture plates, as I found 
this impaired cell retrieval and viability. I found the optimal method was to incubate 
colonic LP digests in non-adherent polystyrene (FACS) tubes in the absence of 
mitogens such as PMA or ionomycin. This allowed me to measure spontaneous 
cytokine levels. 
  Colonic  LP  cells  from  CX3CR1
+/gfp  mice  were  isolated  and  incubated 
together with brefeldin A (BFA) and monensin and the presence of intracellular 
TNF! and IL10 was assessed by flow cytometry.  All F4/80
+ CX3CR1
+ populations   135 
in P1 to P4 produced both TNF! and IL10 under baseline conditions, but there 
were  marked  differences  in  the  pattern  of  cytokines  produced  by t h e  d i f f erent 
subsets.  In  particular,  the  proportion  of  cells  producing  IL10  alone  increased 
progressively from the Ly6C
high monocyte stage (P1) to the CX3CR1
high m! (P4) 
(Fig. 5.1). Conversely, the frequency of cells producing TNF! alone decreased 
significantly as the cells differentiated (Fig. 5.1). Surprisingly, cells producing both 
TNF! and IL10 were found in all populations, particularly after cells had left the 
Ly6C
highMHCII
negCX3CR1
int  (P1)  stage.  As  a  result,  72.4±2.9%  of  cytokine 
producing  CX3CR1
high m "  were  positive  for  IL10  either  alone  or  together  with 
TNF!, and only 27.6±3.0% produced TNF! alone.  In contrast, 79.5±3.7% of the 
Ly6C
highMHCII
negCX3CR1
int  monocytes  (P1)  produced  TNF!  alone,  or  together 
with IL10, while only 20.6±3.7% produced IL10 alone (Fig. 5.1C).  
  To confirm the progressive switch towards IL10 production that occurred as 
colonic m" differentiated from Ly6C
high monocytes, I next took advantage of IL10 
reporter mice (VertX mice; (252)) to assess constitutive expression of IL10 without 
the  need  for  any  in  vitro  culture  step.  As  CX3CR1  expression  could  not  be 
examined in these mice, I had to use the alternative gating strategy detailed in 
Figure  4.4 t o  i d e n t i f y  t h e  i n d i v i d u a l  m!  populations.  This  showed t h a t  Ly6C
high 
monocytes  (P1)  made  little  IL10,  whereas  the  majority  of  F4/80
+MHCII
+ m ! 
produced IL10 constitutively (Fig. 5.2A and B). This production of IL10 was an 
unusual property of colonic m!, as splenic, peritoneal and CSF-1 generated BM 
m! all failed to produce IL10 constitutively (Fig. 5.2C). Similarly, CD11b
+ CD11c
+ 
F4/80
neg DC and eosinophils from the colon failed to produce IL10 (Fig. 5.2A and 
B).   
  To extend these findings, qRT-PCR was used to analyse mRNA expression 
by  freshly  isolated  FACS-purified  subsets  from  resting  CX3CR1
gfp/+  mice.  This 
confirmed  that  IL10  mRNA  levels  increased  progressively  from  Ly6C
high 
monocytes (P1) through P2 and P3 to CX3CR1
high m! (Fig. 5.3A).  Also consistent 
with the ICS data, the levels of mRNA for TNF! remained constant across the 
CX3CR1
+ populations (Fig. 5.3B).  In contrast, the level of mRNA for IL6 and iNOS 
was decreased in CX3CR1
high m! compared with Ly6C
high colonic monocytes (Fig. 
5.3C  and  D),  supporting  the  idea  of  a  switch  from  pro- t o  a n t i -inflammatory 
cytokine production.   136 
  Thus,  the  phenotypic  maturation  process  of  Ly6C
high  monocytes  to 
CX3CR1
high m! in the steady state colon is associated with a transition from the 
predominant  production  of  pro-inflammatory  TNF!,  IL6 a n d  i N O S,  to  the 
constitutive production of IL10. 
5.3 TLR Responsiveness of Intestinal CX3CR1
+ Subsets 
  It is generally accepted that intestinal m! are unresponsive to classical m! 
stimuli  such  as  TLR  ligands  (171).  In  contrast,  blood  monocytes  are  known  to 
respond fully to stimulation by producing a wealth of pro-inflammatory mediators 
(171). Therefore if Ly6C
high monocyte differentiation occurs in the intestine, one 
would expect that as differentiation proceeds, the responsiveness to exogenous 
stimuli  would  alter.  Thus  I  next  set  out  to  examine  the  responsiveness  of  the 
CX3CR1-defined populations to TLR stimulation. 
  For  intestinal  LP  populations  to  respond  to  TLR  stimulation  they  must 
possess the corresponding receptors.  I therefore first examined the expression of 
TLR2, TLR4 and CD14 by P1-P4 using flow cytometry. As shown in Figure 5.4, 
TLR2 was uniformly expressed by all CX3CR1
+ subsets (P1-P4), as was CD14.  In 
contrast, TLR4 expression increased progressively from P1 to CX3CR1
high m! in 
P4 (Fig. 5.4C). Expression of these pattern recognition receptors (PRR) was not a 
property of all CD11b
+ cells in the colonic LP, as SiglecF
+CX3CR1
neg eosinophils 
were  negative  for  TLR2,  TLR4  and  CD14  (Fig.  5.4A-C).  Similarly,  the  CD11b
+ 
CD11c
highSSC
low DC population in the CX3CR1
neg fraction failed to express TLR4, 
although  appeared  to  be  heterogeneous  for  TLR2  and  CD14  expression  (Fig. 
5.4A-C).  I  also  attempted  to  examine  the  expression  of  intracellular  TLR3  and 
TLR9  using  commercially  available  monoclonal  antibodies,  but  was  unable  to 
detect expression on any cell type tested including BM-derived and peritoneal m! 
(not shown). Thus to examine the full range of TLR expression, the  CX3CR1
+ 
populations in P1 to P4 were FACS-purified and mRNA levels for TLR1-9 were 
analysed  by  qRT-PCR.  This  revealed  that  intestinal  CX3CR1
+  populations 
expressed most TLR at a similar level to, or greater than BMM used as a control 
population (Fig. 5.5). An exception to this was TLR2, which appeared to decrease 
between P1 and P4 (Fig. 5.5). The Ly6C
+MHCII
+CX3CR1
int cells within P2 also 
appeared  to  express  lower  levels  of  TLR1  and  TLR3  than  other  populations, 
although the significance of this is unclear.     137 
  Thus having established that most cells in P1 to P4 express TLR, I next 
assessed TNF! and IL10 production by the CX3CR1
+ subsets after stimulation 
with LPS or BLP, agonists for TLR4 and TLR2 respectively. Consistent with their 
close  relationship  to  blood  monocytes, L y 6 C
highMHCII
negCX3CR1
int  (P1)  and 
Ly6C
+MHCII
+CX3CR1
int (P2) cells amongst whole digests from the resting colon 
showed a robust response to LPS compared with their unstimulated counterparts 
(Fig.  5.6).  This  response  was  dominated  by  TNF!  production  and  although  a 
substantial proportion of stimulated P1 or P2 cells produced both IL10 and TNF!, 
virtually none produced IL10 alone (Fig. 5.6A-C). In contrast, the Ly6C
negMHCII
+ 
CX3CR1
int (P3) cells showed little response to LPS stimulation above baseline, 
with  no  significant  increase  in  the  frequency  of  cells  producing  either  cytokine 
compared with resting conditions. LPS stimulated CX3CR1
high m! also showed a 
small  but  significant  increase  in  the  number  of  cells  producing  TNF! a l o n e  
compared with baseline and there was a significant increase in the proportion of 
cells  producing  both  IL10  and  TNF!  (Fig.  5.6A-C).  LPS  stimulation  caused  a 
significant  reduction  in  the  frequency  of  cells  producing  IL10  alone  in  all 
populations.  
  Stimulation  with  BLP  did  not  induce  such  powerful  changes  in  cytokine 
production,  but  it  did  show  the  same  pattern  of  progressive  reduction  in 
responsiveness to exogenous stimulation as Ly6C
high monocytes differentiated into 
CX3CR1
high m !  (Fig.  5.7).  In  addition,  whereas  the  Ly6C
highMHCII
negCX3CR1
int 
cells in P1 again responded to BLP with a TNF! dominated response, the lesser 
response of CX3CR1
high m! involved both TNF! and IL10 (Fig. 5.7A-C).  
  These  results  demonstrate  that  under  normal  physiological  conditions, 
maturation  of  Ly6C
high  monocytes  into  CX3CR1
high m !  is  associated  with  a 
progressive loss of reactivity to exogenous stimuli such as TLR ligation. 
5.4 Phagocytic Activity of CX3CR1
+ LP Myeloid Cells 
  A crucial function of tissue m! is their ability to maintain tissue homeostasis 
by  scavenging  apoptotic  or  senescent  cells  as  well  as  clearance  of  microbial 
material or malignant cells. Phagocytosis is likely to be a particularly important 
function  of  intestinal  m!  due  to  the  close  proximity  of  the  microbiota,  whose 
chance entry across the epithelial layer needs to be controlled.  In addition, there   138 
is extremely high turnover of epithelial cells in the gut. Therefore I next set out to 
examine the phagocytic ability of individual colonic LP CX3CR1
+ cells. 
  To  this  end,  whole  colonic  isolates  were  incubated  with  pHrodo  E.  coli 
bioparticles  and  their  uptake  assessed  by  flow  cytometry.  pHrodo  E.  coli 
bioparticles  become  highly  fluorescent  when  in  the  acidic  environment  of  the 
phagosome  following  internalisation,  thereby  allowing  clear  identification  of 
actively phagocytic cells. As shown in Figure 5.8, Ly6C
highMHCII
negCX3CR1
int cells 
(P1)  and  Ly6C
+MHCII
+CX3CR1
int  cells  (P2)  were  poor  at  phagocytosing  the 
bioparticles, as there was little difference in fluorescence between cells incubated 
at 37°C and cells incubated at 4°C as a control. Although cells in P3 showed signs 
of  some  phagocytosis,  CX3CR1
high m !  (P4)  showed  very  high  levels  of 
phagocytosis as evidenced by the large shift in pHrodo fluorescence over control 
samples at 4°C (Fig. 5.8A and B). In contrast, CX3CR1
int CD11b
+ DC (P5) and 
CD103
+ DC from the colon appeared to lack any significant phagocytic activity 
(Fig. 5.8C). 
  These  results  demonstrate  that  as  Ly6C
high  monocytes  mature  into 
CX3CR1
high m!, their phagocytic ability increases significantly (Fig. 5.8D).    
5.5 Costimulatory Molecule Expression 
  It has been reported that human intestinal m! express only low levels of 
costimulatory molecules (171) and therefore I next assessed the expression of the 
costimulatory molecules CD40, CD80 and CD86 by each of the CX3CR1-defined 
subsets  in  freshly  isolated  colonic  isolates.  This  revealed  that  as  Ly6C
high 
monocytes mature into CX3CR1
high m!, the level of CD40 and CD80 expression is 
relatively  constant,  so  that C X 3 C R 1
high m !  expressed  low  levels  of  both  these 
costimulatory molecules (Fig. 5.9A and B). In contrast, the level of CD86 increased 
progressively between P1 and P4, with the latter uniformly expressing CD86 (Fig. 
5.9C). The significance of the differential expression of the individual costimulatory 
molecules is unclear. 
5.6 Are Intestinal Macrophages 'Alternatively Activated'? 
  As  described  in  Chapter  1,  tissue  m!  are  highly  specialised  to  perform 
specific  functions  dependent  on  their  environment,  probably  dictated  by  local   139 
cytokines/chemokines and cellular interactions. As I have shown, intestinal m! are 
phenotypically and functionally distinct from other tissue m! such as those found 
in the peritoneal cavity or spleen, in that they produce IL10 and do not respond in 
a 'classical' manner to pro-inflammatory stimuli despite the expression of class II 
MHC. To explore this further, I tested the hypothesis that they might represent a 
population of 'alternatively' activated (M2) m!. M2 m! are characterised by high 
IL10  production,  the  expression  of  CD206  (mannose  receptor),  the  enzyme 
arginase-1 and vascular endothelial growth factor (VEGF), and are generally found 
in environments dominated by the TH2 cytokines IL4 and IL13 (72). Therefore I 
assessed the expression of these markers in the CX3CR1
+ subsets of colonic m!. 
The  expression  of  CD206  protein  increased  progressively  as  P1  monocytes 
differentiated into CX3CR1
high m! (P4) and this was confirmed at the mRNA level 
in FACS-purified subsets using qRT-PCR (Fig. 5.10A and B). However, the levels 
of mRNA for arginase-1 and VEGF actually appeared to decrease between P1 
and  P4  (Fig.  5.10C a n d  D ).    Thus  none  of  the  cells  at  any  stage  of  the 
differentiation continuum meet the criteria of M2 m!.   
  More recently the terms 'regulatory' or 'M2-like' have been applied to m! 
found under conditions which favour immune suppression such as tumours, in the 
placenta or after Fc#R cross-linking (62). In addition to the M2 markers IL10 and 
CD206, these regulatory m! express the scavenger receptor CD163 and receptors 
for TGF$ and IL10 (83). qRT-PCR analysis of sorted colonic m! subsets revealed 
that the mRNA levels for CD163 and TGF$R2 expression increased progressively 
as Ly6C
high monocytes differentiate into CX3CR1
high m! (Fig. 5.10E and F).  
  Collectively these data suggest that steady state intestinal m! most closely 
resemble regulatory/M2-like m! of the currently defined functional subsets. 
5.7 Cytokine Production During Inflammation 
  As shown in Chapter 3, intestinal inflammation is associated with dramatic 
changes in the composition of the colonic LP myeloid cell compartment. There is a 
massive  infiltration  of  the  mucosa  by  Ly6C
highMHCII
negCX3CR1
int  (P1)  and 
Ly6C
+MHCII
+CX3CR1
int  cells  (P2),  the  cells  which I  f o u n d  in  this  chapter  to 
produce high levels of TNF! and to be highly responsive to TLR stimulation under   140 
resting  conditions.  In  the  next  experiments,  I  examined  the  functions  of  the 
subsets I found in inflamed colon.   
  First I assessed the baseline cytokine production of the P1-P4 subsets in 
whole colonic digests obtained from CX3CR1
+/gfp mice on day 4 of DSS-induced 
colitis.  This revealed that a significantly greater proportion of the newly arrived 
Ly6C
high monocytes (P1) and their CX3CR1
int derivatives (P2 and P3) from colitic 
mice produced TNF! alone compared with the same populations in resting mice 
(Fig. 5.11). Similarly, there was a significant increase in the frequency of TNF!
+IL-
10
+ cells within P2 and P3 from colitic mice compared with the same populations 
in naïve mice. In contrast, the presence of inflammation did not lead to an increase 
in TNF! production by CX3CR1
high cells. Indeed inflammation caused a significant 
increase  in  the  proportion  of  cells  making  IL10  alone  within  this  population 
compared with resting conditions. 
  I next examined cells obtained from colitic animals for the production of 
TNF! and IL10 following TLR stimulation. This demonstrated that although LPS 
stimulation  resulted  in  an  increase  in  TNF!
  producing  cells  in  most  colitic 
populations  when  compared  with  unstimulated  cells,  the  frequency  of  cells 
producing TNF! alone was highest amongst the Ly6C
high monocytes in P1 and 
decreased  progressively  as  the  cells  matured  into  CX3CR1
high m !  (Fig.  5.12).  
LPS  stimulation  of  colitic  populations  resulted  in  a  significant  increase i n  t h e  
abundance of TNF!
+IL-10
+ cells within each population.  However, whereas single 
producers of TNF! dominated the LPS-induced response by Ly6C
high monocytes, 
cells producing both TNF! and IL-10 dominated as cells progressed towards the 
CX3CR1
high compartment (Fig. 5.12).  Again, stimulation with the TLR2 agonist 
BLP led to similar changes in the pattern of cytokine production, but consistent 
with the results I obtained from resting mice, the effects of BLP were less than 
those of LPS (Fig. 5.13). 
  Taken  together  these  data  demonstrate  that  during  inflammation, 
CX3CR1
int  cells  (P1,  P2  and  P3)  show  increased  pro-inflammatory  cytokine 
production and P1 and P2 show robustly enhanced responses to TLR ligation.  In 
contrast, the cytokine signature of CX3CR1
high m! was unaltered by the presence 
of  inflammation  and  the  majority  of  cytokine  producing  cells  in  this  subset   141 
remained IL10
+, although TLR stimulation caused some increase in the frequency 
of CX3CR1
high m! producing TNF! and IL10. 
5.8 Summary 
  In this chapter I investigated whether the functional properties of CX3CR1-
defined LP populations were altered as Ly6C
high monocytes differentiated in situ 
into CX3CR1
high m!. I was able to demonstrate that in steady state colon, there 
was a progressive switch in the baseline cytokine profile from the production of 
pro-inflammatory TNF! and IL6 by Ly6C
high colonic monocytes to high levels of 
constitutive IL10 production by CX3CR1
high m!. In parallel, there was progressive 
hyporesponsiveness to TLR stimulation as cells moved from P1 to P4, together 
with  the  acquisition  of  regulatory  m!  and  phagocytic  activity.  During  acute 
inflammation, the ability to produce increased amounts of TNF! was restricted to 
P1 and P2, the cells at the earliest stage of development and whose numbers 
increased  the  most  in  the  local  infiltrate.  In  contrast,  the  CX3CR1
high  cells  that 
remained did not acquire pro-inflammatory activity and retained their predilection 
to produce IL10.  Thus intestinal m! adapt to their environment under steady state 
conditions by losing the ability to respond in a classical pro-inflammatory manner, 
together with acquiring receptors that would assist in the uptake of microbes and 
becoming  avidly  phagocytic.  Inflammation  seems  to  involve  the  enhanced 
recruitment  of  pro-inflammatory  monocytes  rather  than  changes  in  the  resident 
cells.  I  next  investigated  directly  the  contribution  of  pro-inflammatory  Ly6C
high 
monocytes to intestinal pathology. 
 
 
 
 
 
 Figure 5.1: Cytokine Production by Colonic Macrophage Subsets in Steady State 
Colon 
Whole digests of colonic LP cells were isolated from resting CX3CR1+/gfp mice and incubated with 
BFA and monensin in medium alone and analysed for the presence of intracellular TNF! and 
IL10 by flow cytometry after 4.5hrs.  A. Representative TNF! and IL10 staining by each subset of 
m"  together  with  the  isotype  control.  B.  The  mean  percentage  +  1SD  of  IL10+,  TNF!+ a n d  
IL10+TNF!+ cells within P1, P2, P3 and P4.  C. The frequency of IL10+, TNF!+ and IL10+TNF!+ 
cells within P1, P2, P3 and P4 as a proportion of the total cytokine producing cells. Results 
shown  are  the  means  +  1SD  for  3-4  mice/group  and  are  representative  of  2  individual 
experiments. (* p<0.05, ** p<0.01, *** p<0.001. One-way ANOVA followed by Bonferroni’s post-
test) 
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Figure 5.2: Constitutive Production of IL10 by Intestinal Myeloid Subsets 
Colonic LP cells were isolated from resting VertX (IL10-eGFP) mice and individual populations 
were identified on the basis of CD11b, Ly6C, MHC II, F4/80 and CD11c as shown in Figure 4.4.  A. 
Representative IL10-eGFP expression by Ly6ChighMHCIIneg monocytes (P1), Ly6C+MHCII+ cells 
(P2), Ly6CnegMHCII+F4/80+ (P3+P4), Ly6CnegMHCII+CD11c+F4/80neg DC and eosinophils. B. The 
mean proportion of GFP+ cells within each LP population + 1SD. Results are representative of 
three individual experiments with 3-4 individual mice. C. Representative IL10-eGFP expression 
(black line) by CSF-1 generated BM macrophages (d7), resident peritoneal exudate cell (PEC; 
F4/80+MHCIIneg) macrophages and splenic (F4/80+CD11blowMHCIIint) macrophages compared with 
the  background  fluorescence  of  same  populations  from  WT  mice.  (*  p<0.05,  **  p<0.01,  *** 
p<0.001. One-way ANOVA followed by Bonferroni’s post-test) 
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Figure 5.3: Quantitative Analysis of Cytokine mRNA expression by CX3CR1 Defined 
Subsets of Colonic Macrophages 
P1-P4 subsets from the colonic LP were purified by FACS and mRNA isolated. Levels of mRNA 
for IL10 (A), TNF! (B), IL6 (C) and iNOS (D) were analysed by qRT-PCR. Results shown are 
mean expression relative to Cyclophilin A (CPA) using the 2-䂴C(t) method. The mean was obtained 
from  two  independent  experiments  using  cells  pooled  from  eleven/twelve  mice.  Primer 
sequences are detailed in Table 2.4. 
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AFigure 5.4: TLR expression by CX3CR1 Defined  Subsets of Colonic Macrophages 
Colonic  LP  cells  were  isolated  from  resting  CX3CR1+/gfp  mice  and  live-gated  CD45+ C D 1 1 b + 
CX3CR1+  subsets  (P1-P4),  CX3CR1negSSChigh  intestinal  eosinophils  and  CX3CR1negCD11b+ 
SSClowCD11c+ DC were examined for the expression of TLR2 (A), CD14 (B) and TLR4 (C) by 
flow  cytometry.  Shaded  histograms  represent  staining  with  the  appropriate  isotype  controls. 
Results representative of 3 individual experiments. 
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 Figure 5.5: TLR expression by Purified CX3CR1 Defined Subsets of Colonic 
Macrophages 
Colonic  LP  cells  were  isolated  from  resting  CX3CR1+/gfp  mice  and  live-gated  CD45+ C D 1 1 b + 
CX3CR1+ subsets (P1-P4) were FACS-sorted and mRNA isolated.  Results show the expression 
of TLR1-9 mRNA by each CX3CR1+ population compared with M-CSF generated BM-derived 
macrophages (BMM) as analysed by qRT-PCR analysis. Results shown are mean expression 
relative  to  Cyclophilin  A  (CPA)  using  the  2-䂴C(t)  method.  The  mean  was  obtained  from  two 
independent  experiments  using  cells  pooled  from  eleven/twelve  mice.  Primer  sequences  are 
detailed in Table 2.4. 
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Figure 5.6: Cytokine Production by Colonic Macrophage Subsets in Response to 
TLR4 Stimulation 
Whole digests of colonic LP cells were isolated from resting CX3CR1+/gfp mice and incubated with 
BFA and monensin together with 1µg/ml LPS and analysed for the presence of intracellular TNF! 
and  IL10  by  flow  cytometry  after  4.5hrs.  A.  Representative  TNF!  and  IL10  staining  by  each 
subset of m" together with the isotype control. B. The mean percentage + 1 SD of IL10+, TNF!+ 
and IL10+TNF!+ cells within P1-P4 after culture in medium alone (from Figure 5.1) or together with 
LPS.  C. The frequency of IL10+, TNF!+ and IL10+TNF!+ cells within P1-P4 as a proportion of the 
total cytokine producing cells. Data are representative of 2 individual experiments with 3 or 4 mice.   
(*  p<0.05,  **  p<0.01,  ***  p<0.001  vs.  responses  in  medium  alone  using  a  one-way  ANOVA 
followed by Bonferroni’s post-test) 
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Figure 5.7: Cytokine Production by Colonic Macrophage Subsets in Response to 
TLR2 Stimulation 
Whole digests of colonic LP cells were isolated from resting CX3CR1+/gfp mice and incubated with 
BFA and monensin together with 1µg/ml BLP and analysed for the presence of intracellular TNF! 
and  IL10  by  flow  cytometry  after  4.5hrs.  A.  Representative TNF!  and  IL10  staining  by  each 
subset of m" together with the isotype control. B. The mean percentage + 1 SD of IL10+, TNF!+ 
and IL10+TNF!+ cells within P1-P4 after culture in medium alone (from Figure 5.1) or together 
with BLP.  C. The frequency of IL10+, TNF!+ and IL10+TNF!+ cells within P1-P4 as a proportion of 
the total cytokine producing cells. Data are representative of 2 individual experiments with 3 or 4 
mice. (* p<0.05, ** p<0.01, *** p<0.001 vs. responses in medium alone using a one-way ANOVA 
followed by Bonferroni’s post-test) 
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sFigure 5.8: Phagocytic Activity of CX3CR1 Defined Subsets of Colonic Macrophages 
Whole digests of colonic LP cells were isolated from resting CX3CR1+/gfp mice and incubated with 
pHrodo  E.  coli  bioparticles  for  15  mins a t  3 7 ° C  ( black  line)  or  at  4°C  as  a  control  (shaded 
histogram). A. Representative pHrodo dye fluorescence of CX3CR1 defined P1 to P4 subsets. B. 
pHrodo dye fluorescence of P1 to P4 shown as a composite histogram. C. Representative pHrodo 
dye fluorescence of CD11b+F4/80negCD11c+CX3CR1int DC (P5) and CD103+ DC D. 䂴MFI (MFI at 
37°C-MFI at 4°C control) + 1 SD for P1-P4. Data are representative of 2 individual experiments 
with 4-5 mice. (*p<0.05, **p<0.01, ***p<0.001. One-way ANOVA followed by Bonferroni’s post-test) 
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 Figure 5.9: Expression of Costimulatory Molecules by CX3CR1 Defined Subsets of 
Colonic Macrophages 
Colonic  LP  cells  were  isolated  from  resting  CX3CR1+/gfp  mice  and  live-gated  CD45+CD11b+ 
CX3CR1+ subsets (P1-P4) were examined for the expression of CD40 (A), CD80 (B) and CD86 
(C)  by  flow  cytometry.  Shaded  histograms  represent  staining  with  the  appropriate  isotype 
controls. Numbers represent 䂴MFI (MFI-MFI of isotype). Results representative of 3 individual 
experiments. 
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 Figure 5.10:Expression of Alternatively Activated Macrophage Markers by CX3CR1 
Defined Subsets of Colonic Macrophages 
A. Colonic LP cells were isolated from resting CX3CR1+/gfp mice and live-gated CD45+CD11b+ 
CX3CR1int  and  CX3CR1high  cells  were  examined  for  the  expression  of  CD206  (mannose 
receptor) by flow cytometry. Populations 1 to 4 were FACS-purified and the level of mRNA for 
CD206 (B), arginase-1 (C), VEGF (D), CD163 (E) and TGF#R2 (F) was assessed by qRT-PCR 
analysis. Results shown are mean expression relative to cyclophilin A (CPA) using the 2-䂴C(t) 
method. The  mean  was  obtained  from  two  independent  experiments  using  cells  pooled  from 
eleven/twelve mice. Primer sequences are detailed in Table 2.4 
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Figure 5.11:Cytokine Production by Colonic Macrophage Subsets During 
Inflammation 
Whole digests of colonic LP cells were isolated from d4 colitic CX3CR1+/gfp mice and incubated 
with BFA and monensin in medium alone and analysed for the presence of intracellular TNF! and 
IL10 by flow cytometry after 4.5hrs. A. Representative TNF! and IL10 staining by each subset of 
m"  together  with  the  isotype  control.  B.  The  mean  percentage  +  1  SD  of  IL10+,  TNF!+ a n d  
IL10+TNF!+ cells within P1-P4 from resting mice (upper panel; from Figure 5.1) or from colitic 
mice (lower panel). C. The frequency of IL10+, TNF!+ and IL10 +TNF!+ cells within P1-P4 as a 
proportion of the total cytokine producing cells. Data are representative of 2 individual experiments 
with 3 or 4 mice. (* p<0.05, ** p<0.01, *** p<0.001 vs. responses by same populations from resting 
mice using a one-way ANOVA followed by Bonferroni’s post-test) 
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Figure 5.12: Cytokine Production by Colonic Macrophage Subsets in Response to 
TLR4 Stimulation During Inflammation 
Whole digests of colonic LP cells were isolated from d4 colitic CX3CR1+/gfp mice and incubated 
with BFA and monensin together with 1µg/ml LPS and analysed for the presence of intracellular 
TNF! and IL10 by flow cytometry after 4.5hrs. A. Representative TNF! and IL10 staining by each 
subset of m" together with the isotype control. B. The mean percentage + 1 SD of IL10+, TNF!+ 
and IL10+TNF!+ cells within P1-P4 after culture in medium alone (upper panel; from Figure 5.11) 
or together with LPS (lower panel).  C. The frequency of IL10+, TNF!+ and IL10+TNF!+ cells within 
P1-P4 as a proportion of the total cytokine producing cells. Data are representative of 2 individual 
experiments with 3 or 4 mice. (* p<0.05, ** p<0.01, *** p<0.001 vs. responses in medium alone 
using a one-way ANOVA followed by Bonferroni’s post-test) 
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Figure 5.13: Cytokine Production by Colonic Macrophage Subsets in Response to 
TLR2 Stimulation During Inflammation 
Whole digests of colonic LP cells were isolated from d4 colitic CX3CR1+/gfp mice and incubated 
with BFA and monensin together with 1µg/ml BLP and analysed for the presence of intracellular 
TNF! and IL10 by flow cytometry after 4.5hrs. A. Representative TNF! and IL10 staining by each 
subset of m" together with the isotype control. B. The mean percentage + 1 SD of IL10+, TNF!+ 
and IL10+TNF!+ cells within P1-P4 after culture in medium alone (upper panel; from Figure 5.11) 
or together with BLP (lower panel).  C. The frequency of IL10+, TNF!+ and IL10+TNF!+ cells within 
P1-P4 as a proportion of the total cytokine producing cells. Data are representative of 2 individual 
experiments with 3 or 4 mice. (* p<0.05, ** p<0.01, *** p<0.001 vs. responses in medium alone 
using a one-way ANOVA followed by Bonferroni’s post-test) 
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6  Chapter 6                                          
The Contribution of Ly6C
high Monocytes to 
Colonic Inflammation 
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6.1 Introduction 
  In the previous chapters, I demonstrated that under physiological conditions 
Ly6C
high monocytes are recruited continuously to the intestinal mucosa. Here they 
appear to differentiate into long-lived CX3CR1
high m! that are avidly phagocytic 
and adept at producing IL10, but do not respond in a pro-inflammatory manner to 
TLR stimulation. My results in Chapter 3 demonstrated that in DSS colitis there 
was an accumulation of the P1 and P2 subsets of pro-inflammatory CX3CR1
int 
cells  and  a  parallel  loss  of  CX3CR1
high m !.  As  these  results  suggest  that  the 
normal  local  differentiation  process  might  be  arrested  in  inflammation,  the 
experiments  in  this  chapter  were  designed  to  gain  further  insight  into  how  the 
differentiation  and  recruitment  of  Ly6C
high  monocytes  are  regulated  during 
inflammation.  First  I  determined  the  fate  of  Ly6C
high  monocytes  that  had  been 
transferred into mice with DSS colitis and then I explored the role of the CCR2 
chemokine receptor that is expressed on these monocytes in m! recruitment and 
pathology  in  colitis.  Finally,  I  assessed  the  fate  of  recruited  cells  during  the 
resolution  of  colitis  to  examine  whether  Ly6C
high  monocytes  recruited  during 
inflammation  could  differentiate  into  CX3CR1
high m !  once  the  inflammatory 
stimulus had been removed. 
6.2 Monocyte Differentiation During Inflammation 
  First,  I  adoptively  transferred  purified  Ly6C
high  BM  monocytes  from 
CX3CR1
+/gfp CD45.1
+/CD45.2
+ mice into CD45.1
+ B6 mice on d3 of DSS colitis 
(Fig. 6.1A) and assessed the phenotype of donor cells in the LP after 24hrs and 
96hrs. To ensure that recipient mice survived until this later time point, mice were 
taken off DSS on d5 and were returned to normal drinking water for the remainder 
of the study. Consistent with the adoptive transfer studies in steady state mice, 
donor cells could be found in the LP within 24hrs after transfer (Fig. 6.1B) and over 
75% had acquired class II MHC at this time, therefore moving into the population I 
had  defined  as  P2  (Ly6C
+MHCII
+CX3CR1
int)  (Fig.  6.1C).  Very  few  donor  cells 
could be detected 96hrs after transfer, but the majority of these had lost Ly6C 
expression and acquired class II MHC (Fig. 6.1C). However, in contrast to my 
studies on steady state colon, donor cells in inflamed mucosa did not upregulate 
CX3CR1 and move into P4 (CX3CR1
high). Indeed 95% of donor cells remained in 
P3 (Ly6C
negMHCII
+CX3CR1
int) (Fig. 6.1). As in my studies of steady state mice, it 
is unlikely that the donor cells found in the inflamed colonic LP at 96hrs are blood   157 
contaminants,  because  donor  cells  in  the  bloodstream  all  lacked  class  II  MHC 
expression (Fig. 6.2).   
  These  results  support  the  idea  that  disruption  of  tissue  homeostasis  in 
inflammation causes a blockade in the normal differentiation pattern of Ly6C
high 
monocytes in the colon, which goes some way to explaining the accumulation of 
CX3CR1
int cells under these conditions. 
6.3 The Role of Ly6C
high Monocytes during Inflammation  
  These experiments indicate that Ly6C
high monocytes can give rise to both 
'resident' and pro-inflammatory m! in the intestine, with their fate depending on the 
context into which they are recruited. During inflammation Ly6C
high monocytes and 
their immediate descendents accumulate in the gut, retain their responsiveness to 
TLR  stimulation  and  produce  pro-inflammatory  cytokines  such  as  TNF!.  To 
examine  whether  this  recruitment  of  Ly6C
high  monocytes  contributes  to  the 
pathology  of  DSS  colitis,  I  took  advantage  of  CCR2-deficient  mice  which  lack 
these cells in their bloodstream.   
  WT and CCR2-deficient mice received 2% DSS for 6 days, during which 
time  their  bodyweight  and  total  clinical  score  were  measured.  This  revealed  a 
striking difference in the disease progression between CCR2 KO mice and their 
WT counterparts. As expected, WT mice lost weight progressively from day 4 and 
this  was  accompanied  by  increasing  disease  severity  (Fig.  6.3A  and  B). I n  
contrast,  CCR2-deficient  mice  failed  to  lose  weight  even  after  6  days  of  DSS 
administration. Consistently, CCR2 KO mice also had significantly lower clinical 
scores over the course of the study (Fig. 6.3B) and the extent of colon shortening 
was significantly less in CCR2-deficient mice (Fig. 6.3C). Furthermore, histological 
analysis of H&E stained sections of colitic WT and KO colon demonstrated that the 
disrupted  architecture,  epithelial  damage  and  massive  inflammatory  leucocyte 
infiltration seen in WT mice was virtually absent in CCR2 KO mice (Fig. 6.3D).  
This was not due to differences in DSS consumption, as water intake was similar 
in the two groups (Fig. 6.3E).   
  Thus  the  absence  of  CCR2  protects  mice  from  DSS-induced  colitis. 
However many cell types have however been reported to express CCR2, including   158 
monocytes, eosinophils and neutrophils as well as other non-myeloid cells such as 
T cells. Therefore I thought it important to assess which CCR2
+ cells might explain 
the phenotype of CCR2 KO mice, concentrating on innate immune cells, which are 
the  main  drivers  of  DSS-induced  colitis.  Therefore  I  examined  the  intestinal 
myeloid cell compartment of WT and CCR2-deficient mice four days after feeding 
DSS using the alternative gating strategies I described in Chapter 4 for analysing 
non-CX3CR1-GFP mice. 
  As before, DSS administration led to a significant increase in CD11b
+ cells 
in  the  LP  of  WT  mice  (Fig.  6.4),  which  involved  Ly6G
+  neutrophils,  SiglecF
+ 
eosinophils  and  monocytes/m!.  CCR2  KO  mice  showed  significantly  less 
recruitment of total CD11b
+ cells than WT mice with colitis, as well as significantly 
lower numbers of neutrophils and eosinophils (Fig. 6.5 and 6.6). However these 
cells made up higher proportions of the infiltrate in CCR2 KO mice than in WT 
mice (Fig. 6.5 and 6.6). Indeed the numbers of eosinophils and neutrophils in the 
inflamed  CCR2  KO  colon  were  higher  than  those  I  found  in  an  independent 
experiment  on  resting  CCR2  KO  mice.  This  recruitment  of  eosinophils  and 
neutrophils to the CCR2 KO colon was consistent with the fact that I could not 
detect CCR2 expression by these cell types in blood (Fig. 6.5 and 6.6). 
  In  stark  contrast,  the  expansion  of  CD11b
+SiglecF
negLy6G
negLy6C
high 
MHCII
neg monocytes (P1), which was marked in WT mice, was almost absent in 
CCR2-deficient mice, with a 24-fold reduction compared with WT mice (Fig. 6.7A-
C). CCR2 KO mice also had significantly lower proportions and absolute numbers 
of Ly6C
+MHCII
+ cells (P2) compared with their WT counterparts (Fig. 6.7D and E).  
It must be noted that there were small but significant increases in cells in P1 and 
P2 in inflamed CCR2 KO colon compared with the numbers of these populations 
found in an independent experiment on resting CCR2 KO mice. During colitis, the 
LP of WT mice also contained significantly more F4/80
+MHCII
+ m! than CCR2 KO 
(Fig. 6.8A and B), although both WT and CCR2 KO mice had greater numbers of 
F4/80
+MHCII
+ m! during colitis compared with steady state numbers. In contrast, 
there was little difference in the numbers of CD11b
+ DC during DSS colitis in the 
'inflamed' CCR2 KO colon compared with resting intestine. Although resting CCR2 
KO colon contained significantly fewer CD11b
+ DC than WT colon, this difference 
was not seen during DSS colitis (Fig. 6.8C).    159 
  Thus  the  reduced  susceptibility  of  CCR2-deficient  mice  to  chemically 
induced  colitis  correlated  with  a  selective  lack  of  accumulation  of  Ly6C
high 
monocytes and their immediate progeny in the mucosa, supporting the idea that 
Ly6C
high monocytes are the mediators of inflammation.  
  Competitive co-transfer experiments that I carried out at the beginning of 
my project established that CCR2 is needed for entry of monocytes into the gut in 
addition to its known role of mediating monocyte exit from the BM (22). These 
were performed to complete a publication by my predecessor Andrew Platt, and 
were carried out before I had established the refined gating and sorting strategies 
used elsewhere in my project. In this study, whole unpurified BM cells from WT 
(CD45.1
+) or CCR2 KO (CD45.2
+) donor mice were fluorescently labelled and co-
transferred into CD45.2
+ WT recipients at a 1:1 ratio on day 5 of colitis (Fig. 6.9A 
and B). Donor derived F4/80
+ cells were evident in the colon after 24hrs and could 
be  distinguished  within  the  total  F4/80
+  fraction  on  the  basis  of  Far-Red 
fluorescence  (Fig.  6.9C).  Of  the  Far-Red
+  cells  present  in  the  colon,  the  vast 
majority (>85%) were of WT origin (CD45.1
+) and only a small number of CCR2 
KO derived cells could be seen (CD45.1
neg) (Fig. 6.9D and E). In contrast, analysis 
of the donor cells present in the spleen of the same recipients showed that there 
was an approximately equal abundance of WT and CCR2 KO-derived donor cells 
(Fig. 6.9D and E). 
  Taken  together  these  results  demonstrate  that  recruitment  of  Ly6C
high 
monocytes into the colonic mucosa is a CCR2-dependent process.  In contrast, 
accumulation  of  Ly6C
high  monocytes  in  the  spleen  appears  to  be  relatively 
unaffected by CCR2-deficiency. 
6.4 Pathogenic Role of Ly6C
high Monocytes in Inflamed Colon  
  The previous experiments indicated that the CCR2-dependent recruitment 
of Ly6C
high monocytes was critical for the development of colitis and to explore this 
further,  I  examined  whether  adoptive  transfer  of  WT  Ly6C
high  monocytes  into 
CCR2 KO mice could restore their susceptibility to DSS colitis. To this end, CCR2 
KO  mice  receiving  DSS  received  purified  Ly6C
high  BM  monocytes  from  WT 
(CD45.1
+) mice on d1 and d3 of DSS colitis. As before, untransferred CCR2 KO 
mice were less susceptible to colitis, showing reduced bodyweight loss and clinical   160 
disease scores compared with WT animals (Fig. 6.10). This was not affected by 
transfer of WT monocytes, even though I could find donor cells that had been 
recruited to the intestine (Fig. 6.10A and B). As in previous experiments, by day 6 
of colitis, the majority of donor cells present in the colonic LP of recipient CCR2 
KO mice now expressed class II MHC (Fig. 6.10C).  However, a greater proportion 
of  donor  cells  remained  Ly6C
+  when  transferred  into  colitic  CCR2  KO  mice 
compared  with  what  I  had  seen  in  resting  KO  mice,  suggesting  that  the 
differentiation process might be altered in CCR2 KO mice receiving DSS. As the 
donor monocytes used in this experiment were obtained from WT mice, I could not 
examine CX3CR1 expression by donor derived cells. 
  These  experiments  suggest  that  adoptive  transfer  of  WT  Ly6C
high 
monocytes  into  CCR2  KO  mice  does  not  recapitulate  the  disease  progression 
seen  in  WT  mice  and  so  could  indicate  that  Ly6C
high  monocytes  alone  are 
insufficient for establishing disease. Alternatively, it could be that the experimental 
setup was not optimal and transfer of more monocytes on different days might 
have  given  a  different  result.  However  I  did  not  have  time  to  repeat  this 
experiment. 
6.5 Monocytes and Macrophages in the Resolution of Colonic 
Inflammation 
  Thus far, my studies of acute DSS colitis have shown a critical role for the 
recruitment and accumulation of pro-inflammatory Ly6C
high monocytes. However 
my  earlier  studies  had  shown  that  these  monocytes  can  also  repopulate  the 
resident m! populations of the steady state mucosa. Therefore the question arose 
as to whether the monocytes that accumulate during active inflammation might 
differentiate further once colitis resolves. 
  To  assess  this,  I  adopted  a  colitis  regime  in  which  CX3CR1
+/gfp  mice 
received  2%  DSS  in  their  water  for  4  days  and  were  then  returned  to  normal 
drinking  water  for  the  remainder  of  the  study.  As  shown  in  Figure  6.11A, 
withdrawal of DSS resulted in all mice returning to their initial bodyweight within 
around 1 week, although there was considerable variability in the recovery rates of 
individual mice. Recovery of bodyweight was accompanied by the restoration of 
normal intestinal architecture (Fig. 6.11B)   161 
  As in my previous experiments, the acute phase of colitis was associated 
with  a  reversal  in  the  normal  ratio  of  CX3CR1
high a n d  C X 3 C R 1
int  cells  due  to 
expansion of the latter population and a decrease in the absolute numbers of the 
CX3CR1
high m! (Fig. 6C-E). This continued even after DSS withdrawal, with the 
proportion of CX3CR1
int cells remaining high until at least 3 days after stopping 
DSS and the frequency of CX3CR1
high cells continuing to fall to almost zero at this 
time. Thereafter, the proportions of CX3CR1
high cells began to increase gradually 
and this was paralleled by a decrease in the proportion of CX3CR1
int cells (Fig. 
6.11C and D). However, even by 14 days after withdrawing DSS, the proportions 
and  numbers o f  C X 3 C R 1
high  cells  had  not  recovered  to  normal.  This  pattern 
suggested  that  these  CX3CR1
int  cells  recruited  during  active  colitis  may  be 
converting into CX3CR1
high 'resident' m! during recovery, as is the case under 
steady state conditions. 
  To test this possibility, I employed BrdU labelling as a means of tracking 
newly recruited cells. Mice received 2% DSS and BrdU in their drinking water for 4 
consecutive days and were then returned to normal drinking water for the following 
14 days. The efficiency with which newly recruited monocytes enter the CX3CR1
int 
compartment was confirmed by the large accumulation of BrdU
+ cells seen in this 
compartment during DSS and BrdU administration. There was also accumulation 
of BrdU
+ cells in the CX3CR1
high compartment, although this was less than for the 
CX3CR1
int compartment (~10%) (Fig. 6.11F). Removal of DSS and BrdU at d4 
resulted in the rapid loss of BrdU
+ cells within both the CX3CR1
int and CX3CR1
high 
fractions,  with  no  BrdU
+  cells  identifiable  14  days  after  cessation  of  DSS  (Fig. 
6.11F). This suggests that the vast majority of monocytes recruited to the inflamed 
colon do not subsequently differentiate into long-lived CX3CR1
high m!, even during 
the repair phase that occurs after the removal of the inflammatory agent.   
  I also tried to examine the fate of newly recruited Ly6C
high monocytes during 
the resolution of DSS colitis using an adoptive transfer system. Purified Ly6C
high 
BM monocytes were transferred into d3 colitic mice and DSS administration was 
stopped 24hrs later. I then attempted to find the donor cells in the colon after a 
further 3 days, but was unsuccessful (data not shown). However this was before I 
had fully optimised the monocyte transfer system and when identification of donor 
cells was difficult as outlined in section 4.1. Given more time this experiment would 
have been repeated using the optimised transfer system.   162 
6.6 Summary 
  In this chapter I set out to examine the fate of Ly6C
high monocytes recruited 
to the inflamed mucosa during DSS colitis. Altogether the results confirmed my 
previous findings that newly recruited Ly6C
high monocytes do not differentiate into 
CX3CR1
high m !  under  inflammatory  conditions.  Rather  they  remain  within  the 
CX3CR1
int  compartment,  confirming  that  the  context  of  the  milieu  into  which 
Ly6C
high monocytes arrive determines their differentiation outcome.   
  I also showed that the development of intestinal pathology was dependent 
on the CCR2 chemokine receptor. This effect was due to the deficient recruitment 
of Ly6C
high monocytes to the inflamed mucosa, leading to the lack of accumulation 
of pro-inflammatory m!, rather than an effect on other inflammatory cells. Studies 
of resolving inflammation showed that the population of resident CX3CR1
high m! 
returned gradually towards normal, as the numbers of pro-inflammatory decreased 
and the intestine repaired. However, the recovery of the resident m! population 
did  not  seem  to  reflect  differentiation  of  the  recently  recruited  inflammatory 
monocytes and m!, which appeared to be short lived. Figure 6.1: Fate of Adoptively Transferred Ly6Chigh Monocytes in the Inflamed 
Mucosa 
A.  2x106  purified  Ly6Chigh  BM  monocytes  from  CD45.1+/CD45.2+  CX3CR1+/gfp  mice  were 
adoptively transferred into CD45.1+ WT mice on d3 of DSS colitis and the presence of donor cells 
within the colonic LP was analysed 24hrs and 96hrs later. B. Representative dot plots of CD45.2 
and  CX3CR1-GFP  expression  on  live-gated  CD11b+  LP  cells  in  the  colon  of  mice  that  had 
received  PBS  or  monocytes  24hrs  and  96hrs  before.  Gates  for  CX3CR1int  and  CX3CR1high 
populations were set using the CX3CR1-GFP expression of donor monocytes in the bloodstream.  
C.  Expression  of  Ly6C  and  class  II  MHC  by  endogenous  CD11b+  cells  (left  panel)  or  donor 
CD45.1+CD45.2+ cells (middle and right panels) at indicated time points. 1 individual experiment 
with 2 recipient mice at each time point. 
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Figure 6.2: Fate of Adoptively Transferred Ly6Chigh Monocytes in the Bloodstream of 
Colitic Mice 
A.  2x106  purified  Ly6Chigh  BM  monocytes  from  CD45.1+/CD45.2+  CX3CR1+/gfp  mice  were 
adoptively transferred into CD45.1+ WT mice on d3 of DSS colitis and the presence of donor cells 
within the colonic LP was analysed 24hrs and 96hrs later. B. Representative dot plots of CD45.2 
and  CX3CR1-GFP  expression  on  live-gated  CD11b+  LP  cells  in  the  colon  of  mice  that  had 
received PBS or monocytes 24hrs and 96hrs before. C. Expression of Ly6C and class II MHC by 
endogenous CD11b+ cells (left panel) or donor CD45.1+CD45.2+ cells (middle and right panels) at 
indicated time points. 1 individual experiment with 2 recipient mice at each time point. 
164 
Analysis of CD45.1 
recipient mice for 
presence of CD45.1/
CD45.2 (donor) cells Figure 6.3: Progress of DSS Colitis in CCR2-deficient Mice 
WT or CCR2 KO mice received 2% DSS in their drinking water for 6 days and their bodyweight (A) 
and clinical disease score (B) was recorded daily.  Results are the means + 1 SD for 6 mice/group.  
C. On day 6 mice were culled and their colons measured. D. On day 7 sections of distal colon 
were fixed in 10% formalin, embedded in paraffin and stained with H&E for histological analysis 
(final  magnification  x100).  E.  Water  consumption  (ml/mouse)  on  each  day  of  colitis.  Results 
representative of at least 2 individual experiments. (*p<0.05, **p<0.01, ***p<0.001, Student’ t test)  
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Figure 6.4: Enumeration of CD11b+ Myeloid Cells in Colon of CCR2 KO Mice with DSS 
Colitis  
WT or CCR2 KO mice received 2% DSS in their drinking water for 4 days and the proportion of 
live-gated CD45+ CD1 1b + cells was examined by flow cytometry. A. Representative dot plots of 
live-gated CD45+ CD1 1b + cells obtained from d4 colitic WT or CCR2 KO mice.   B. The mean 
absolute numbers of CD11b+ cells per colon of d4 colitic WT or CCR2 KO mice compared with the 
numbers in the resting colon from Figure 4.9. Results are the means + 1SD and are representative 
of 2 individual experiments with 3-4 mice/group.  (*p<0.05, ***p<0.0001, Student’s t test)  
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Figure 6.5: Presence of Neutrophils in the Mucosa of CCR2 KO Mice with DSS Colitis 
WT or CCR2 KO mice received 2% DSS in their drinking water for 4 days and the presence of 
Ly6G+ neutrophils in the LP was examined by flow cytometry. A. Representative dot plots of Ly6G 
expression by live-gated CD45+ CD11b+ cells obtained from d4 colitic WT or CCR2 KO mice.  B. 
The mean frequency of Ly6G+ neutrophils amongst the total CD11b+ cell compartment in WT and 
CCR2 KO mice. C. The absolute numbers of CD11b+ Ly6G+ neutrophils per colon of d4 colitic WT 
or CCR2 KO mice compared with those in resting colon from Figure 4.10. D. Expression of CCR2 
on  blood  neutrophils  (Ly6G+Ly6Cint)  from  resting  WT  (black  line)  or  CCR2  KO  (red  line)  mice 
compared with the isotype control (shaded histogram). Results are the means + 1SD and are 
representative of 2 individual experiments with 3-4 mice/group.  
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Figure 6.6: Presence of Eosinophils in the Mucosa of CCR2 KO Mice with DSS Colitis 
WT or CCR2 KO mice received 2% DSS in their drinking water for 4 days and the presence of 
SiglecF+ eosinophils was examined by flow cytometry. A. Representative staining of SiglecF on 
live-gated CD45+ CD1 1b + Ly6Gneg cells obtained from d4 colitic WT or CCR2 KO mice. B. The 
mean frequency of SiglecF+ eosinophils amongst the CD11b+ Ly6Gneg fraction in WT and CCR2 
KO mice. C. The absolute numbers of eosinophils per colon of d4 colitic WT or CCR2 KO mice 
compared  with  those  in  resting  colon  from  Figure  4.10.  D.  Expression  of  CCR2  on  blood 
eosinophils (SSChighF4/80+) from resting WT (black line) or CCR2 KO (red line) mice compared 
with the isotype control (shaded histogram). Results are the means + 1SD and are representative 
of 2 individual experiments with 3-4 mice/group. (*p<0.05, Student’s t test) 
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Figure 6.7: Monocyte/Macrophage Subsets in the Mucosa of CCR2 KO Mice with DSS 
Colitis 
WT or CCR2 KO mice received 2% DSS in their drinking water for 4 days and the composition of 
the CD11b+ SiglecFneg Ly6Gneg fraction was examined by flow cytometry. A. Representative dot 
plots of Ly6C and class II MHC expression by live-gated CD45+ CD11b+ SiglecFneg Ly6Gneg cells 
and the proportions (B) and absolute numbers (C) of Ly6Chigh MHCIIneg (P1) cells per colon of d4 
colitic  WT  and  CCR2  KO  mice  compared  with  those  in  resting  colon  from  Figure  4.11.  The 
proportions (D) and absolute numbers (E) of Ly6C+ MHCII+ (P2) cells per colon of d4 colitic WT 
and CCR2 KO mice compared with those in resting colon from Figure 4.11. The results are the 
means + 1SD and are representative of 2 individual experiments with 3-4 mice/group. (*p<0.05, 
**p<0.01, ***p<0.001, Student’s t test) 
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Figure 6.8: Class II MHC+ Resident Macrophages and DC in the Mucosa of CCR2 KO 
Mice with DSS Colitis  
WT or CCR2 KO mice received 2% DSS in their drinking water for 4 days and the composition of 
the CD11b+ SiglecFneg Ly6Gneg fraction was examined by flow cytometry. A. Representative dot 
plots of F4/80 and CD11c expression by live-gated CD45+ CD1 1b + SiglecFneg Ly6Gneg Ly6Cneg 
MHCII+ cells and the absolute numbers of (B) F4/80+ MHCII+  (P3+4) cells or (C) CD11c+ F4/80neg 
MHCII+  (incl. P5) cells per colon of d4 colitic WT or CCR2 KO mice compared with those in resting 
colon  from  Figure  4.12.  Resting  data  is  the  same  data  as  shown  in  Figure  4.12).    Results 
represent the means + 1SD for 3 (WT) or 4 (CCR2 KO) mice and are representative of 2 individual 
experiments. (**p<0.01, Student’s t test) 
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Resting  d4 colitis  Resting  d4 colitis Figure 6.9: Competitive Adoptive Transfer of WT and CCR2KO BM Cells into Colitic 
Mice 
A. Whole BM cells from CD45.1+ WT mice and CD45.2+ CCR2 KO mice were labelled with Cell 
Tracker Red (FarRed) and 12x106 cells were adoptively transferred into CD45.2+ WT mice at a 1:1 
ratio on d5 of DSS colitis. The presence of donor cells within the colonic LP and the spleen was 
analysed 24hrs later. B. Representative dot plots of CD45.1 and FarRed fluorescence by BM cells 
prior to transfer, showing approximately equal proportions of WT (CD45.1+FarRed+) and CCR2 KO 
cells (CD45.1negFarRed+). C. Gating strategy used to identify donor cells whereby FarRed cells 
were  selected  from  the  total  F4/80+  fraction  of  colonic  LP  cells.  D.  Representative  dot  plots 
showing the frequency of WT (CD45.1+FarRed+) and CCR2 KO cells (CD45.1negFarRed+) amongst 
live-gated F4/80+ FarRed+ cells in the spleen and colonic LP 24hrs after transfer. Results are the 
means + 1SD and are representative of 2 individual experiments with 4 recipient mice. 
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Figure 6.10: Effects of Adoptively Transferring WT Ly6Chigh Monocytes on the 
Outcome of DSS Colitis in CCR2 KO Mice 
CCR2 KO (CD45.2) mice received 2% DSS for 6 days and received 1-2x106 purified Ly6Chigh BM 
monocytes from CD45.1 WT mice by intravenous infusion on d1 and d3 of colitis. Bodyweight (A) 
and clinical disease score (B) was measured daily and compared with untransferred WT mice 
receiving 2% DSS. Results are the means ± 1 SD for 3 mice (WT and PBS) and 2 mice (Ly6Chigh 
recipients)  are  representative  of  a  single  experiment.  C.  Representative  CD45.1  and  CD45.2 
staining by live-gated CD11b+ LP cells from d6 ‘colitic’ CCR2 KO mice that received PBS or BM 
monocytes and the expression of Ly6C and class II MHC on donor cells (CD45.1+CD45.2neg). 
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Figure 6.11: Myeloid Cells in Colon during Recovery from DSS Colitis 
A. Bodyweights in CX3CR1+/gfp mice receiving 2% DSS and BrdU in their drinking water for 4 days 
and were then returned to normal drinking water. B. Representative H&E sections of distal colon at 
each time point showing intense crypt lengthening and inflammation that does no resolve until 14 
days after withdrawing DSS (final magnification x100). C. Representative contour plots showing 
the proportion of CX3CR1int and CX3CR1high cells amongst live-gated CD45+CD11b+CX3CR1-GFP 
LP cells from resting mice or mice culled at d1, d3, d8 and d14 after DSS withdrawal. D. The mean 
proportion ± 1SD (D) and absolute numbers (E) of CX3CR1int and CX3CR1high cells within the total 
CD11b+CX3CR1-GFP+ fraction at each time point. F. The frequency of BrdU+ cells within live-gated 
CD45+ CD11b+ CX3CR1int and CX3CR1high populations at the indicated time points after DSS and 
BrdU withdrawal. Results are the means ± 1SD and are representative of a single experiment with 
4 mice at each time point. 
A 
2% DSS  Normal drinking water 
CX3CR1-GFP 
C
D
1
1
b
 
d0  d4 + 1  d4 +3  C 
D 
B 
d4 +8  d4 +14 
78  22  27  73  6  94  47  53  55  45 
E 
d0  d4 + 1 
d4 +3  d4 +8 
d4 +14 
173 
d0 d4+1 d4+3 d4+8 d4+14
0
5
10
15
20
25
30
35
CX3CR1hi
CX3CR1int
%
 
C
D
1
1
b
+
 
B
r
d
U
+
 
v
i
a
b
l
e
 
c
e
l
l
s
F   174 
!
!
!
!
!
!
7  Chapter 7                                          
The Role of CD200R1 in the Regulation of 
Intestinal Macrophage Activity 
 
 
 
 
 
 
 
   175 
7.1 Introduction 
  As  discussed  in  previous  chapters,  resident  intestinal  m!  are 
hyporesponsive to classical stimuli such as TLR ligands and in Chapter 5 I showed 
that  this  state  of  hyporesponsiveness  was  acquired  in  situ  as  Ly6C
high 
'inflammatory'  monocytes  matured  into  CX3CR1
high  m!.  Although  a  number  of 
mechanisms have been proposed to maintain colonic m! in this 'regulatory' state, 
the exact reason is unknown and it is likely that multiple mechanisms may be 
involved,  including  immunomodulatory  cytokines  such  as  IL10  and  TGF!.  In 
addition,  intestinal  m!  express  a  number  of  surface  receptors  that  have  been 
associated with inhibitory function, although their role(s) have not been studied in 
any detail.  
  One inhibitory receptor that has been shown to regulate m! responsiveness 
at mucosal surfaces is CD200R1. Binding of its ligand, CD200, has been shown to 
cause inhibition of different m! populations including microglia of the CNS and 
alveolar m!, which share features with intestinal m! (113, 119).  Notably, loss of 
CD200R1-CD200  signalling  increased  susceptibility  to  inflammation  in  the  lung 
(119). In addition, Snelgrove and co-workers suggested that m! in the gut might 
express CD200R1, but the cells involved were not characterised precisely and the 
role  of  the  CD200R1-CD200  regulatory  axis  in  the  intestinal  compartment  has 
never been formally tested.  Therefore in this chapter, I set out to investigate the 
involvement  of  CD200R1  in  the  regulation  of  intestinal  m!  behaviour  using  a 
combination of KO mice.    
7.2  Expression of CD200R1 by Colonic Macrophages 
  I  first  assessed  the  expression  of  CD200R1  by  individual  myeloid  cell 
populations in the colonic LP (Fig. 7.1). As the majority of work in this chapter was 
carried out before I had established the detailed gating strategies described in 
previous  chapters  and  the  mice  did  not  express  CX3CR1-GFP,  the  subsets 
described here were based on less complex patterns of surface molecules, with 
m! routinely identified simply on the basis of F4/80 and class II MHC expression. 
Based on the work shown in my previous chapters and as illustrated in Figure 7.1, 
the vast majority of this population are equivalent to CX3CR1
high cells in P4 (Fig. 
7.1A and B).   176 
   Initially  I  experienced  technical  problems  using  the  recommended 
concentration of the anti-CD200R1 (OX-110) antibody (5µg/ml), which appeared to 
stain both WT and CD200R1 KO cells when compared with the isotype control. 
However, careful titration of the antibody showed that 0.5µg/ml was optimal for 
providing reproducible staining of WT cells that was not present in the CD200R1 
KO (Fig. 7.1C). This showed that F4/80
+MHCII
+ intestinal m! expressed CD200R1 
at a level comparable to alveolar m! (Fig. 7.1C-E). In contrast, F4/80
low MHCII
neg 
SSC
high intestinal eosinophils and Ly6C
highMHCII
neg monocytes (P1 cells) appeared 
to  lack  CD200R1  expression  (Fig.  7.1D).  Resident  peritoneal  m!  also  lacked 
CD200R1 expression, whereas WT BMM expressed low but significant levels of 
the receptor when compared with CD200R1 KO BMM (Fig. 7.1E). 
7.3  CD200 Expression in Steady State Colon 
  For CD200R1 to play a role in the gut, its ligand, CD200, should also be 
available.  Therefore  I  next  examined  the  expression  of  CD200  by  both 
haematopoietic  (CD45
+)  and  non-haematopoietic  (CD45
neg)  cells,  as  previous 
reports have shown that CD200 can be expressed by a wide variety of cells. As 
shown in Figure 7.2, the CD45
neg population contained cells that expressed high 
levels  of  CD200.  Of  these  CD200
+  cells,  approximately  40%  expressed  CD31 
(PECAM-1), a marker of endothelial cells and ~25% of these CD200
+CD31
+ cells 
co-expressed  LYVE-1,  the  lymphatic  endothelial  marker  (Fig.  7.2A).  Thus  both 
vascular and lymphatic endothelium in the intestine express high levels of CD200. 
I was unable to identify the remaining CD200
+ population of non-haematopoietic 
cells, and it was notable that intestinal epithelial cells did not express CD200 (Fig 
7.2B).   
  I  next  explored  the  expression  of  CD200  by  intestinal  lymphocyte 
populations.  This  revealed  that  as  in  other  tissues  (119,  258),  the  majority  of 
mucosal B cells (B220
+) and a small proportion of CD4
+ T lymphocytes expressed 
CD200 at low levels.  In contrast, CD8
+ T cells lacked CD200 expression (Fig. 
7.2C and D).     177 
7.4 Characterisation of Colonic Macrophages from CD200R1 
KO Mice 
  Previous studies have shown that disruption of the CD200-CD200R1 axis 
results  in  the  expansion  and  activation  of  tissue  m!  populations,  as  well  as 
increased  susceptibility  to  inflammation  (113).  Thus,  having  established  that 
intestinal m! show selective expression of CD200R1 and that its ligand, CD200, is 
highly abundant in the mucosa, I next sought to determine the importance of this 
regulatory axis in controlling colonic m! behaviour by examining colonic m! from 
resting CD200R1-deficient mice. 
  Colonic  LP  cells  were  isolated  from  WT  or  CD200R1  KO  mice  and 
examined  for  the  expression  of  F4/80  and  class  II  MHC  to  identify  m!.    Initial 
analysis showed that CD200R1 KO mice had fewer total viable leucocytes (live-
gated CD45
+) in colonic isolates than WT mice (Fig. 7.3A-C). In parallel, CD200R1 
KO colon had a significantly higher frequency of F4/80
+MHCII
+ m! and also had 
an additional population of F4/80
+MHCII
int cells that was not evident in WT mice 
(Fig. 7.3D and E). This additional F4/80
+MHCII
int population in CD200R1 KO colon 
did  not  express  Ly6C,  suggesting  they  did  not  represent  recently  arrived 
monocytes  or  'inflammatory'  m!  (Fig.  7.3G).  However  these  proportional 
differences  did  not  translate  into  a  significant  difference  in  absolute  numbers, 
probably  reflecting  the  difference  in  total  leucocyte  numbers  between  WT  and 
CD200R1 KO mice (Fig. 7.3F). There were no differences in the proportions or 
numbers of the F4/80
+MHCII
neg fraction, which contains SiglecF
+ eosinophils and 
Ly6C
high monocytes (Fig. 7.3F). 
  Next, I assessed whether CD200R1 deficiency leads to m! hyperactivation 
in  the  intestine  by  examining  the  levels  of  costimulatory  molecule  and  TLR 
expression. This revealed that colonic m! from both WT and CD200R1 KO mice 
failed  to  express  CD40  and  expressed  CD86  at  comparable  levels  (Fig.  7.4).  
Similarly  there  was  no  difference  in  the  levels  of  TLR2  and  TLR4  expression 
between WT and KO.     
7.5 TLR Responsiveness of CD200R1 KO Macrophages   
  To examine further the role of CD200R1 in m! function, I next compared 
the  responses  of  CSF-1  generated  BMM  from  WT  and  CD200R1  KO  mice  to   178 
stimulation  with  LPS,  IFN!  or  a  combination  of  these  stimuli.  As  expected, 
stimulation  of  WT  BMM  with  LPS  and/or  IFN!  led  to  upregulation  of  CD40 
expression  (Fig.  7.5A).  Similarly  CD86  expression  was  upregulated  by  either 
stimulus and even more when cells were treated with both LPS and IFN! (Fig. 
7.5B).  Stimulation  of  WT  BMM  with  IFN!  also  resulted  in  class  II  MHC 
upregulation, but this effect was lost when BMM were incubated with both LPS 
and IFN! (Fig. 7.5C).  Importantly, there were no differences in the upregulation of 
costimulatory molecules or class II MHC between WT and CD200R1 KO BMM.  
  Next, I used intracellular cytokine staining to assess the production of TNF" 
by  WT  and  CD200R1  KO  colonic  m!  after  TLR  stimulation.  Due  to  technical 
issues,  I  was  unable  to  assess  the  individual  class  II  MHC-defined  F4/80
+ 
populations in this experiment and could only analyse total F4/80
+MHCII
+ cells. As 
expected, stimulation with either BLP or LPS resulted in little or no increase in 
TNF"  production  by  F4/80
+MHCII
+  cells  from  WT  mice  compared  with 
unstimulated cells. CD200R1 KO m! also did not respond to TLR stimulation and 
there  were  no  differences  in  TNF"  production  by  either  unstimulated  or  TLR-
stimulated colonic m! from WT and CD200R1 KO mice. Together these results 
indicate that CD200R1-deficiency does not result in intrinsic hyper-responsiveness 
of m! in the gut (Fig. 7.6A and B).  
7.6 Characterisation of Aged CD200R1 KO Mice  
  I then went on to examine whether the disruption of the CD200-CD200R1 
regulatory  axis  predisposed  mice  to  intestinal  inflammation  in  vivo.  First,  I 
monitored for the development of spontaneous intestinal inflammation in cohorts of 
CD200R1 KO mice maintained under SPF conditions for up to 18 months. There 
were no signs of weight loss or clinical disease throughout this period (data not 
shown) and when culled at 16-18 months of age, CD200R1 KO mice had identical 
body  weights  and  colon  lengths  to  age-matched  mice  (Fig.  7.7A  and  B).  
Furthermore,  there  was  no  evidence  of  histological  abnormalities  such  as 
inflammatory infiltrates or epithelial disruption in either WT or CD200R1 KO mice 
at this age (Fig. 7.7C). 
  To  confirm  the  lack  of  spontaneous  inflammation,  I  examined  the 
composition of the colonic LP myeloid compartment in aged WT and CD200R1 KO   179 
mice.  As shown in Figure 7.7D, comparable numbers of living haematopoietic 
cells were retrieved from aged WT and KO mice and the numbers and proportions 
of the B- and T-lymphocytes in the colonic mucosa were also identical (Fig. 7.8). 
Despite  the  lack  of  overt  inflammation,  there  were  significantly  more  Ly6G
+ 
neutrophils in the mucosa of aged CD200R1-deficient mice compared with their 
WT  counterparts  (Fig.  7.9).  However  there  were  equivalent  proportions  and 
absolute  numbers  of  F4/80
+MHCII
neg  cells  (eosinophils  and  monocytes)  and 
F4/80
+MHCII
+ m! in the two strains (Fig. 7.10A-E). Consistent with the results in 
young  KO  mice,  aged  CD200R1  KO  mice  had  an  expanded  population  of 
F4/80
+MHCII
int  cells  within  the  LP  compared  with  their  WT  counterparts  (Fig. 
7.10C-E).  
  In an attempt to examine whether the activation status of the F4/80
+MHCII
int 
or  F4/80
+MHCII
+  populations  differed  between  WT  and  CD200R1  KO  mice,  I 
assessed their expression of CD40.  As in young mice, there was no difference in 
the expression of CD40 by either F4/80
+MHCII
int or F4/80
+MHCII
+ cells from WT 
and  CD200R1  KO  mice  (Fig.  7.11A).  Similarly,  the  expanded  F4/80
+MHCII
int 
population did not express Ly6C (Fig. 7.11B), suggesting that these cells did not 
represent recently arrived monocytes. Consistently, there were no differences in 
the FSC/SSC profiles of these cells from the two strains (Fig. 7.11C). 
  Finally to assess whether m! derived from aged CD200R1 KO mice were 
hyper-responsive to stimulation, I examined TNF" production by BM-derived m! 
after culture with LPS or BLP.  As expected, both LPS and BLP stimulation caused 
a significant increase in the frequency of TNF"
+ m!, but as in young mice, there 
was  no  significant  difference  between  the  responses  mounted  by  m!  from 
CD200R1 KO m! and WT mice (Fig. 7.12). 
  Taken together these data demonstrate that CD200R1-deficiency does not 
render animals susceptible to spontaneous intestinal disease as they age and this 
is  reflected  in  the  relatively  normal  composition  of  the  intestinal  myeloid  (and 
lymphoid) compartment in CD200R1 KO mice.    180 
7.7 Experimental Colitis in CD200R1 KO Mice 
  Although CD200R1-deficient mice did not develop spontaneous intestinal 
pathology even after 16-18 months, I postulated that there could be more subtle 
defects  in  m!  homeostasis  that  might  be  revealed  in  response  to  exogenous 
damage.  Therefore I next examined the development of acute colitis in CD200R1 
KO mice after feeding DSS.   
  As previously described, continuous administration of 2% DSS led to the 
development of colitis in WT mice within 5 to 6 days, as determined by significant 
weight loss and increasing clinical disease scores (Fig. 7.13A and B). There was 
no significant difference in the overall pattern of disease in CD200R1 KO mice, 
although  these  mice  showed  greater  variability  in  weight  loss,  clinical  disease 
score and colon shortening compared with the same parameters in WT mice (Fig. 
7.13A-C). This increased variability was found in three individual experiments and 
was  not  due  to  differences  in  the  intake  of  DSS,  as  water  consumption  was 
comparable in all experimental groups (Fig. 7.13D). Analysis of H&E sections of 
inflamed colon revealed identical histological damage in WT and CD200R1 KO 
mice (Fig. 7. 13E). 
  I  next  assessed  if  there  were  any  differences  in  the  composition  of  the 
intestinal myeloid cell compartment of WT and KO mice during colitis. Consistent 
with my results from previous chapters, DSS administration led to infiltration of the 
colon by CD11b
+ myeloid cells and there were no differences in the numbers and 
proportions  of  these  cells  in  WT  and  KO  colon  (Fig.  7.14A).  The  frequency  of 
Ly6G
+  neutrophils  within  the  CD11b
+  fraction  of  colon  cells  was  also  similar 
between colitic WT and CD200R1 KO mice (Fig. 7.14B).  As I found in previous 
experiments, there was expansion in the numbers of F4/80
+MHCII
neg cells in the 
inflamed  colon,  which  included  SiglecF
+  eosinophils  and  Ly6C
high  monocytes 
(equivalent to P1 in CX3CR1
+/gfp mice). There were no significant differences in 
the abundance of these populations between colitic WT and CD200R1 KO mice 
and together these results demonstrate that lack of CD200R1 does not affect the 
susceptibility  of  mice  to  chemically  induced  colitis,  or  to  alterations  in  the 
inflammatory myeloid cell recruitment.      181 
7.8 Characterisation of CD200 KO Mice 
  Although it is generally accepted that CD200 is the only ligand of CD200R1, 
other CD200 receptors have been reported (108). Thus it remained possible that 
CD200-dependent  regulation  of  intestinal  m!  function  could  exist  without  the 
involvement  of  CD200R1.  To  investigate  this,  I  next  characterised  intestinal 
myeloid cells and susceptibility to colitis in CD200 KO mice. 
  The proportions and absolute numbers of total viable intestinal leucocytes 
were  identical  in  resting  CD200  KO  and  WT  colon,  as  were  the  numbers  of 
F4/80
+MHC
neg  cells  (Fig.  7.15A-C).  However,  the  colon  of  CD200  KO  mice 
contained significantly fewer F4/80
+MHCII
+ m! than WT colon (Fig. 7.15D-F). As 
in CD200R1 KO mice, there was also an increased proportion of F4/80
+MHC
int 
cells in resting CD200-deficient colon, whereas these cells were rare in WT colon 
(Fig. 7.15E).  However this did not translate into significant differences in absolute 
numbers  of  F4/80
+MHC
int  cells,  probably  reflecting  the  decreased  number  of 
F4/80
+MHCII
+ m !  in  CD200  KO  colon.  M!  isolated  from  CD200-deficient  mice 
showed no difference in activation status compared with WT mice, as determined 
by CD40 expression (Fig. 7.15G). Interestingly however, the level of CD200R1 
expression by CD200 KO F4/80
+MHCII
+ m! was slightly increased compared with 
that in WT colonic m! (Fig. 7.15G). 
  I also thought it important to examine whether there was any histological 
evidence  of  spontaneous  intestinal  inflammation  in  CD200  KO  mice.  However 
analysis  of  H&E  stained  sections  revealed  no  inflammatory  infiltrates,  crypt 
elongation or epithelial disruption (Fig. 7.16).  Consistent with this, there was no 
significant difference in the frequency of neutrophils in the LP of resting WT and 
CD200 KO mice, although there was a trend towards increased proportions and 
numbers of neutrophils in CD200 KO colon (Fig. 7.16B). 
7.9 Experimental Colitis in CD200 KO Mice 
  Previous studies in CD200 KO mice have shown they are more susceptible 
to  a  number  of  forms  of  immunopathology  (113,  116,  119)  and  therefore  I 
examined whether lack of CD200 would influence the development of DSS colitis.    182 
  Consistent with my previous experiments, WT mice began to lose weight 
and developed clinical disease symptoms by d4 of DSS administration. Although 
CD200 KO mice showed slightly delayed disease onset, with statistically lower 
bodyweight loss at d4 and d5, their weight loss and disease score accelerated 
after this point so that by d6, there were no differences in weight loss or disease 
score between WT and CD200 KO mice (Fig. 7.17A and B). There were also no 
differences  in  colon  shortening  and  both  strains  showed  identical  histological 
features of colitis (Fig. 7.17C and D).   
  Although insufficient CD200 KO mice were available for me to repeat these 
experiments or to assess the functional characteristics of CD200 KO colonic m!, 
these studies suggest that spontaneous colitis or intestinal m! hyperactivity is not 
a feature of CD200 deficiency. Furthermore, lack of CD200 does not render mice 
more susceptible to chemical colitis.  
7.10 Effects of CD200-Fc Fusion Protein on Macrophage 
Responsiveness 
  In a final attempt to assess the importance of the CD200R1-CD200 axis in 
regulating m! behaviour, I used a CD200-Fc fusion protein to ligate CD200R1 in 
vitro, as this has been shown previously to attenuate pro-inflammatory cytokine 
production  (119,  125,  259).  CSF-1  generated  BMM  were  stimulated  with  LPS, 
IFN! or with LPS + IFN! in vitro, with or without pre-incubation with CD200-Fc 
fusion protein. Pre-treatment of BMM with CD200-Fc fusion protein had no effect 
on the frequency of TNF"-producing cells after stimulation with LPS (Fig. 7.18), or 
on the upregulation of CD40, CD86 and MHC class II after stimulation with LPS, 
IFN! or LPS and IFN! (Fig. 7.19).  
7.11 Summary 
  The  results  in  this  chapter  demonstrate  that  despite  expression  of 
CD200R1  by  resident  colonic  m!  and  the  high  abundance  of  CD200  in  the 
intestine, deletion of CD200R1 had no consistent effect on the number, activation 
status and TLR-responsiveness of intestinal m!. In addition, CD200R1 KO mice 
did not develop spontaneous intestinal inflammation, even when maintained under 
SPF  conditions  for  up  to  18  months.    CD200R1  KO  mice  also  had  normal 
susceptibility  to  DSS-induced  colitis.  Together  with  the  lack  of  abnormalities  in   183 
intrinsic m! function, these results suggest that the absence of CD200R1 does not 
lead to m! hyperactivity in the intestine. Similar results were seen in CD200 KO 
mice, which showed normal colonic m! numbers and activation status, as well as 
no  enhanced  susceptibility  to  spontaneous  or  DSS  induced  colitis.  Preliminary 
studies also indicated that deliberate ligation of CD200R1 on m! in vitro did not 
alter their activation by innate stimuli. Thus, taken together, these studies suggest 
that it is unlikely the CD200R1-CD200 regulatory axis alone plays an essential role 
in controlling m! behaviour in the steady state or inflamed colon. CD200R1 
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Figure 7.1: CD200R1 Expression by Myeloid Cells from Different Tissues 
Colonic LP cells were isolated from resting WT mice and live-gated CD45+ cells were analysed for 
the expression of F4/80 and class II MHC. A. Representative dot plots showing the gating strategy 
used  in  this  chapter,  where  m!  were  identified  as  F4/80+MHCII+  and  where  eosinophils  and 
monocytes could be distinguished in the F4/80lowMHCIIneg gate by their SSC profile. B.  Expression 
of CX3CR1-GFP by live-gated CD45+F4/80+MHCII+ cells from resting CX3CR1+/gfp mice, showing 
that  the  vast  majority  are  CX3CR1high.  C.  Titration  of  anti-CD200R1  antibody  using  live-gated 
CD45+F4/80+MHCII+ colonic LP cells from WT (black) or CD200R1 (red) mice, showing the optimal 
concentration to be 0.5µg/ml. Expression of CD200R1 by intestinal eosinophils and monocytes (D) 
and by m! from bronchoalveolar lavage (BAL), peritoneum or CSF-1 generated BMM (E) from 
resting WT (black) and CD200R1 KO (red) mice. Shaded histograms represent appropriate isotype 
control. Numbers represent the mean fluorescence intensity (MFI). Representative of 2 individual 
experiments.  
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Figure 7.2: CD200 Expression in the Colon 
A.  Colonic  LP  cells  were  isolated  from  WT  (black  line)  or  CD200  KO  (red  line)  mice  and  the 
expression of CD200 by live-gated CD45neg cells (middle panel) was examined together with the 
expression  of  the  endothelial  markers  CD31  (PECAM-1)  and  LYVE-1  on  CD45neg  cells  was 
examined by flow cytometry. Shaded histogram represents staining with the appropriate isotype 
control. B. Expression of CD200 on epithelial cells obtained from the first EDTA-wash step during 
colon isolation. C. Representative CD200 expression by live-gated CD45+ colonic B220+ (B cells), 
CD3+CD4+  (CD4+  T  cells)  and  CD3+CD8+ cells  (CD8+  T  cells)  from  WT  colon  and  the  mean 
proportion  +  1SD  of  CD200+  cells  within  each  lymphocyte  population.  Shaded  histograms 
represent appropriate isotype control. Representative of 2 individual experiments.  
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Figure 7.3: Characterisation of Colonic Macrophages in CD200R1 KO Mice 
Colonic LP cells were isolated from resting WT and CD200R1 KO mice and analysed for the 
expression of CD45, F4/80, MHC II and Ly6C by flow cytometry.  A. Representative dot plots of 
CD45  expression  on  single  cells  from  WT  and  CD200R1  KO  mice.  The  percentage  (B) a n d  
absolute numbers (C) of live-gated CD45+ cells per colon. D. Representative dot plots of F4/80 
and class II MHC expression by live-gated CD45+ cells from WT and CD200R1 KO mice. The 
percentage  (E)  and  absolute  numbers  (F)  of  live  F4/80+MHC  IIneg,  F4/80+MHC  IIint a n d  
F4/80+MHCIIhigh  (m!)  live  cells  per  colon.  Results  are  the  mean  percentages  and  absolute 
numbers + 1SD for 3-4mice/group and are representative of at least 3 individual experiments. G. 
Representative expression of Ly6C by F4/80+MHCIIint and F4/80+MHCIIhigh cells                      
(* p<0.05,**p<0.01, ***p<0.001. Student’s t test) 
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Figure 7.4: Activation Status of Colonic Macrophages from CD200R1 KO Mice 
Colonic LP cells were isolated from resting WT and CD200R1 KO mice and live-gated CD45+ 
F4/80+MHCII+  cells  analysed  for  the  expression  of  CD40,  CD86,  TLR2  and  TLR4  by  flow 
cytometry.  A. Representative dot plots of F4/80 and class II MHC expression on CD200R1 KO LP 
cells, showing G1 (F4/80+MHCIIint) and G2 (F4/80+MHCIIhigh) gates used in subsequent plots. B. 
Expression of CD40, CD86, TLR2 and TLR4 by cells in G1 and G2.  Numbers represent the mean 
fluorescence intensity (MFI) for WT (black) and CD200R1 KO (red) cells. Representative of 2 
individual experiments.  
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Figure 7.5: Responsiveness of CD200R1 KO Bone Marrow Derived Macrophages to 
Pro-inflammatory Stimuli 
CSF-1 generated BM macrophages (BMM) from WT or CD200R1KO mice were harvested after 6 
days of culture and incubated for 24hrs in medium alone (Med), 1µg/ml LPS, 100U IFN" or LPS 
and  IFN".  Expression  of  CD40  (A),  CD80  (B)  and  class  II  MHC  (C)  was  determined  by  flow 
cytometry.  Results  shown  are  the  mean  fluorescence  intensity  (MFI)  for  WT  (white  bars)  and 
CD200R1 KO (grey bars) cells + 1 SD for 3 mice/group and are representative of 2 individual 
experiments. 
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Figure 7.6: TNF# Production by Colonic Macrophages from CD200R1 KO Mice  
following TLR Stimulation 
Colonic LP cells were isolated from resting WT or CD200R1 KO mice and incubated for 4.5hrs 
with BFA and monensin in either medium alone, or together with 1µg/ml LPS or 1µg/ml BLP and 
analysed for the presence of intracellular TNF# by flow cytometry.  A. Representative CD11b and 
TNF#  staining  of  colonic  F4/80+MHCII+  cells  from  WT  or  CD200R1  KO  mice.  B.  The  mean 
frequency of TNF#+ m! from WT and CD200R1 KO mice + 1SD for 3-4 mice/group and results are 
representative of 2 individual experiments.    
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Figure 7.7: Absence of Spontaneous Intestinal Inflammation in Aged CD200R1 KO 
Mice 
WT and CD200R1 KO mice were maintained under SPF conditions for 16-18months, after which 
time their bodyweights (A) and colon lengths (B) were assessed. C. Histological analysis of H&E 
stained sections of distal colon from aged WT and CD200R1 KO mice (final magnification x400). 
D. The number of colonic LP cells per colon from aged WT or CD200R1 KO mice. Results are the 
means + 1SD for 3-4 mice/group and are representative of 2 individual experiments. 
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190 Figure 7.8: T- and B-lymphocytes in the Colonic Mucosa of Aged CD200R1 KO Mice 
LP cells were isolated from the colon of resting 16 month old WT and CD200R1 KO mice and live-
gated CD45+ cells were analysed for the expression of CD19 and CD3 by flow cytometry to detect 
B- and T-lymphocytes, respectively. A. Mean proportion of CD3+ T-cells amongst live-gated CD45+ 
cells.   B. Representative dot plots of CD4 and CD8 expression showing the composition of the 
CD3+ compartment. C. The frequency of CD19+ B cells amongst live-gated CD45+ cells. Results 
are the means + 1SD and represent 1 experiment with 4mice/group. 
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Figure 7.9: Presence of Neutrophils in the Colon of Aged CD200R1 KO Mice 
LP cells were isolated from the colon of resting 16 month old WT and CD200R1 KO mice and 
analysed for the presence of Ly6G+ neutrophils by flow cytometry.  A. Representative staining of 
Ly6G and CD11b amongst live-gated CD45+ cells.   The proportion of Ly6G+ cells within the live 
CD11b+ fraction (B) and absolute numbers (C) of Ly6G+ cells per colon. Results are the means + 
1SD and represent 1 experiment with 4 mice/group. (* p<0.05, Student’s t test) 
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Figure 7.10: Characterisation of Colonic Macrophages from Aged CD200R1 KO Mice 
Colonic LP cells were isolated from the colon of resting 16 month old WT and CD200R1 KO mice 
and live-gated cells analysed for the expression of CD45, F4/80 and MHC II by flow cytometry.  
The  percentage  (A)  and  absolute  numbers  (B)  of  live-gated  CD45+  cells  per  colon.  C. 
Representative dot plots of F4/80 and class II MHC expression by live-gated CD45+ cells from WT 
and CD200R1 KO mice.  The percentages (D) and absolute numbers (E) of live F4/80+ MHC IIneg, 
F4/80+ MHC IIint and F4/80+ MHC IIhigh (m!) cells per colon.   Results are the mean percentages 
and  absolute  numbers  +  1SD  and  represent  1  experiment  with  4  mice/group.  (*  p<0.05,  ** 
p<0.005, Student’s t test) 
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Figure 7.11: Characterisation of Colonic Macrophages from Aged CD200R1 KO Mice 
A. Colonic LP cells were isolated from resting 16 month old WT and CD200R1 KO mice and live-
gated CD45+ F4/80+ MHCII+ populations assessed for the expression of Ly6C and CD40 by flow 
cytometry.  B. Expression of Ly6C and CD40 by F4/80+ MHCIIint cells (G1) and F4/80+ MHCII+ cells 
(G2) from WT (black) or CD200R1 KO (red) mice C. FSC and SSC profiles of F4/80+ MHCIIint cells 
(G1) and F4/80+ MHCII+ cells (G2) from aged WT or CD200R1 KO mice.   Representative of 1 
experiment. 
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Figure 7.12: TLR Responsiveness of BM Macrophages from Aged CD200R1 KO Mice 
CSF-1 generated BM macrophages (BMM) from 18 month aged WT or CD200R1KO mice were 
harvested after 6 days of culture and cultured with BFA and monensin for 4.5hrs in medium alone 
(Med), or together with 1µg/ml LPS or 1µg/ml BLP.   Representative TNF# expression by WT or 
CD200R1 KO BMM (A) and the frequency of TNF#+ cells after culture (B).  Results shown are the 
mean frequency of TNF#+ cells for WT (white bars) and CD200R1 KO mice (grey bars) + 1 SD and 
represent one experiment with 3 mice/group. 
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 Figure 7.13: Progress of Experimental Colitis in CD200R1 KO Mice 
WT or CD200R1 KO mice received 2% DSS in their drinking water for 7 days and their bodyweight 
(A) and clinical disease score (B) was recorded daily.  Results are the means ± 1 SD for 6 (WT) 
and 11 (CD200R1 KO) mice per group. On day 7 mice were culled and their colons measured and 
compared with resting mice (d0) (C). D. Water consumption (ml) per mouse on each day of colitis.  
On day 7 sections of distal colon were fixed in 10% formalin, embedded in paraffin and stained 
with  H&E  for  histological  analysis  (final  magnification  x100).  Identical  degrees  of  architectural 
destruction and inflammation were seen.  Results representative of 3 individual experiments. 
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Figure 7.14: Characterisation of Myeloid Cells in Colon of CD200R1 KO Mice with 
DSS-induced Colitis 
WT or CD200R1 KO mice received 2% DSS in their drinking water for 7 days. On day 7 mice were 
culled, their colons removed and LP cells isolated.  Live-gated CD45+ LP cells were assessed for 
the  expression  of  CD11b,  Ly6G,  F4/80,  MHC  II,  Ly6C,  and  SiglecF  by  flow  cytometry. A. The  
proportion of CD11b+ cells amongst the CD45+ live fraction. B. The proportion of Ly6G+ neutrophils 
amongst CD11b+ leucocytes.  C. Representative dot plots of F4/80 and class II MHC expression by 
CD45+  Ly6Gneg  cells  (upper  panels)  and  the  composition  of  the  F4/80+MHCneg  fraction  (lower 
panels). D. The proportion of Ly6Chigh monocytes and SiglecF+ eosinophils amongst F4/80+MHCneg 
cells.  Data  are  the  means  +  1SD  for  3-4  mice/group  and  are  representative  of  2  individual 
experiments. 
B 
C 
MHC II 
WT  CD200R1 KO 
Gated: Live CD45+ Ly6Gneg 
F
4
/
8
0
  38.9  14.0 
WT CD200R1 KO
0
25
50
75
100
%
 
C
D
1
1
b
+
 
o
f
 
C
D
4
5
+
 
l
i
v
e
 
c
e
l
l
s
WT CD200R1 KO
0
10
20
30
40
%
 
L
y
6
G
+
 
o
f
 
C
D
1
1
b
+
 
l
i
v
e
 
c
e
l
l
s
35.3  16.7 
SiglecF 
L
y
6
C
 
WT  CD200R1 KO 
D 
WT CD200R1 KO
0
25
50
75
100 Ly6C+
SiglecF+
%
 
F
4
/
8
0
+
M
H
C
n
e
g
 
c
e
l
l
s
38.0  61.6  39.5  59.6 
197 A 
Figure 7.15: Characterisation of the Intestinal Myeloid Compartment of Resting 
CD200 KO Mice 
Colonic LP cells were isolated from resting WT and CD200 KO mice and live-gated cells were 
analysed  for  the  expression  of  CD45,  CD200,  F4/80  and  MHC  II  by  flow  cytometry.  A.  
Representative dot plots of CD45 and CD200 expression by live-gated cells. The percentages (B) 
and  absolute  numbers  (C)  of  live-gated  CD45+  cells  per  colon.  D.  Representative  dot  plots  of 
F4/80 and class II MHC expression by live-gated CD45+ LP cells from WT and CD200 KO mice.  
The percentages (E) and absolute numbers (F) of F4/80 + MHCIIneg, F4/80+ MHCIIint and F4/80 + 
MHCIIhigh live cells per colon. G. Expression of CD40 and CD200R1 by F4/80+ MHCIIhigh m! from 
WT (black) or CD200 KO mice (red). Results are the mean percentages and absolute numbers + 
1SD and represent 1 experiment with 4 mice/group. (* p<0.05, ** p<0.005, Student’s t test) 
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Figure 7.16: Absence of Spontaneous Intestinal Inflammation in CD200 KO Mice  
A.  Sections  of  distal  colon  from  resting  WT  or  CD200  KO  mice  were  fixed  in  10%  formalin, 
embedded in paraffin and stained with H&E for histological analysis (final magnification x100). B. 
Colonic LP cells were isolated from resting WT and CD200 KO mice and live-gated CD45+ cells 
were analysed for the expression of Ly6G by flow cytometry. Representative expression of Ly6G 
and CD11b by live-gated CD45+ cells and the proportion of Ly6G+ neutrophils within the CD45+ live 
fraction. C. The absolute numbers of Ly6G+ neutrophils per colon of resting WT and CD200 KO 
mice.  Results are the means + 1SD and represent a single experiment with 3-4 mice/group. 
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C Figure 7.17: DSS Colitis in CD200 KO Mice 
WT or CD200 KO mice received 2% DSS in their drinking water for 7 days and their bodyweight 
(A)  and  clinical  disease  score  (B)  was  recorded  daily.  Results  are  representative  of  a  single 
experiment and show the means ± 1SD for 5 (WT) and 6 (CD200 KO) mice. On day 7 mice were 
culled and their colons measured and compared with resting mice (d0) (C). D. Sections of distal 
colon from d7 colitic WT and CD200KO mice were fixed in 10% formalin, embedded in paraffin 
and stained with H&E for histological analysis showing identical patterns of colonic ulceration, loss 
of crypt architecture and inflammation (final magnification x100).  (*p<0.05, Student’s t test) 
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Figure 7.18: Effects of CD200-Fc Fusion Protein on Responsiveness of BMM to TLR  
Ligation 
CSF-1  generated  BM-derived  macrophages  (BMM)  from  WT  or  CD200R1  KO  mice  were 
harvested after 7 days of culture and incubated for 4.5 hrs in medium alone (Med), with 1µg/ml 
LPS, 100U IFN" or with LPS + IFN" together with BFA and monensin, after which the TNF#+ cells 
was determined by flow cytometry. Cells were incubated or not with 2.5µg/ml CD200-Fc fusion 
protein  from  1  hr  before  addition  of  TLR  ligands.  A.  Representative  histograms  of  TNF# 
expression by WT and CD200R1 KO BMM after culture under different conditions. B. Results are 
the mean proportions of TNF#+ BMM for WT (white bars) and CD200R1 KO (grey bars) + 1 SD 
and represent a single experiment with 3 mice/group. (* p<0.05, *** p<0.001. One-way ANOVA 
followed by Bonferroni’s post-test) 
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Figure 7.19: Effects of CD200-Fc Fusion Protein on Responsiveness of BMM to TLR  
Ligation 
CSF-1  generated  BM-derived  macrophages  (BMM)  from  WT  or  CD200R1  KO  mice  were 
harvested after 7 days of culture and cultured for 4.5 hrs in medium alone (Med), with 1µg/ml LPS, 
100U IFN" or with LPS + IFN", together with BFA and monensin.  Cells were incubated or not with 
2.5µg/ml CD200-Fc fusion protein from 1 hr before addition of TLR ligands. Expression of MHC 
class II (A), CD40 (B) and CD86 (C) was determined by flow cytometry. Results are the mean 
fluorescence  intensity  (MFI)  for  WT  (white  bars)  and  CD200R1  KO  (grey  bars)  +  1  SD  and 
represent a single experiment with 3 mice/group.    203 
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8  Chapter 8                                          
General Discussion 
   204 
8.1 Introduction 
  The intestinal immune system has a constant task to perform in that it must 
respond  robustly  to  pathogenic  insult,  but  such  responses  mounted  towards 
innocuous antigens such as dietary proteins or commensal microorganisms would 
be  wasteful  and  dangerous.  Indeed  breakdown  in  the  discrimination  between 
harmless and harmful antigens results in the development of chronic inflammatory 
conditions such as IBD, where active immune responses are targeted against the 
commensal bacteria (130).  M! appear to play a central role in the pathogenesis of 
IBD, producing large quantities of pro-inflammatory cytokines and chemokines and 
thereby perpetuating inflammation. However intestinal m! are also crucial for the 
maintenance  of  tissue  homeostasis  under  resting  conditions  (260).  How  one 
population of cells can play such contrasting roles is unclear. 
  It  is  well  established  that  resident  intestinal  m! p o s sess  functional 
adaptations that are not seen in other peripheral tissue m!, allowing them to exist 
in  the  microbe  and  antigen  rich  environment  of  the  intestinal  mucosa  without 
provoking  inflammation.  Studies  with  m!  from  human  small  intestinal  biopsies 
have shown that intestinal m! are extremely phagocytic and can kill bacteria very 
efficiently  (171).  However  neither  phagocytosis  nor  stimulation  of  gut  m! w i t h  
bacterial  products  or  pro-inflammatory  cytokines  results  in  'classical'  activation 
characterised  by  pro-inflammatory  mediator  release  (171).  Rather  resident 
intestinal m! appear to produce immunomodulatory cytokines such as IL10 and 
TGF!  (178,  179).  However,  the  composition  of  the  intestinal  m! p o p u l a t i o n  
changes markedly during IBD, with the accumulation of a phenotypically distinct 
population  of  pro-inflammatory  CD14
+ m !  in  the  inflamed  mucosa  (242). I t   is 
unclear whether these pro-inflammatory m! represent newly recruited cells, or if 
resident m! can alter their phenotype and function. As a result it is also unknown 
whether distinct precursor populations are involved in replenishing the different m! 
populations. A better understanding of m! subsets and their relationship to one 
another could allow them to be selectively targeted as a means of dampening 
inflammation during IBD. 
  My project set out to build on previous studies in the lab examining m! of 
the mouse colon in steady state and experimental colitis, which had been carried 
out  by  a  former  PhD  student,  Andrew  Platt.  These  studies  concluded  that  the   205 
mouse colon contained two independent subsets of m! that were distinguishable 
on the basis of TLR2 (222). In the steady state, F4/80
+TLR2
neg m! were shown to 
dominate  and  they  were  unresponsive  to  TLR  stimulation,  as  well  as  lacking 
expression  of  both  class  II  MHC  and  CCR2.  During  experimental  colitis,  these 
F4/80
+TLR2
neg m !  were  outnumbered  by  newly  recruited  F4/80
+TLR2
+ m ! t h a t  
expressed  class  II  MHC  and  high  levels  of  CCR2,  and  produced  TNF! i n  
response  to  TLR  stimulation.  However  when  I  started  my  project  there  was 
growing concern that many of the standard techniques used to identify MP in the 
intestinal mucosa were not reliable. Not only were there major discrepancies in the 
ways in which different investigators isolated and defined mucosal m!, but there 
was increased appreciation that markers such as F4/80, CD11b, class II MHC and 
in particular CD11c, could not discriminate between m! and DC when used in 
isolation (261, 262). Therefore with the benefit of access to more powerful tools 
such as multi-parameter flow cytometry and CX3CR1-GFP reporter mice, the aims 
of this thesis were to carry out a comprehensive re-examination of the phenotype, 
function and origin of m! in the mouse colon under different conditions.   
8.2 Macrophages in Steady State Colon 
8.2.1  The Phenotype of Macrophages in the Steady State Mucosa 
  Although much progress had been made in examining the phenotype and 
function of colonic m! before I started my work, the studies in the lab had been 
restricted to 4-colour flow cytometry and had identified m! solely on the basis of 
F4/80.  Using  the  improved  methodology  available  to  me,  I  quickly  identified 
several  problems  with  the  earlier  findings.  Firstly,  there  appeared  to  be  a 
population of non-haematopoietic cells that expressed F4/80 and secondly, other 
leucocytes such as eosinophils also expressed F4/80, albeit at low levels. As a 
result, four colour flow cytometry was inadequate to identify and characterise m! 
accurately. At this time, there were no published protocols for analysing mouse 
intestinal  m!  using  more  detailed  methods  and  therefore  in  Chapter  3,  I  first 
established multi-colour staining methods and gating strategies to assess the m! 
populations of the colonic mucosa under physiological conditions. 
  As I was starting my work, findings in the Agace and Pabst labs suggested 
that  mutually  exclusive  expression  of  CD103  and  CX3CR1  could  be  used  to 
identify mucosal DC and m! respectively (189). This contested previous studies   206 
which had classified CX3CR1
+ MP in the intestine as DC because they expressed 
CD11c and class II MHC. The controversy surrounding classification of intestinal 
MP  as  m!  or  DC  may  appear  semantic,  but  it  does  have  important  functional 
implications.  Although  both  m!  and  DC  are  'professional  phagocytes'  that  can 
express class II MHC, their roles in immunity are quite distinct. DC in peripheral 
tissues  survey  the  environment,  take  up  antigen  and  migrate  via  afferent 
lymphatics to the draining LN. Here they interact with and cause the differentiation 
of  naïve  T  cells  into  antigen-specific  effector  T  cells  that  subsequently  migrate 
back to the periphery to carry out effector functions. In contrast, it is generally 
accepted that m! are sessile, tissue resident cells that play an important role in 
tissue remodelling and homeostasis. In addition, m! scavenge foreign material in 
their local environment and eliminate it in highly degradative lysosomes. Although 
'activated' m! may upregulate class II MHC and present antigen to T cells, this is 
likely to involve previously primed T cells in the tissue and not in the LN. Thus 
accurate  classification  of  MP  is  essential  for  understanding  their  function  and 
contribution to homeostasis and protective immunity. 
  Using CX3CR1-GFP and CD11b expression, I found that there were three 
clear subsets of myeloid cells in the resting mucosa: CX3CR1
neg, CX3CR1
int and 
CX3CR1
high. As noted above, CX3CR1
+ MP have been reported previously in the 
steady state intestinal mucosa (28, 169), but these studies did not always assess 
the level of CX3CR1 and some analysed the CX3CR1
+ population as a single 
entity  (195).  In  addition,  many  of  these  reports  used  cells  that  had  been  pre-
enriched using density gradients or by gating on CD11c and class II MHC, on the 
assumption they were DC (28, 169, 195, 263). In contrast, my work showed that 
the  level  of  CX3CR1  expression  not  only  discriminated  between  different  cell 
types, but also that some of the resulting populations were heterogeneous. The 
largest  population  was  CX3CR1
high  and  these  appeared  to  a  homogeneous 
population of m!. They uniformly expressed F4/80 and class II MHC and most 
expressed CD11c to some degree. They also displayed typical m! morphology 
and had high phagocytic activity. Recent studies that have identified CX3CR1
high 
cells in the resting intestine have also concluded that these are sessile tissue m! 
rather than DC, despite the presence of CD11c and class II MHC (189, 264). This 
is supported by the fact that they do not express CCR7 or migrate in afferent 
lymph  to  the  MLN  and  are  inefficient  at  priming  naïve  T  cells  in  vitro  (189). 
Furthermore, as I found, the numbers of CX3CR1
high m! are independent of flt3L   207 
(189), but instead are expanded by CSF-1 and reduced in CSF-1R KO mice (195). 
Very recent work which was reported while I was writing up provided further strong 
evidence to support my conclusions that CX3CR1
high MP are highly phagocytic 
tissue resident m! (265). 
  As noted above, the expression of CD11c by the CX3CR1
high m! has led to 
considerable  confusion  in  identifying  DC  and  m!  in  the  gut.  However  there  is 
growing appreciation that many, if not all, tissue m! can express CD11c. Indeed 
some  groups  have  gone  to  extraordinary  lengths  to  show  that  CD11c  cannot 
discriminate  between  DC  and  m!.  Bradford  et  al  created  CD115-GFPxCD11c-
DTR  mice  to  demonstrate  that  the  administration  of  DT  results  in  complete 
ablation  of C D 1 1 5 -GFP
+ m !  in  most  tissues,  including  the  colon  (266).  In  my 
hands, the level of CD11c expression by CX3CR1
high m! was extremely variable, 
being  dependent  on  the  clone  of  antibody  and  the  particular  fluorochrome 
conjugate. In some of my experiments, CD11c expression appeared to define two 
populations
  of  CX3CR1
high  cells,  but  more  often,  CD11c  showed  a  continuous 
distribution. In addition, analysis of cytokine production and phagocytic activity did 
not suggest this population was heterogeneous. My findings contrast with those of 
Rivollier and colleagues, who suggest that CD11c defines two distinct populations 
of  F4/80
+  MP  in  mouse  colon,  of  which  only  the  CD11c
+  population  was 
replenished  by  Ly6C
high  monocytes  (265).  However  it  is  notable  that  their 
microarray  analysis  revealed  that  there  were  very  few  differences  in  gene 
expression between the CD11c-defined 'subsets'. Thus the exact importance of 
the level of CD11c expression by CX3CR1
high m! is unclear, but it may be that 
CD11c  expression  is  indicative  of  the  maturation  status  of  m!,  increasing  as 
monocyte/m! mature, in a similar fashion to that of F4/80 expression. Certainly in 
my hands, CD11c was expressed at higher levels by m! in the colon than in other 
tissues. This was also the case for class II MHC which was expressed at very high 
levels  on  all  CX3CR1
high  colonic  m!,  but  not  on  m!  resident  in  the  peritoneal 
cavity. Together with the fact that colonic m! expressed much higher levels of 
CX3CR1 than any other myeloid cell I examined, these results suggest that local 
factors in the intestinal mucosa have unique effects on the differentiation of m! 
during maturation from monocytes (see below).  
  The  CX3CR1
int  cells  I  identified  in  the  resting  colon  have  also  not  been 
studied in any depth previously, or were not characterised at all as a separate   208 
subset  (169,  189,  196).  As  a  result,  no  consensus  has  been  reached  on  the 
identity of these cells. By analysing the entire CD11b
+ CX3CR1
int compartment 
without prior bias, I was able to show that in the resting state, this population was 
extremely  heterogeneous,  comprising  at  least  four  subsets  which  could  be 
discriminated  on  the  basis  Ly6C,  class  II  MHC,  F4/80  and  CD11c  expression. 
Given that the Ly6C
highMHCII
neg, Ly6C
+MHCII
+ and Ly6C
negMHCII
+F4/80
+CD11c
neg 
cells all expressed F4/80 to some degree and were not expanded by flt3L, they 
appeared  to  belong  to  the  m!  lineage.  I  referred  to  them  as  P1,  P2  and  P3 
respectively, and to the CX3CR1
high cells as P4. On the basis of the pattern of 
Ly6C and class II MHC staining, I proposed that P1, P2 and P3 represented cells 
at  different  stages  of  maturation,  starting  with  P1  which  was  phenotypically 
indistinguishable from Ly6C
high monocytes in blood, via P2 to the F4/80
+MHCII
+ 
cells in P3 that were similar to the resident CX3CR1
high population, except for the 
level of CX3CR1. These findings are consistent with the study of Schulz et al, 
which  reported  that  the  CX3CR1
int  compartment  in  normal  small  intestine 
contained monocyte-like cells and CD11b
+ cells that expressed variable levels of 
class II MHC (189). However, this earlier work did not characterise these cells, or 
consider whether they were related to the CX3CR1
high m!. A more recent study 
also described the presence of both CX3CR1
int and CX3CR1
high cells in resting 
colon, with the CX3CR1
high population outnumbering the CX3CR1
int cells (264). 
However this study did not detect heterogeneity within the CX3CR1
int population, 
and indeed they specifically reported that Ly6C
+ cells were absent, which is in 
complete contrast to my results. The reason for this difference is unclear, as this 
study used a similar cell isolation technique and did not use a gating strategy that 
would  have  caused  any  populations  to  be  omitted  from  analysis.  Indeed  the 
presence  of  Ly6C
highMHCII
neg  monocytes  in  the  resting  colon  was  particularly 
unexpected given these cells are typically associated with acute inflammation (12, 
22). Nevertheless the presence of Ly6C
high monocytes was consistent in all my 
studies  and  their  presence  in  the  resting  small  intestine  and  colon  has  been 
confirmed  by  recent  unpublished  studies  of  the  Malissen  group  that  I  became 
aware  of  while  writing  up.  Using  Ly6C  and  CD64  expression,  these  studies 
identified a similar pattern of monocyte/m! maturation that I found using Ly6C and 
class II MHC, which they have dubbed the 'monocyte waterfall'.  
  The  remaining  CX3CR1
int  cells  were  Ly6C
negMHCII
+F4/80
negCD11c
+ a n d  
expanded markedly in response flt3L. The presence of flt3L-responsive cells within   209 
the CX3CR1
int compartment has been reported previously, although the authors 
did not characterise the cells involved (189). The same study also showed that 
cells  with  a  similar  phenotype  could  be  found  migrating  in  lymph  draining  the 
intestine, albeit at very low frequencies (189).  Similar findings have been made in 
lymph  of  mesenteric  lymphadenectomised  mice  (Cerovic,  V.  personal 
communication). Thus it appears that the CX3CR1
int compartment may contain 
small numbers of true DC, and interestingly these are CD103
neg, suggesting that 
separating  DC  and  m!  on  the  basis  of  CD103  and  CX3CR1  may  not  be  as 
accurate as currently proposed. Another study which suggested that the CX3CR1
+ 
compartment might contain both m! and DC relied on F4/80 and CD68 as m! 
markers  (169).  However  direct  comparison  of  my  results  with  this  study  is 
complicated, as the authors used density gradients to pre-enrich mononuclear LP 
cells, pre-gated on CD11c and class II MHC to identify 'DC' and analysed the 
CX3CR1 compartment as a single population. This approach would omit the cells 
that I found in P1 and P2, as these both lack CD11c and the former population 
does not express class II MHC.    
  An  advantage  of  using  CX3CR1  to  define  the  colonic  myeloid  cell 
populations was that it allowed me to identify and exclude CD11b
+ cells that were 
not  related  to  m!  or  DC.  Substantial  numbers  of  CX3CR1
neg  granulocytic  cells 
were  present  in  the  resting  mucosa,  the  majority  of  which  were  eosinophils 
expressing SiglecF and possessing a unique ring-shaped nucleus and eosinophilic 
cytoplasm. Unusually, I found that colonic eosinophils did not express the CCL11 
(eotaxin) receptor, CCR3, which characterises eosinophils in most other tissues 
such as the lung, small intestine and blood (253). Importantly, in my hands, colonic 
eosinophils expressed both F4/80 and CD11c, albeit at low levels, highlighting the 
inadequate  nature  of  using  these  markers  in  isolation  to  discriminate  between 
myeloid cells in the colon. Previous studies (253, 267) have identified eosinophils 
in  the  small  intestinal  lamina  propria,  and  although  in  one  case  all 
CD11b
intCD11c
int cells were considered to be eosinophils (267), this is inconsistent 
with  my  observations  which  would  suggest  that  many  of  such  cells  could  be 
CX3CR1
+ m! or DC.  
  The  apparent  abundance  of  eosinophils  in  the  steady  state  LP  was 
surprising  given  their  usual  association  with  TH2  cell  driven  inflammatory 
responses and their rarity when the normal mucosa is examined microscopically   210 
(262).  Thus  their  numbers  may  be  overestimated  by  studies  such  as  mine 
because they are released more easily by enzymatic digestion during isolation and 
can  be  identified  readily  by  multi-parameter  flow  cytometry  in  whole  colonic 
isolates that have not been enriched using density gradients that would normally 
remove  granulocytes.  Despite  this  proviso,  there  is  increasing  evidence  that 
intestinal eosinophils probably form the single largest population of eosinophils in 
the  body  under  steady  state  conditions  (253).  Why  such  large  numbers  of 
eosinophils are present in the steady state LP remains unclear, but interestingly 
their  presence  is  not  dependent  upon  the  commensal  microbiota,  as  intestinal 
eosinophil  numbers  are  normal  in  germ-free  mice  (268).  Several  potential 
functions have been proposed for intestinal eosinophils. Firstly, they may form a 
specialised  layer  of  innate  defence  at  the  mucosal  barrier,  protecting  against 
helminth infection. Secondly, they have been shown to control colonic epithelial 
barrier function by regulating tight junction proteins such as occludin (269). They 
are also a rich source of cytokines such as TGF! (270), which has many effects in 
the intestine, including the regulation of m! and Treg function (179, 191, 271). 
Finally,  intestinal  eosinophils  may  maintain  IgA-producing  plasma  cells  in  the 
mucosa, as eosinophils have been shown to do with IgG-secreting plasma cells in 
the BM.  This process is dependent on APRIL and IL6 (272), and although not 
reported  here,  I  found  colonic  eosinophils  to  produce  IL6  constitutively. 
Alternatively,  IL6  together  with  TGF!  has  been  shown  to  facilitate  the 
differentiation of TH17 cells (273) and thus eosinophil-derived IL6 could maintain 
IL17  levels  in  the  intestinal  mucosa.  Therefore  eosinophils  may  contribute  to 
protective immunity by supporting IgA production and/or IL17 production, as well 
as  acting  as  effector  cells  in  their  own  right.  Investigations  of  the  role  of 
eosinophils in the intestinal LP are currently being pursued by a number of groups 
and work on eosinophil-deficient mice (dblGATA mice; (274) should shed further 
light on their function. 
  As well as eosinophils, a very small population of Ly6G
highCD11b
+Ly6C
int 
neutrophils could also be found in the CX3CR1
negCD11b
+ fraction of cells from 
healthy colon. The low number of neutrophils in the resting mucosa is consistent 
with the fact that neutrophils are only recruited into tissues during inflammation 
and it is unlikely these cells play a significant role in the steady state.   211 
  Thus  it  is  clear  that  the  MP  compartment  of  the  intestinal  mucosa  is 
extremely heterogeneous and that conventional markers such as F4/80, CD11b 
and CD11c cannot be used in isolation to identify individual MP populations. My 
findings demonstrate that CD11b and CX3CR1 expression together with F4/80, 
CD11c, Ly6C and class II MHC are powerful ways of identifying individual subsets 
of  MP.  Consistent  with  previous  findings  (189),  CX3CR1
high  cells  represent  a 
homogeneous  population  of  tissue  resident  m!,  whereas  the  CX3CR1
int 
compartment  contains  cells  that  are  indistinguishable  from  Ly6C
high  blood 
monocytes,  and  cells  that  are  phenotypically  and  morphologically  similar  to 
CX3CR1
high m!. In addition, this population also includes a flt3L responsive DC 
population, which has not been characterised previously. Having identified these 
CX3CR1-defined  populations o f  m !,  I  went  on  to  examine  if  they  represented 
independent subsets of m!, or if a relationship existed between them. 
8.2.2  Ontogeny of Steady State Colonic Macrophages 
  As discussed in Chapter 1, a paradigm has arisen over the last decade that 
tissue resident and pro-inflammatory m! are derived from Ly6C
low and Ly6C
high 
blood  monocytes  respectively.  In  Chapter  4,  I  set  out  to  investigate  whether 
CX3CR1
high and CX3CR1
int were derived from distinct monocyte subsets. My first 
approach  involved  transferring  BM  monocytes  from  CD45.2
+ C X 3 C R 1
+/gfp  mice 
into unmanipulated resting CD45.1
+/CD45.2
+ CX3CR1
+/gfp mice. Although this did 
provide evidence that Ly6C
high monocytes could migrate to the steady state colon, 
it was extremely difficult to identify donor cells in the LP under these conditions, 
due to the small number of cells involved. 
  To overcome this problem, I decided to use recipients whose endogenous 
intestinal  m! h a d  b e e n   reduced.  The  first  system  involved  the  depletion  of 
endogenous MP using DT in the CD11c-DTR mouse. Although this mouse was 
generated to allow the selective ablation of DC, my studies confirmed the idea that 
most tissue m! express CD11c to some degree (266). Indeed I found that DT 
administration resulted in almost complete depletion of the colonic F4/80
+CD11c
-/+ 
m!, whereas CD11c
highCD11b
+F4/80
neg DC were affected less profoundly. Similar 
findings  have  been  reported  very  recently  by  the  Kelsall  group  (265),  showing 
extensive colonic m! depletion in this model, including 'CD11c
neg' cells. In addition, 
as  noted  above,  DT  efficiently  depleted  CD115
+  colonic  m! i n  CD115-  212 
GFPxCD11c-DTR mice (266). However these results are in contrast to another 
previous study (196), which reported a selective effect on DC and preservation of 
colonic m ! i n  CD11c-DTR>WT  BM  chimeric  mice  that  allow  prolonged  DT 
administration.  This  could  account  for  the  differences  in  the  selectively  of  cell 
ablation,  although  it  should  be  noted  that  the  Kelsall  group  also  used  CD11c-
DTR>WT BM chimeric mice, and so other factors may be involved. 
  By utilising CD11c-DTR mice as recipients for adoptive transfer studies, I 
was  able  to  demonstrate  that  Ly6C
high  monocytes  efficiently  replenished  the 
CX3CR1
high m! compartment. This seemed to involve the progressive phenotypic 
maturation of Ly6C
high monocytes in the mucosa itself, via stages identical to those 
I identified as P1-P4 in resting colon. By suggesting that Ly6C
high monocytes are 
the  precursors  of  tissue  resident  CX3CR1
high m !,  these  results  appear  to 
contradict  the  current  monocyte  paradigm.  However  they  are  consistent  with 
previous studies which demonstrated that Ly6C
high monocytes could repopulate 
CX3CR1
high MP cells in the colon of mice depleted chronically using the CD11c-
DTR model (196). However in contrast to my observations, these authors reported 
that a small proportion of donor cells remained in the CX3CR1
int compartment, 
even  two  weeks  following  transfer.  In  my  hands,  all  donor  cells  adopted  the 
CX3CR1
high p h e n o t y p e  w i thin  4  days  and  one  explanation  for  this  discrepancy 
could  be  that  Varol  and  colleagues  administered  DT  from  one  day  before  and 
throughout  the  two  week  period  after  BM  monocyte  transfer.  This  prolonged 
depletion  may  result  in  a  degree  of  inflammation  and  an  arrest  in  monocyte 
differentiation such as I found in DSS colitis. However it is believed that DT does 
not generate significant inflammation (251, 265). An alternative explanation could 
be that some of the CX3CR1
int progeny of Ly6C
high monocytes found by Varol et 
al. could be equivalent to the CD11c
highF4/80
neg DC I identified in P5. Although I 
was unable to detect DC arising from donor monocytes in my experiments, I did 
not examine this exhaustively. In addition, DC of this kind in the gut are thought to 
be  derived  from  pre-DC  (196),  but  it  is  possible  that  the  long  term  depletion 
protocol  used  by  Varol  allowed  accumulation  of  small  numbers  of  monocyte-
derived DC as has been demonstrated in other tissues (275). 
   Although  these  experiments  in  CD11c-DTR  depleted  mice  were  further 
evidence that CX3CR1
high m! appeared to be derived from so-called 'inflammatory' 
Ly6C
high monocytes, I was concerned that the recruitment of monocytes following   213 
DT-mediated depletion of resident CD11c
+ MP may not reflect m! maintenance 
during  true  'steady  state'  conditions.  As  discussed  above,  DT  administration 
results in extensive and rapid MP cell depletion thereby generating an empty niche 
that  will  be  replenished  rapidly,  allowing  recruitment  of  cells  that  are  not 
necessarily  recruited  to  the  normal  mucosa.  Therefore,  I  next  used  CCR2-null 
mice as recipients for adoptive transfer experiments. Due to the indispensible role 
of  CCR2  in  Ly6C
high  monocyte  BM  egress  (22),  these  mice  have  a  selective 
depletion of blood and tissue monocytes and their immediate progeny. In parallel, I 
found they lacked Ly6C
high monocytes in the colon, but had relative preservation of 
resident  colonic  m!.  Thus  I  predicted  these  mice  might  allow  enhanced 
visualisation of monocyte recruitment in the absence of significant effects on tissue 
homeostasis. I found that adoptively transferred Ly6C
high monocytes entered the 
colonic mucosa of CCR2 KO mice and differentiated into CX3CR1
high m!, exactly 
as happened when CD11c-DTR mice were used as recipients. In CCR2 KO mice, 
the maturation of donor monocytes from P1 to P2, then to P3 and finally to P4 
(CX3CR1
high m !)  was  even  clearer.  Again  this  was  accompanied  by  the 
upregulation of class II MHC and F4/80, as well as increased levels of CD11c. 
However, the time taken for Ly6C
high monocytes to mature into CX3CR1
high m! 
appeared to be longer in CCR2 KO mice than in the CD11c-DTR system, taking 
up to 7 days rather than 4 days. This may reflect the possibility that there is more 
physiological maturation of monocytes in the relatively replete mucosa of CCR2 
KO mice, whereas it may be forcibly accelerated in the severely depleted mucosa 
of  CD11c-DTR  mice.  Two  further  important  features  were  revealed  by  these 
studies.  Firstly,  that  the  differentiation  process  of  Ly6C
high  monocytes  was  gut 
specific, as CX3CR1
highMHCII
+ donor cells were not found in the bloodstream or 
lung parenchyma of recipient mice. As reported previously (29, 196), donor cells in 
the bloodstream lose Ly6C, but did not become CX3CR1
high or acquire class II 
MHC expression. Secondly, Ly6C
low monocytes failed to migrate to the intestinal 
mucosa,  even  in  MP-depleted  mice,  which  is  consistent  with  previous  studies 
examining Ly6C
low monocyte recruitment, although Ly6C
low monocytes were found 
to migrate to PP (196). 
  These experiments showed that adoptively transferred Ly6C
high monocytes 
entered  the  colonic  LP  and  became  CX3CR1
high m !. H o w e v e r ,  this  did  not 
necessarily demonstrate that the endogenous cells in intact colon underwent the 
same differentiation process, even though this was suggested by the presence of   214 
the  different  phenotypic  subsets  in  P1-P4  and  by  the  fact  that  the  absence  of 
Ly6C
high monocytes in CCR2 KO mice was associated with a significant reduction 
in  mature  gut  m!.  Thus  I  next  employed  BrdU  to  investigate  the  population 
dynamics  of  endogenous  colonic  CX3CR1
+  myeloid  subsets.  I  found  that  3hrs 
after  pulsing  with  BrdU,  around  a  quarter  of  all  BM  Ly6C
high  monocytes  were 
labelled, consistent with their generation from actively dividing pro-monocytes (11). 
In contrast, no Ly6C
high monocytes in the bloodstream were labelled at this time, 
consistent with their non-cycling status (12). More importantly, I found no BrdU 
incorporation  by  any  of  the  CX3CR1-defined  colonic  myeloid  subsets,  implying 
that these cells were not in active cell division in the tissue. By 12hrs after the 
single pulse of BrdU, a greater frequency (~60%) of the BM Ly6C
high monocyte 
pool was now labelled and BrdU
+ Ly6C
high monocytes were now in the circulation. 
Consistent with their appearance in the bloodstream, a small proportion of cells in 
P1 in the colon were also BrdU
+, suggesting that by this time, precursors had 
incorporated BrdU in the BM, entered the blood and migrated to the steady state 
mucosa.  Importantly  at  12hrs,  significant  numbers  of  BrdU
+  cells  could  not  be 
detected in the other CX3CR1
+ populations in the colon.  
  I next used a long-term BrdU administration protocol to examine the fate of 
monocytes in the colon over a longer period. Mice received BrdU for 6 days and 
then were returned to normal drinking water, with the hypothesis being that if cells 
in P1, P2 and P3 were successive, short-lived intermediaries in transition they 
would show stepwise accumulation of BrdU, but then lose it rapidly upon BrdU 
withdrawal. In contrast, the CX3CR1
high m! population should accumulate BrdU-
labelled cells more gradually and retain them longer. The results confirmed this 
idea, as BrdU
+ cells rapidly accumulated in P1 during BrdU administration, but 
then  disappeared  very  quickly  from  this  compartment  upon  cessation  of  BrdU. 
BrdU
+  cells  also  accumulated  in  P2  with  slightly  slower  kinetics,  although  their 
numbers  decayed  just  as  quickly  upon  removing  BrdU.  P3  showed  slower 
accumulation  of  BrdU
+  cells  and  these  persisted  longer  after  BrdU  withdrawal, 
before  decaying  rapidly  thereafter.  The  proportion  of  BrdU
+ C X 3 C R 1
high  m! 
increased slowly and continued even after BrdU withdrawal. Rather surprisingly, 
the frequency of BrdU
+ cells in CX3CR1
high population not only lagged behind that 
in other populations, but showed a slower increase which did not parallel exactly 
the disappearance of BrdU
+ cells from the CX3CR1
int compartments. This could 
suggest that only a proportion of the CX3CR1
int cells differentiate into CX3CR1
high   215 
m!.  Alternatively, this could be evidence that at least some of the CX3CR1
high m! 
are not derived from Ly6C
high monocytes and that the gradual accumulation of 
BrdU
+  cells  within  the  CX3CR1
high  compartment  could  represent  in  situ  self-
renewal.  Such  a  mechanism  has  been  shown  to  be  responsible  for  the 
maintenance of other tissue m! populations such as Langerhans cells in the skin, 
microglia in the CNS and alveolar m! in the lung (56, 57, 60). These appear to be 
derived from non-haematopoietic stem cells in the yolk sac in foetal life which are 
then maintained by local turnover. The idea that there may be some monocyte 
independent  m!  in  the  colon  is  consistent  with  the  presence  of  colonic  m! i n  
CCR2 KO mice and with the fact that 5-7% of colonic m! were of host origin in 
CX3CR1
+/gfp ! CX3CR1
+/gfp BM chimeric mice. In addition, studies using intestinal 
grafts (189) provide little evidence for continuous replacement of the CX3CR1
+ MP 
population in the steady state as would be expected if derived from circulating 
monocytes.  However  recent  unpublished  studies  by  the  Malissen  group  using 
CCR2 KO x WT mixed BM chimeras have shown that when CCR2 KO precursors 
have  to  compete  with  CCR2-sufficient  cells,  the  intestinal  m!  pool  is  almost 
completely composed of WT-derived cells, paralleling exactly the loss of CCR2 KO 
circulating monocytes. Thus my results could be explained by the fact that in intact 
CCR2 KO mice, those monocytes remaining may use other chemokine receptors 
to enter the mucosa. Furthermore the fact that CX3CR1
+ MP are not lost in small 
intestinal grafts (189) could simply indicate that these cells have a long lifespan 
once fully differentiated, which would be consistent with my BrdU and adoptive 
transfer  studies.  A  dependence  of  resident  colonic  m!  on  replenishment  by 
Ly6C
high monocytes is also supported by recent studies using parabiosis of WT 
and CCL2 KO mice which have shown that CCL2 is crucial for the maintenance of 
the m! pool in the resting intestine (276). 
  To the best of my knowledge, my results are the first demonstration that 
resident  CX3CR1
high  intestinal  m!  in  resting  state  are  generated  from  Ly6C
high 
monocytes via a local differentiation process that involves a number of CX3CR1
int 
intermediary steps. As a result, it appears that CX3CR1
int and CX3CR1
high m! in 
colon are directly related to each other, rather than being independent populations 
of 'inflammatory' and 'resident' m!, as recently suggested (264). It is difficult to 
exclude completely the possibility that a few colonic m! may be truly 'resident' and 
derived from mesenchymal precursors early in foetal life, and only lineage tracking 
strategies such as those used to study the origins and maintenance of microglia   216 
and  Langerhans  cells,  would  provide  insight  into  this  possibility.  However,  my 
studies  suggest  that  most  if  not  all  resident  colonic  m!  are  derived  from  a 
continuous process of replenishment by circulating Ly6C
high monocytes.  
8.2.3 Functional Attributes of CX3CR1
high Macrophages and their 
CX3CR1
int Precursors 
  I then went on to examine the functions of the subsets I had defined on the 
basis of CX3CR1 expression. Unlike m! in other tissues, bulk populations of m! 
from the intestine are known to be unresponsive to stimulation by classical stimuli 
such as TLR ligands (171). In contrast, the blood monocytes that I proposed to be 
the precursors of resident colonic m! are fully responsive to stimulation (12, 22). 
Thus  I  was  interested  to  see  if  and  how  the  functions  of  the  different  subsets 
changed during the in situ differentiation process that I had uncovered. Analysis of 
the spontaneous production of TNF! and IL10 by intracellular cytokine staining 
revealed that all subsets contained cells that produced TNF! alone, IL10 alone 
and rather surprisingly, cells that produced both IL10 and TNF!. However there 
were  marked  differences  in  the  pattern  of  cytokine  production  in  the  different 
CX3CR1-defined  populations.  Specifically,  there  was  an  incremental  transition 
from  predominant  TNF!  production  by  the  Ly6C
highMHCII
neg  cells  in  P1,  to 
dominance of IL10 production amongst mature resident CX3CR1
high m!. This was 
confirmed using both IL10-reporter (VertX) mice and qRT-PCR, while qRT-PCR 
analysis  also  showed  that  the  levels  of  mRNA  for  IL6  and  iNOS  were 
downregulated in resident CX3CR1
high m! compared with their Ly6C
high monocyte 
precursors.  Thus  the  production  of  pro-inflammatory  mediators  appears  to  be 
extinguished as Ly6C
high monocytes mature, giving rise to anti-inflammatory, IL10 
producing CX3CR1
high m!. This switch to IL10 production did not appear to reflect 
differentiation into alternatively activated 'M2' m!, because although CX3CR1
high 
m! also acquired high levels of CD206 and CD163, they did not upregulate the M2 
markers arginase-1 and VEGF. Instead they appeared to represent a population of 
regulatory m !,  which  are  characterised  by  high  IL10  production  and  CD163 
expression  and  have  be  identified  in  the  placenta,  the  developing  embryo  and 
infiltrating tumours (83).  
  It  is  known  that  IL10  is  exceptionally  difficult  to  detect  via  intracellular 
cytokine staining and I only detected it when colonic LP isolates were maintained   217 
in suspension and not when cultured in low adherence culture plates. Failure to 
detect IL10 using typical culture conditions could be due to the strong adherence 
of  mature  (CX3CR1
high)  m!  to  culture  plates,  which  leads  to  poor  cell  retrieval 
and/or viability. However, by using the intracellular cytokine staining technique I 
was unable to quantify the amount of cytokine production and my attempts using 
sorted populations were hindered by poor cell viability following FACS purification, 
meaning  that  they  could  not  be  cultured  long  enough  to  obtain  suitable 
supernatants.  
  A number of groups have recently focussed on the production of IL10 by 
intestinal m! (139, 178, 183, 223), but in one of these cases m! were identified on 
the basis of CD11b expression alone (223), which I showed to be present on many 
cell  types  in  the  mucosa.  Similarly,  although  Denning  et  al.  (178)  showed  that 
CD11b
+F4/80
+  CD11c
neg  cells  in  the  small  intestine  produced  more  IL10  than 
similar cells in the spleen, my results make it clear that this population probably 
included  some  eosinophils  and  it  also  excluded  the  large  number  of  m! t h a t  
express  CD11c.  Therefore  the  authors  of  that  study  may  have  actually 
underestimated  the  ability  of  m!  to  produce  IL10.  IL10  is  a  critically  important 
mediator in the intestine, as IL10 KO mice develop severe spontaneous colitis 
(226) and m!-specific KO of IL10R mediated signalling replicates this phenotype 
(227), but the role of m! themselves as the source of IL10 has been unclear. The 
production  of  IL10  by  colonic  m!  appears  to  be  partially  dependent  on  the 
presence of the commensal microbiota, as gut m! from mice reared in germ-free 
conditions  produce  significantly  less  IL10  (265,  277).  Surprisingly  however,  the 
detection  of  the  commensal  microflora  may  occur  in  a  MyD88-independent 
manner, as m! isolated from MyD88-deficient mice produce equivalent levels of 
IL10 to those from WT mice (265). Recent studies have suggested that IL10 from 
intestinal m! can drive the generation of FoxP3
+ Treg from naïve precursors in 
vitro (178). However given that naïve T cells are rare in the LP (278) and resident 
intestinal m! do not migrate to the draining LN (189), it seems unlikely they are 
involved in initial priming of Treg. In this respect, the work of Murai et al. (183) and 
Hadis  et  al.  (139)  suggests  that  IL10  derived  from  intestinal  m!  is  needed  to 
maintain FoxP3 expression and Treg function in the intestinal LP. In the absence 
of IL10 from host myeloid cells, Treg cannot suppress T-cell mediated colitis and 
there is a defect in oral tolerance to protein antigens in CX3CR1
gfp/gfp mice that 
have defective IL10 production by small intestinal F4/80
+CD11b
+ m! (139). In the   218 
latter case, m!-derived IL10 is essential for the secondary expansion of FoxP3
+ 
Tregs  in  the  small  intestinal  LP  after  they  had  been  generated  initially  by 
CD103
+DC  in  the  MLN.  Thus  CD103
+ D C  a n d  C X 3 C R 1
high m ! m a y  p l a y  
complementary  and  successive  roles  in  maintaining  Treg-dependent  intestinal 
homeostasis.  The  interaction  of  m!  and  Tregs  in  the  mucosa  is  likely  to  be 
bidirectional  and  affect  the  behaviour  of  m!,  as  monocytes  cultured  with 
CD4
+CD25
+FoxP3
+  Tregs  have  been  shown  to  adopt  an  M2-like/regulatory 
phenotype (279, 280). 
  At first, my finding that Ly6C
high monocytes could give rise to mature IL10-
producing  m!  in  the  colon  seemed  somewhat  surprising,  given  that  they  are 
usually  associated  with  robust  pro-inflammatory  responses.  However  as  noted 
above,  disruption  of  Ly6C
high  monocyte  recruitment  in  CCL2-deficient  mice  is 
accompanied by a reduction in IL10-producing m! in the colonic mucosa (276). 
Furthermore, Ly6C
high monocytes have been shown to give rise to IL10-producing 
m! i n  o ther  tissues,  although  in  these  cases  the  monocytes  were  recruited  to 
inflamed or damaged tissues. For example, Ly6C
high monocytes give rise to anti-
inflammatory  macrophages  that  contribute  to  tissue  repair  during  retinal 
inflammation (281) or following spinal cord (282) or skeletal muscle injury (283). 
Similar Ly6C
high monocyte-derived anti-inflammatory m! have been described in 
the pregnant uterus, where they are involved in the remodelling of the growing 
tissue  (50).  Interestingly,  I  noted  that  CCR2  KO  mice  experienced  breeding 
problems after their first litter, suggesting that CCR2-dependent accumulation of 
m! in the uterus may be of major physiological importance. It would therefore be 
interesting to explore if this is directly related to the lack of tissue remodelling by 
local  m!.  Ly6C
high  monocytes  have  also  been  reported  to  give  rise  to  IL10-
producing,  class  II  MHC
+ m !  in  tumours,  where  they  go  through  very  similar 
differentiation stages to those I observed in the colon (284). Thus there appears to 
be  a  growing  appreciation  that  Ly6C
high  monocytes  can  give  rise  to  anti-
inflammatory IL10-producing m! in many tissues. However my observations are 
unique by showing that this happens continuously in the gut in the absence of 
overt inflammation or damage, and Ly6C
high monocytes are undetectable in other 
steady state tissues including the non-pregnant uterus (285) and the normal retina 
(281). These findings may reflect the 'physiological inflammation' that is produced 
in  the  gut  by  its  enormous  antigenic  load  and  a  constant  flow  of  potentially   219 
responsive cells into the mucosa would be a useful first line of defence against this 
material should it be needed. 
  A surprising feature of my functional analysis was that resident CX3CR1
high 
m! produced TNF! constitutively and the levels of TNF! mRNA and protein did 
not change during maturation from monocytes. This was quite different to what I 
found with another pro-inflammatory mediator, IL6, where mRNA levels decreased 
progressively during maturation. Previous work on human and mouse intestinal 
m! has usually suggested that resident m! do not produce TNF!, although most 
of these studies used heterogeneous populations of cells (222). However, more 
recently, Takada and colleagues reported that steady state colonic m! produced 
some TNF! together with IL10, although these cells were identified merely on the 
basis of CD11b and so could have included other cell types (276). In contrast, I 
found  that  highly  defined  CX3CR1
high m !  produce  TNF!  constitutively  and  the 
intracellular cytokine staining technique I developed showed directly that the vast 
majority of CX3CR1
high cells making TNF! also produced IL10. In contrast, most 
Ly6C
high colonic monocytes did not balance TNF! production with IL10, but this 
developed  as  maturation  proceeded  through  the  P1-P4  subsets.  Why  murine 
CX3CR1
high  resident  colonic  m!  retain  the  ability  to  produce  TNF!  despite 
acquiring  anti-inflammatory  properties  remains  unclear.  However,  although 
classically  considered  as  the  archetypal  pro-inflammatory  cytokine,  TNF!  has 
been shown to have some anti-inflammatory effects. For example, TNF! can limit 
the duration and extent of inflammatory responses by regulating IL12 production 
by m! in vivo (286). In addition, signalling through the TNF!R2 is essential for the 
ability of TGF! to induce a regulatory phenotype in peritoneal m! (287). Thus low-
level TNF! production alone, or in combination with mediators such as IL10 or 
TGF!, may act to regulate colonic m! in an autocrine manner. TNF! is also known 
to induce the expression of metalloproteinases (288) and therefore it may enhance 
the tissue remodelling activity of gut m!. Alternatively, TNF! has been shown to 
induce  CX3CL1  expression  by  endothelial  cells  (289)  and  it  is  interesting  to 
speculate that this may be needed to maintain the CX3CR1-dependent production 
of IL10 that appears to be critical for the homeostatic role of resident intestinal m!. 
A  further  intriguing  possibility  is  that  the  known  ability  of  TNF!  to  increase 
epithelial cell permeability via effects on tight junction proteins such occludin (290), 
might  allow  resident  m!  to  facilitate  the  extension  of  their  protrusions  into  the   220 
intestinal lumen. Therefore it would be interesting to examine the ability of TNF! 
KO intestinal m! to form and extend transepithelial dendrites. 
  The  constitutive  production  of  TNF!  and  expression  of  class  II  MHC  by 
resident colonic m! indicate that they are not merely inert cells, but are probably 
responding actively to their environment. This is supported by their acquisition of 
phagocytic activity. My results extend previous findings that human intestinal m! 
are avidly phagocytic and are able to engulf and eliminate bacteria without prior 
'activation' (171, 173), by showing that this activity was acquired progressively as 
CX3CR1
high m! matured from Ly6C
high monocytes and paralleled the acquisition of 
CD163,  IL10  and  class  II  MHC.  It  should  be  noted  that  the  pHrodo  E.  coli 
bioparticle phagocytosis assay I used to measure phagocytic activity in Chapter 5 
is based on the ability of cells not only to engulf the particles, but also to acidify the 
phagosome. This may explain the apparent lack of phagocytic activity I found in 
monocytes and DC, which are generally regarded as being phagocytic, but have 
less ability to acidify the phagosome than mature m! (291). As the ability to acidify 
the phagosomal compartment is essential for the degradation of captured bacteria 
(292), my results show that as CX3CR1
high colonic m! mature from monocytes, 
they acquire the ability to capture and destroy ingested bacteria.   
  Despite these features of activation, my studies confirmed previous findings 
that resident m! in steady state colon are hyporesponsive to TLR stimulation (171, 
222).  The  loss  of  responsiveness  to  TLR  ligands  developed  progressively  as 
CX3CR1
high m! matured from Ly6C
high monocytes. Whereas Ly6C
high monocytes 
showed  a  robust  TNF!-dominated  response  to  stimulation  with  LPS  or  BLP, 
CX3CR1
high cells responded poorly to TLR stimulation, with any TNF! production 
accompanied by IL10. The mechanisms governing this hyporesponsiveness are 
unclear, however initial studies suggested that this was due to a lack of activating 
receptors such as TLR (171). Indeed the previous work in our lab had proposed 
that  TLR  expression  could  be  used  to  discriminate  between  inflammatory  and 
resident m! in mouse colon. However, as discussed above, the interpretation of 
these  results  is  complicated  by  my  current  observations  which  indicate  that 
appropriately characterised resident CX3CR1
high m! express all TLR at a similar 
level to or higher than CSF-1 generated BM m!. This is consistent with recent 
work by Smythies et al. demonstrating that m! isolated from the normal human 
small bowel express all TLR to some degree (179). However my results contrast   221 
with  recent  findings  from  the  Mueller  group,  which  suggested  that  resident 
CX3CR1
+ m! in mouse colon lack surface TLR2 expression (264). The reason for 
this discrepancy is unclear, although this study used a different clone of antibody 
to detect surface TLR2 expression and my findings were confirmed using qRT-
PCR. Thus my results would suggest that these cells do indeed express TLR2 
protein.  One  difference  between  resident  gut  m!  in  mouse  and  man  is  the 
expression of CD14. Whereas human intestinal m! appear to lack this LPS co-
receptor  (170),  I  found  that  murine  CX3CR1
high  resident  m!,  and  indeed  their 
CX3CR1
int precursors, uniformly expressed CD14, consistent with their expression 
of TLR4. The exact reason and importance of this difference is unclear. However 
the  majority  of  blood  monocytes  in  humans  express  CD14  and  therefore  it  is 
possible that this molecule is equivalent to Ly6C in mice and is lost as monocytes 
mature into resident m! in human gut, an idea consistent with findings on human 
intestinal m! from our collaborators in Lund (Uronen-Hansson, H. and Agace, W. 
personal communication).  
  Together my studies show that under steady state conditions, the CX3CR1
+ 
compartment  in  the  colonic  mucosa  is  phenotypically  and  functionally 
heterogeneous,  but  indicate  that  this  represents  a  differentiation  continuum  in 
which  'inflammatory'  Ly6C
high  monocytes  mature  into  resident  m!,  rather  than 
representing independent subsets. This phenotypic transition is accompanied by 
step-wise  changes  involving  the  acquisition  of  class  II  MHC,  IL10  production, 
phagocytic activity and CD163 expression, as well as resistance to exogenous 
stimulation. The physiological implications of this will be discussed below. 
8.3 Effects of Inflammation on Colonic Macrophages  
  It is well documented that inflammation in the intestine results in marked 
changes in the composition of the m! compartment, with the appearance of m! 
with  heightened  pro-inflammatory  features  and  bactericidal  capacity  (239).  In 
humans with IBD, there is an accumulation of CD14
+ m! that produce a range of 
pro-inflammatory mediators and are responsive to TLR stimulation (242). However 
it is not clear whether this reflects recruitment of new pro-inflammatory m!, or if 
tissue resident cells alter their behaviour and become pro-inflammatory. Therefore 
having established strategies to characterise myeloid cells in the resting colon, I 
set out to explore the changes that occurred during inflammation. To do this I used   222 
the DSS-induced model of acute colitis, which is well documented and leads to a 
reproducible form of inflammation with a well-defined pattern of disease. In the 
protocol I used, mice started to lose weight around 4 days after beginning DSS 
administration  and  this  was  accompanied  by  rectal  bleeding  and  diarrhoea.  In 
addition,  DSS  administration  resulted  in  significant  colon  shortening  and 
histological evidence of destruction of the epithelial monolayer and loss of normal 
intestinal  architecture,  with  crypt  elongation,  ulceration  and  inflammatory  cell 
infiltration.   
  My  analyses  showed  a  massive  expansion  of  the  CD11b
+ m y e l o i d  
compartment  in  colitic  mice,  made  up  predominantly  of  Ly6C
highMHCII
neg 
CX3CR1
int  cells  in  P1  and  Ly6C
+MHCII
+CX3CR1
int  cells  in  P2,  as  well  as 
accumulation  of  CX3CR1
neg  eosinophils  and  neutrophils.  There  was  also  an 
increase  in  the  number  of  F4/80
+MHCII
+Ly6C
neg  cells  in  the  P3  subset  of 
CX3CR1
int  cells,  albeit  to  a  lesser  extent  than  in  P1  and  P2.  Conversely  the 
number of CX3CR1
high cells appeared to diminish as colitis progressed. In parallel 
with  their  increased  numbers,  more  cells  in  P1,  P2  and  P3  produced  TNF! 
spontaneously  in  inflammation  compared  with  the  same  populations  in  resting 
mice. Significantly, the most dramatic expansion was associated with P1 and P2 
cells producing TNF! alone. Interestingly however, the progressive acquisition of 
IL10 still occurred in those cells that did mature, so that the majority of TNF!
+ cells 
in P3 also produced IL10. In addition, the CX3CR1
high population remained biased 
to IL10 production and indeed a greater frequency of this population produced 
IL10  during  inflammation  than  in  resting  colon.  A  characteristic  feature  of  the 
analogous population of CD14
+ pro-inflammatory m! that accumulate in inflamed 
human  intestine  is  their  responsiveness  to  exogenous  stimulation,  unlike  their 
counterparts in resting mucosa. Consistent with this, I found that it was mainly the 
cells in P1 or P2 that showed significant increases in pro-inflammatory cytokine 
production  in  whole  colonic  isolates  from  colitic  mice  stimulated  with  TLR2  or 
TLR4  agonists.  As  in  steady  state  conditions,  there  was  a  progressive  loss  of 
sensitivity to TLR stimulation by the CX3CR1
+ cells as they matured and those in 
P3 and P4 retained their balanced production of both TNF! and IL10 even after 
stimulation. Interestingly, the proportion of colitic P1 and P2 cells producing TNF! 
and/or  IL10  after  TLR  stimulation  was  not  significantly  different  to  that  found 
amongst these cells in resting mice, probably because around 90% of healthy P1   223 
and  P2  cells  produced  TNF!  and/or  IL10  under  these  conditions.  Although  it 
would be important to quantify the amounts of cytokine produced by FACS-purified 
populations  during  colitis,  my  results  support  the  idea  that  the  main  effect  of 
inflammation is the recruitment of more responsive cells, rather than an inherent 
change in the cells that have accumulated. One surprising finding was that the 
Ly6C
high monocytes and their derivatives which accumulated during colitis did not 
express high levels of iNOS, in contrast to a number of studies which have shown 
that  during  inflammation,  Ly6C
high  monocytes  give  rise  to  iNOS
+  myeloid  cells 
which were often referred to as 'TipDC' due to their expression of CD11c (22, 
293). In addition, recent work on T cell-dependent colitis by the Malissen group 
has shown upregulation of iNOS by colonic MP with the same phenotype of my 
P1/P2 cells. However this discrepancy could be explained by the fact that DSS 
colitis is not T cell dependent and so there may not be IFN" available to induce 
iNOS.  
  Together these results imply that the resident CX3CR1
high m! do not alter 
their behaviour during inflammation and that the presence of pro-inflammatory m! 
in colitis appears to be due to enhanced accumulation of Ly6C
high monocytes and 
their  immediate  CX3CR1
int  derivatives.  During  my  project  a  number  of  studies 
documented  the  appearance  of  Ly6C
high  monocytes  in  the  inflamed  intestine, 
where they have been shown to give rise to E-cadherin-expressing inflammatory 
MP in T-cell dependent colitis (250). Although the authors interpreted these cells 
as being 'inflammatory' DC, this was solely on the basis of CD11c expression and 
it  is  probable  that  at  least  some  of  these  cells  were  pro-inflammatory  m!.  As 
discussed  above,  Rivollier  et  al.  (265)  have  recently  shown  that  Ly6C
high 
monocytes replenish the resident m! population following DT-mediated depletion 
of endogenous MP. However in contrast to my results, they have suggested that 
Ly6C
high  monocytes  recruited  to  the  inflamed  colon  develop  into 
CD11b
+F4/80
lowCD11c
+CD103
neg D C ,  r ather  than  pro-inflammatory  m!.  In  their 
study, the progeny of adoptively transferred Ly6C
high monocytes in the inflamed 
colon were shown to have increased expression of TNF!, IL6, iNOS, IL12 and 
IL23 compared with that of donor monocytes in resting recipients. Furthermore, 
these cells possessed potent APC function, being able to drive the differentiation 
of IFN"-producing T cells from naïve precursors. However it is unclear whether 
these cells represent bona fide DC because it is unknown if these cells migrate to   224 
the  draining  LN.  The  unpublished  observations  of  the  Malissen  group  would 
support  my  findings  that  Ly6C
high  monocytes  recruited  during  intestinal 
inflammation  give  rise  to  pro-inflammatory  m!,  on  the  basis  that  they  express 
CD64,  a  marker  which  has  recently  been  shown  by  this  group  to  allow 
discrimination of cells of the m! lineage and DC (294). Similarly, the findings of 
Weber et al. (264) also documented the expansion of the CX3CR1
int population 
during  T-cell  dependent  colitis.  However  these  authors  did  not  find  Ly6C
high 
monocytes  in  the  CX3CR1
+  cell  fraction.  Rather  they  suggest  that  Ly6C
high 
monocytes enter the inflamed mucosa as CX3CR1
neg cells, but this is inconsistent 
with the phenotype of Ly6C
high monocytes in the bloodstream, where they clearly 
express  intermediate  levels  of  CX3CR1.  In  addition  to  accumulation  in  several 
colitis models, Ly6C
high monocytes appear to be essential for protection against T. 
gondii and C. rodentium in the intestine (25, 295, 296). 
  My  experiments  did  not  investigate  whether  the  inflammatory  infiltrate  in 
DSS colitis might involve cell division after Ly6C
high monocytes had arrived in the 
mucosa.  Although  this  has  been  reported  (196),  it  was  only  seen  when  the 
endogenous  MP  were  repeatedly  depleted  using  DT,  which  may  create  an 
environment which is not normally experienced by monocytes in MP-replete mice. 
It would be important to examine the possibility that proliferation is occurring within 
the  CX3CR1
int  compartment  using  BrdU  incorporation  and  Ki-67  expression. 
Nevertheless, my results suggest that the main reason for accumulation of cells in 
P1 and P2 is accelerated recruitment and an arrest in the normal process by which 
monocytes  mature  into  CX3CR1
high m !.  Although  adoptively  transferred 
monocytes acquired class II MHC and lost Ly6C expression in the colitic mucosa, 
they failed to transition into the CX3CR1
high compartment as they did in steady 
state  recipients.  This  is  consistent  with  the  apparent  loss  of  endogenous 
CX3CR1
high m !  as  colitis  progresses.  The  exact  reasons  underlying  the 
breakdown in differentiation in inflammation remain to be elucidated. However, the 
milieu in the inflamed colon is radically different to that during resting conditions, 
with  the  accumulation  of  many  inflammatory  cytokines  and  chemokines  (297). 
These may interfere with the factors that normally drive monocyte differentiation or 
may have direct effects on reprogramming monocytes. It is important to note that 
the  remaining  CX3CR1
high m !  continued  to  produce  IL10  during  inflammation, 
underlining how the fully differentiated m! are unlikely to change in inflammation 
(Fig.  8.1).  This  may  also  reflect  an  attempt  to  re-establish  homeostasis  and   225 
continued  IL10  may  influence  the  differentiation  of  newly  arrived  Ly6C
high 
monocytes. Consistent with this idea, myeloid cell-derived IL10 has been shown to 
limit  differentiation  of  infiltrating  Ly6C
high  monocytes  into  TNF!/iNOS-producing 
MP during T. brucei infection in the liver (298). 
  My subsequent experiments indicated that the recruitment of monocytes to 
the inflamed colon was CCR2-dependent. Although it is recognised that CCR2 is 
essential for monocyte egress from the BM (22), the requirement for CCR2 in the 
entry of Ly6C
high monocytes into inflamed tissues is still a matter of debate. By 
performing competitive adoptive transfer experiments of WT and CCR2 KO BM 
cells into colitic mice, I was able to show that virtually all the recruited cells in the 
inflamed LP were of WT origin, which confirms directly that CCR2 is needed for 
this process. This is consistent with the increased levels of CCL2 found in the 
human  and  murine  intestine  during  inflammation  (222,  299).  However,  this 
contrasts  with  studies  examining  the  recruitment  of  Ly6C
high  monocytes  to  the 
inflamed  bladder  and  T.  brucei  infected  liver,  which  are  unaffected  by  CCR2-
deficiency (293, 300). Thus there may be tissue-specific differences in the role of 
CCR2 in monocyte recruitment during inflammation.  
  CCR2-dependent  expansion  of  the  CX3CR1
int  compartment  appears  to 
central to the pathogenesis of DSS colitis, as CCR2 KO mice were protected from 
this model of colitis and showed defective infiltration of Ly6C
high monocytes and 
Ly6C
+MHCII
+ cells in P1 and P2. The decreased pathology was not due to an 
effect on granulocytes, as although the numbers of eosinophils and neutrophils 
were lower in 'colitic' CCR2 KO mice than in their WT counterparts, these cells still 
showed  marked  recruitment.  In  addition,  WT  blood  neutrophils  and  eosinophils 
showed a complete lack of CCR2 expression in my hands. Although these results 
need to be confirmed by comparing resting and colitic CCR2 KO mice in the same 
experiment, they indicate Ly6C
high monocytes and their CX3CR1
int descendants 
play the major role driving inflammation. Interestingly my finding of lower numbers 
of granulocytes in CCR2 KO mice compared with colitic WT mice could reflect a 
role for inflammatory monocytes in recruiting neutrophils and eosinophils. Indeed 
Ly6C
high  monocytes  recruited  to  the  colon  during  acute  DSS  colitis  have  been 
shown to produce high levels of CCL11 (eotaxin-1) and CXCL2 (MIP-1!) which 
are known chemoattractants for eosinophils and neutrophils, respectively (301). 
Clearly  this  mechanism  is  not  absolutely  essential,  as  there  was  still  some   226 
recruitment  of  neutrophils  and  eosinophils  to  the  'colitic'  mucosa  of  CCR2  KO 
mice. It is also unlikely to play a role in the resting colon, as resting CCR2 KO 
mice had normal numbers of colonic eosinophils, despite the absence of Ly6C
high 
monocytes.  
  To  try  to  examine  the  pathogenic  role  of  Ly6C
high  monocytes  directly,  I 
carried out a preliminary study in which I investigated if susceptibility to DSS could 
be restored in CCR2 KO mice by adoptive transfer with WT Ly6C
high monocytes. 
This  had  no  effect,  even  though  the  CCR2  KO  mice  received  over  3x10
6 W T  
monocytes and they could be detected in the recipient colon. However, it must be 
noted that this experiment was only done once with two recipient mice and it would 
be  important  to  repeat  with  more  recipients  and  if  necessary,  using  more 
transferred  cells.  In  addition,  it  might  have  been  useful  to  use  more  sensitive 
parameters than bodyweight such as histological analysis.  
  The  pro-inflammatory  properties  of  Ly6C
high  monocytes  are  not  always 
harmful in the intestine and they play an essential role in protective immunity. As 
noted above, CCR2-dependent recruitment of Ly6C
high monocytes is important in 
defence against T. gondii (25, 295) and C. rodentium (296). Ly6C
high monocytes 
play a similar role in the clearance of L. monocytogenes from the spleen (22) and 
in  protection  against  systemic  West  Nile  virus  infection  (302).  Presumably  the 
damaging  effects  of  these  cells  are  prevented  because  the  responses  are 
terminated once infection has been resolved. Thus IBD may reflect unregulated 
expansion  of  pro-inflammatory  monocytes  and/or  arrest  in  the  process  that 
normally drives these cells to mature into anti-inflammatory m!. 
  The decreased number of CX3CR1
high cells during acute colitis probably 
reflects arrested monocyte differentiation rather than loss through the damaged 
surface, which is characteristic of DSS colitis, as CX3CR1
high m! numbers also 
decrease in a more chronic colitis model which does not directly affect epithelial 
barrier function (Guilliams, M. and Malissen, B. personal communication). A further 
possible explanation for the loss of CX3CR1
high m! could be that inflammation 
causes  downregulation  of  CX3CR1  expression  and  so  cells  appear  in  the 
CX3CR1
int  compartment.  CX3CR1  is  a  chemokine  receptor,  molecules  which 
usually  downregulate  on  exposure  to  high  levels  of  their  ligand  and  increased 
levels of CX3CL1 have been found in IBD in mouse and man (219, 303). However   227 
there is no evidence that CX3CR1 can downregulate in this way and experiments 
in  the  lab  have  found  that  exogenous  CX3CL1  does  not  affect  CX3CR1 
expression  by  m!  in  vitro  (Bravo,  A.  personal  communication).  One  way  to 
examine  if  this  conversion  can  occur  in  inflamed  colon  would  be  to  transfer 
Ly6C
high BM monocytes into depleted CD11c-DTR mice and allow the monocytes 
time to differentiate into CX3CR1
high m!. Colitis could then be induced in these 
recipient  mice  and  the  donor  compartment  examined  for  evidence  of  loss  of 
CX3CR1 expression.  
  An important function of m! is to promote tissue repair during the resolution 
of inflammation. Recent studies have shown that m! with repair functions can be 
derived from 'inflammatory' Ly6C
high monocytes (281, 282). To investigate whether 
this  might  apply  to  the  intestine,  I  examined  whether  the  Ly6C
high  monocytes 
recruited  during  acute  colitis  could  progress  into  the  CX3CR1
high  compartment 
once DSS was withdrawn. To do this, I adopted a colitis regime in which mice 
were fed 2% DSS for 4 days and then returned to normal drinking water for up to 
18 days. Within 2 weeks after cessation of DSS, all mice recovered both in terms 
of bodyweight and intestinal pathology. There was also a partial restoration of the 
normal frequencies of CX3CR1
high and CX3CR1
int cells. To examine whether the 
reappearance  of  CX3CR1
high  cells  reflected  differentiation  of  the  recruited 
inflammatory monocytes, I used continuous BrdU labelling to track recruited cells. 
As  I  found  in  previous  experiments,  4  days  of  continuous  DSS  and  BrdU 
administration led to labelling of both CX3CR1
int and CX3CR1
high cells. When DSS 
and  BrdU  were  removed  there  was  a  rapid  decay  of  BrdU
+  cells  in  both  the 
CX3CR1
int a n d  C X 3 C R 1
high  populations  within  8  days  and  there  was  no 
preferential accumulation of BrdU
+ cells in the CX3CR1
high compartment, as would 
be  expected  if  CX3CR1
int  cells  recruited  during  inflammation  were  transitioning 
into CX3CR1
high cells during the recovery phase. Indeed the rapid loss of BrdU
+ 
cells  from  the  CX3CR1
high  compartment  during  this  period  would  appear  to 
contradict  my  earlier  BrdU  findings  in  steady  state  mice  that  suggested 
CX3CR1
high cells were long lived. However as discussed above, CX3CR1
high m! 
are lost as colitis progresses and therefore it is possible that the BrdU
+ cells that 
accumulated in the CX3CR1
high compartment during the early phase of colitis were 
simply lost before I examined the colon when it began to repair.   228 
  To address further the fate of recruited monocytes in the resolution phase 
of colitis, I adoptively transferred Ly6C
high monocytes into mice on day 4 of colitis, 
before withdrawing DSS and examining the colon one week later. However as 
discussed in Chapter 6, this experiment used CX3CR1
+/gfp mice both as donors 
and recipients, making the identification of donor cells impossible. Therefore the 
fate  of  the  recruited  monocytes  during  the  resolution  of  acute  colitis  remains 
unclear and it would be interesting to conduct a more comprehensive analysis of 
the  colonic  CX3CR1
+  compartment  during  this  phase,  to  examine  if  and  when 
recruited  Ly6C
high  monocytes  start  to  repopulate  the  CX3CR1
high  compartment. 
One  way  this  may  be  done  would  be  to  adoptively  transfer  CD45  congenic 
Ly6C
high m o n o cytes  at  different  time  points  after  the  cessation  of  DSS  and 
establish at what point the normal differentiation resumes.   
8.4 Factors Influencing Colonic Macrophage Behaviour 
8.4.1  The Role of Cytokines and Chemokines 
  The results here, together with previous work, show that resident intestinal 
m! adapt to their environment by becoming anti-inflammatory and hyporesponsive 
to exogenous stimulation. My experiments indicate that this feature reflects in situ 
differentiation  of  Ly6C
high  monocytes  and  is  unique  to  the  gut,  as  transferred 
monocytes did not acquire the same MHCII
+CX3CR1
high phenotype elsewhere. In 
Chapter 4 I attempted to gain insight into what factors in the normal mucosa might 
be  responsible  for  inducing  these  adaptations.  First  I  FACS-sorted  Ly6C
high 
MHCII
neg  monocytes  from  the  resting  colon  and  BM  and  examined  if  their 
phenotype changed during culture in vitro. Unfortunately the low number of colonic 
monocytes  I  could  obtain  and  their  poor  viability  after  culture  hindered  this 
approach.  Despite  these  problems,  colonic,  but  not  BM  Ly6C
high  monocytes 
cultured overnight in medium alone started to acquire class II MHC expression, 
suggesting that factors in the mucosa had already begun to influence these early 
stages of the monocyte differentiation process. In contrast, the expression levels 
of CX3CR1 and Ly6C did not changed on cultured colonic monocytes. However 
this is consistent with my adoptive transfer studies which showed that loss of Ly6C 
and  upregulation  of  CX3CR1  occurred  after  class  II  MHC  acquisition  and  took 
around 2-3 days.   229 
  To circumvent the problems with yield and viability, I next used sorted BM 
Ly6C
high monocytes to examine the effects of specific mediators present in the 
mucosa  with  known  effects  on  m!  biology.  These  were  TGF!,  CSF-1  and 
CX3CL1. However none of these factors induced phenotypic changes in cultured 
monocytes  and  there  was  no  evidence  of  acquisition  of  a  mucosal  m! 
appearance. With the benefit of hindsight, these experiments were probably not 
carried  out  under  optimal  conditions.  Firstly,  the  purified  monocytes  were  only 
cultured  for  24hrs,  whereas  my  adoptive  transfer  experiments  suggest  that  the 
differentiation of monocytes into the resident m! phenotype probably takes 4-7 
days  in  vivo.  Secondly,  it  is  unlikely  that  monocytes  in  the  mucosa  would  be 
exposed to these factors in isolation, and so it would have been interesting to 
combine these factors. Furthermore, as discussed below, mediators in the mucosa 
other than those tested may play a role in influencing monocyte differentiation. 
  A number of possible factors have been implicated in defining the specific 
characteristics  of  gut  m!,  although  many  reports  have  concentrated  on  what 
accounts for their TLR responsiveness. IL10 can prevent TLR function by inducing 
inhibitors  of  the N F -#B  pathway  such  as  Bcl-3  and  I#BNS  (229,  230).  As 
discussed  above,  functional  IL10R  signalling  by  m!  is  needed  to  maintain 
intestinal homeostasis and hence m! from IL10 KO mice have a pro-inflammatory 
cytokine profile and respond vigorously to TLR stimulation (177), and these mice 
develop spontaneous colitis (226). Interest in IL-10-IL10R signalling in maintaining 
homeostasis  in  the  gut  has  been  fuelled  further  by  GWAS  showing  that 
polymorphisms  in  the  IL10R  gene  increase  susceptibility  of  IBD  and  recently 
transplant of IL10R-sufficient BM has been shown to ameliorate Crohn's disease 
(228).  Together  these  findings  suggest  that  failure  of  haematopoietic  cells  to 
respond appropriately to IL10 is a major factor in IBD pathogenesis.  
  IL10 is produced by a variety of cells in the mucosa including Tregs and as 
discussed above, by m! themselves. Therefore, whether IL10 acts in an autocrine 
manner to self-regulate m! behaviour is unclear. It is also unknown if IL10 can 
influence  in  situ  monocyte  differentiation,  but  analysis  of  the  colonic  myeloid 
compartment of 'pre-colitic' IL10 KO mice could provide some insight, as could 
examination  of  monocyte  differentiation  after  adoptive  transfer  of  Ly6C
high 
monocytes  into  'pre-colitic'  IL10  KO  mice.  However  one  complication  of  these 
approaches is that the mucosa of IL10 KO mice may not be normal, even before   230 
colitis appears, as these KO mice have increased intestinal epithelial permeability 
and heightened levels of TNF! in the mucosa by 2 weeks of age, long before the 
development  of  overt  inflammation  (304,  305).  Better  approaches  would  be  to 
generate mice with selective defects in the production of, or responsiveness to 
IL10 in monocytes and m!. Although this has been done using STAT3 KO and the 
LysM promoter (227), and these mice develop IBD, STAT3 is not specific to the 
IL10R  signalling  pathway  and  other  myeloid  cells,  such  as  neutrophils,  can 
express LysM. Therefore it would be useful to find a more specific promoter such 
as  CD115,  CD68  or  CX3CR1.  As  well  as  examining  the  intestinal  myeloid 
compartments in such animals, it would be interesting to investigate the fate of 
adoptively  transferred  monocytes  from  these  mice  in  the  normal  steady  state 
colon.  Together  these  studies  would  provide  some  insight  into  whether  IL10 
directly  affects  the  expression  of  CX3CR1  and  class  II  MHC  on  maturing 
monocytes, as well as its specific role in m! function in the intestine.  
  Another  cytokine  likely  to  be  involved  in  modulating  m!  behaviour  and 
influencing monocyte maturation in the mucosa is TGF!. Indeed TGF!, along with 
IL8, has been shown to attract monocytes to the intestine (232). TGF! is abundant 
in the steady state intestine, being produced by a range of cells including stromal 
cells, epithelial cells, mast cells and regulatory T cells, as well as by m! (179, 
271). TGF! inactivates NF-#B signalling in human small intestinal m! via a failure 
of  NF-#B  to  translocate  to  the  nucleus  caused  by  repression  of  the  Smad7 
molecule, which normally inhibits TGF! signalling (179). The importance of this 
pathway  is  suggested  by  the  finding  that  Smad7  is  upregulated  in  human  IBD 
leading  to  unrestrained  NF-#B  activation  (233).  Furthermore,  TGF!  has  been 
shown  to  condition  m!  in  the  foetal  intestine  to  acquire  the  anti-inflammatory 
cytokine  profile  and  LPS  resistance  typical  of  adult  gut  m!  (271).  In  addition, 
intestinal tissue-conditioned medium causes human blood monocytes to adopt an 
intestinal  m!  phenotype  characterised  by  reduced  CD14  expression  and 
resistance  to  TLR  stimulation  and  this  is  dependent  on  TGF!  (179,  271).  The 
expression  of  TGF!2R  increased  incrementally  as  monocytes  matured  into 
resident colonic m!, supporting the idea that these cells acquire responsiveness to 
TGF! and that this mediator may play an important role in determining their fate in 
vivo. However, it is not clear whether TGF! specifically influences the upregulation 
of  CX3CR1  and  class  II  MHC.  Similar  approaches  to  those  described  for   231 
assessing the role of IL10 could be used to test this, such as conditional KO of 
TGF!R on m!. This approach has been used to show that peritoneal m! from 
CD68-TGF!RDN mice, which fail to respond to TGF!, produce less IL10 than WT 
m!, and resolution of DSS colitis is impaired in these mice (306). However the 
nature  of  the  baseline  colonic  LP  m!  populations  in  these  mice  under  normal 
conditions is unclear. In addition, it would be interesting to examine the effects of 
intestinal stromal cell-conditioned medium on the differentiation of BM or colonic 
Ly6C
high monocytes in vitro, as has been done with blood monocytes in human 
studies (179). 
  Although CSF-1 did not have an effect on BM monocytes cultured in vitro, 
this mediator is essential for m! differentiation from monocytes and it is present in 
the steady state gut (307). The importance of CSF-1 is highlighted by the paucity 
of most tissue m! in CSF-1-deficient mice (41) and by the fact that CSF-1R KO 
mice lack small intestinal CX3CR1
+ m! (195). As an alternative way of assessing 
the effects of CSF-1 on gut m!, I administered recombinant CSF-1 in vivo. This 
caused a small, but significant increase in the number of CX3CR1
high colonic m! 
and parallel reductions in P1 and P2, suggesting that CSF-1 may act locally to 
promote  differentiation  of  recently  recruited  monocytes.  However,  CSF-1  may 
cause  increased  survival  or  even  turnover  of  already  differentiated  CX3CR1
high 
m!. Alternatively, it may accelerate the output and differentiation of monocytes 
before leaving the BM and these alternatives could be investigated using BrdU 
incorporation  studies  and  Ki-67  staining.  In  addition  to  facilitating  m! 
differentiation, CSF-1 has also been shown to cause resident m! in the pregnant 
uterus to produce chemokines such as CCL2 (MCP-1), enhancing the recruitment 
of further monocytes (50). However, the reduced numbers of cells in P1 and P2 I 
found  after  exogenous  CSF-1  treatment,  suggest  that  its  effects  were  on 
enhanced  differentiation  of  colonic  monocytes,  rather  than  accelerated 
recruitment. It is noteworthy to mention that the effects I saw with CSF-1 treatment 
were not dramatic and this may reflect the low dose I used. Although I chose the 
dose of 20,000 U/day of rCSF-1 based on an early study by Hume et al. (49), a 
very recent study used 1,000,000 U/day to cause doubling of m! numbers in the 
spleen (308). Therefore it would be important to repeat this experiment using a 
higher dose of CSF-1 to assess its effects on the different colon m! populations 
more precisely.    232 
  In view of the fact that the key feature of resident gut m! is the acquisition 
of unusually high levels of CX3CR1, and that its ligand CX3CL1 is produced in the 
mucosa  (203,  204),  it  seems  logical  to  propose  that  this  mediator  might  be 
involved in regulating local m! maturation. Studies within our group, as well as 
those  of  others  (169)  (Bravo,  A.  personal  communication),  suggest  that  mice 
lacking  CX3CR1  (CX3CR1
gfp/gfp  mice)  have  no  defect  in  the  number  of  their 
colonic m!. However, as discussed above, CX3CR1-deficiency is associated with 
reduced IL10 production by intestinal m!, suggesting that the CX3CR1-CX3CL1 
axis may be crucial for maintaining the status of colonic m!. This contrasts with 
recent  findings  showing  that  CX3CR1
gfp/gfp  mice  have  small  reductions  in  the 
number of brain-resident microglia (309). Furthermore, we have been unable to 
find any effects of soluble or membrane-bound CX3CL1 on m! function in vitro, 
although others have shown it may inhibit/enhance m! function (203, 217). It is 
controversial whether disruption of the CX3CR1-CX3CL1 axis results in altered 
susceptibility to experimental colitis, with conflicting results being reported (169, 
219,  310).  Another,  not  exclusive  possibility  could  be  that  the  high  levels  of 
CX3CR1  on  resident  m! m a y  be  involved  in  their  positioning  adjacent  to  the 
CX3CL1-expressing  epithelial  monolayer.  This  would  be  consistent  with 
fluorescence microscopic analysis showing that CX3CR1
+ MP tend to associate 
with the epithelium (189). In addition, although never directly shown to occur in the 
colon, CX3CR1 appears to be needed for the formation of transepithelial dendrites 
by CX3CR1
+ m!, allowing them to sense and sample the contents of the intestinal 
lumen  (193,  203).  Unfortunately  it  is  currently  impossible  to  discriminate 
CX3CR1
int from CX3CR1
high cells by immunohistochemistry and therefore it is not 
clear if these anatomical properties are features of bona fide CX3CR1
high m! or 
other CX3CR1
+ cells including the DC I identified in P5. Furthermore, it is unknown 
if CX3CR1
high and CX3CR1
int occupy different locations in the mucosa, as might 
be predicted. 
  In addition to the mediators discussed above, other factors such as TSLP, 
VIP and RA may play a role in influencing m!, as they have been shown to induce 
tolerogenic properties in mucosal DC (234, 235, 311). Also PPAR" ligands have 
been suggested to regulate intestinal m! activity (312). In addition, mucosal blood 
vessels  may  imprint  selective  properties  on  extravasating  monocytes,  an  idea 
supported by work suggesting that transendothelial migration of monocytes affects 
their subsequent differentiation (37).   233 
8.4.2  Control of Macrophage Function by Inhibitory Receptors 
  As discussed in Chapter 1, the activation state of tissue m! is likely to be 
influenced by signals received through both activating and inhibitory receptors. In 
Chapter  7  I  set  out  to  investigate  whether  the  inhibitory  receptor  CD200R1 
contributed  to  the  maintenance  of  colonic  m!  in  their  partially  inert  state,  as 
CD200R1  has  been  implicated  in  the  regulation  of  many  other  tissue  m! 
populations, although previous work had not examined CD200R1 expression on 
well characterised gut m! (113, 116, 119). I found that CD200R1 was expressed 
by mature colonic m! at levels similar to that of alveolar m!, which have been 
shown to uniformly express this receptor (119). In contrast, peritoneal m! lacked 
any expression of CD200R1 and CSF-1 generated BM m! expressed only low 
levels of the receptor. Other intestinal leucocytes such as eosinophils appeared to 
lack  CD200R1  expression,  as  did  the  Ly6C
highMHCII
neg  colonic  monocytes, 
suggesting  this  is  a  selective  property  of  mature  mucosal  m!.  Unfortunately, 
because these experiments were carried out prior to the optimisation of the gating 
strategies used in the rest of this thesis, I was unable to assess how CD200R1 
expression  changed  during  the  maturation  from  monocytes  to  CX3CR1
high m !. 
However  this  could  be  assessed  easily  using  the  new  gating  strategy  or  by 
crossing the CD200R1 KO mice with CX3CR1
+/gfp mice. It is also noteworthy to 
mention  that  I  experienced  difficulties  when  analysing  CD200R1  expression 
initially, as I found identical staining by WT and CD200R1 KO cells using the only 
commercially  available  antibody.  This  required  careful  titration  of  the  antibody 
using CD200R1 KO cells as the control to obtain conditions which allowed specific 
staining. This is clearly a technical issue that needs to be considered in future 
work when CD200R1 expression is being assessed. 
  The ligand for CD200R1, CD200, was also abundant in the resting colonic 
mucosa,  being  expressed  at  high  levels  on  vascular  and  lymphatic  endothelial 
cells and at low levels on mucosal B cells. This pattern is consistent with CD200 
expression seen in other tissues, such as the lung (119, 313). Because KO of 
CD200  has  been  shown  to  lead  to  heightened  m!  activity  in  multiple  tissues 
including the MLN, spleen and CNS (113) and to increased immunopathology in 
the lung during influenza infection (119), I postulated that deletion of CD200R1 
would lead to an alteration of m! behaviour in the colon. However CD200R1 KO 
mice had normal numbers of mature F4/80
+MHCII
+ colonic m! and these showed   234 
no  signs  of  enhanced  activation  as  determined  by  costimulatory  molecule 
expression. However CD200R1 KO mice did have an additional F4/80
+MHCII
int 
population of cells which was not present to any great extent in WT mice. These 
F4/80
+MHCII
int cells did not seem to represent recently recruited cells equivalent to 
the  P1  and  P2  cells  I  identified  in  CX3CR1
+/gfp  mice,  as  they  lacked  Ly6C 
expression. Furthermore they did not appear to express higher levels of CD40 and 
CD80 costimulatory molecules or TLR, suggesting they were not simply 'activated' 
states  of  the  F4/80
+MHCII
+ m !  population.  However  it  must  be  noted  that  the 
numbers of the F4/80
+MHCII
int population were variable between experiments and 
their significance is still unclear. 
  Although  I  was  unable  to  examine  the  production  of  TNF!  by  these 
populations of F4/80
+MHCII
int and F4/80
+MHCII
+ separately, analysis of the total 
m! p o p ulation  showed  that  CD200R1  KO  colonic  m!  did  not  show  increased 
production of TNF! in response to LPS stimulation. It is important to note that 
there were differences in the level of detection of intracellular cytokines in these 
experiments compared with the results in Chapter 5, which may reflect the fact 
that by the time the latter experiments were performed I had optimised the protocol 
for detecting intracellular cytokines. CSF-1 generated BMM from CD200R1 KO 
mice also did not show increased TNF! production in response to LPS stimulation 
alone or together with IFN". These findings of normal TNF! responsiveness seem 
to contradict previous studies on the ability of the CD200-CD200R1 axis to inhibit 
m! activation (113, 119, 125). However others have suggested that TLR signalling 
may overcome the ability of CD200R1 to regulate m! responses to IFN" (126). 
Interestingly however, in some reports the regulatory effects of CD200R1 have 
only been seen when CD200R1 is co-ligated with a source of CD200 at the time of 
stimulation (119). Thus the role of CD200R1 in vivo may require contact between 
m! and CD200-expressing cells at the same time as exposure to an activating 
stimulus.  
  My findings that CD200R1 does not play an essential role in controlling m! 
activation in the steady state intestine were supported by the fact that CD200R1 
KO  mice  did  not  develop  any  signs  of  spontaneous  intestinal  inflammation, 
systemic lymphoproliferative disease or autoimmunity, even when followed for up 
to 18 months of age. Similarly, CD200R1 KO mice showed identical susceptibility   235 
to DSS-induced colitis to WT mice, with no differences in the composition of the 
colon m! pool or inflammatory infiltrates in colitis.  
!!! Although CD200 is the only known ligand for CD200R1, CD200 has been 
shown  to  ligate  other  CD200R  (110)  and  so  I  carried  out  similar  analyses  of 
intestinal m! in CD200 KO mice. These mice had a significant decrease in the 
number of F4/80
+MHCII
+ m! in the resting mucosa compared with WT mice, but 
this  was  not  accompanied  by  an  increase  in  the  number  F4/80
+MHCII
int  cells. 
Although this could suggest that there is a selective loss of the F4/80
+MHCII
+ m! 
in the absence of CD200, I only had sufficient mice to carry out this experiment 
once and it would be important to repeat. If correct, it could suggest that CD200 
may play a role in the survival of mature colonic m!. However, as in CD200R1 KO 
mice, there was no evidence of spontaneous pathology or inflammatory infiltrates 
in the colon of the CD200 KO mice, which were brought from Bristol and kept 
under SPF conditions in our facility. These animals also showed no increase in 
susceptibility  to  DSS  colitis.  As  CD200  KO  mice  have  been  reported  to  have 
increased susceptibility to autoimmunity in the eye, brain and joint (113, 114, 314), 
my  results  may  indicate  a  differential  role  for C D 2 0 0 -CD200R1  regulation  in 
different  forms  of  immunopathology.  Significantly,  the  disorders  in  which 
neutralisation or deletion of CD200 leads to increased inflammation are associated 
with  T  cell  driven  m!  activation.  In  contrast,  DSS-induced  colitis  is  driven 
predominantly by innate leucocytes, as evidenced by normal disease progression 
in NK-depleted SCID mice (315). Therefore it would be interesting to assess the 
progress  of  other,  T  cell  dependent  forms  of  intestinal  pathology  in  CD200  or 
CD200R1 KO mice. 
  Previous studies have identified the role of CD200R1 in the regulation of 
myeloid  cell  activity  by  manipulating  the  CD200-CD200R1  axis  in  vitro  using 
agonistic CD200-Fc fusion proteins or with antagonistic anti-CD200R1 antibodies 
(119, 120, 314). Thus I used this approach to examine the TLR responsiveness of 
CSF-1  generated  BMM  from  WT  and  CD200R1  KO  mice.  Although  this 
experiment indicated that BMM from CD200R1 KO mice had a marginally higher 
TNF! response to LPS stimulation, inclusion of a CD200-Fc fusion protein had no 
effect  on  the  TNF!  response  by  BMM  from  WT  mice,  again  suggesting  that 
signals delivered through CD200R1 had little effect on m! responses to LPS and   236 
supporting my observations of normal function by colonic m! from CD200R1 KO 
mice. 
  Thus, in contrast to alveolar m! in the lung which have been shown to be 
regulated  via  the  CD200R1-CD200  axis  (119),  CD200R1  appears  to  play  no 
essential role in the control of colonic m! activity. This raises the possibility that 
distinct  regulatory  mechanisms  regulate  m!  at  different  mucosal  surfaces. 
However, one cannot exclude the possibility that CD200R1 might be important in 
combination  with  other  regulatory  factors  and  it  is  probably  not  surprising  that 
redundant mechanisms are involved. 
8.5 Concluding Remarks 
  Taken together, my results reveal unsuspected heterogeneity in the MPS of 
the colonic mucosa. By using CX3CR1 to define mucosal myeloid cell subsets, I 
have  been  able  to  show  that  'inflammatory'  Ly6C
high  monocytes  are  constantly 
recruited  to  the  steady  state  LP,  where  they  subsequently  undergo  an  in  situ 
differentiation process to replenish the majority CX3CR1
high m! population. This 
phenotypically identifiable maturation process is accompanied by an alteration in 
functional capacity, so that resident CX3CR1
high m! are relatively desensitised to 
exogenous stimuli, but remain avidly phagocytic and produce IL10 constitutively. 
These features, combined with their close association with the epithelium in vivo, 
probably allow resident m! to act as non-inflammatory waste disposal units for 
cellular debris and any bacteria that breach the epithelial monolayer. CX3CR1
high 
resident m! are probably the cells that have been shown to extend dendrites into 
the intestinal lumen, although the exact significance of luminal sampling by m! is 
unclear,  as  the  vast  majority  of  these  cells  do  not  migrate  to  the  MLN  (189). 
However evidence is emerging that CX3CR1
+ m! may be able to transfer captured 
antigen to mucosal CD103
+ DC, which then transport it to the MLN. In addition, it 
has  recently  been  proposed  that  bona  fide C D 1 0 3
+  DC  can  also  extend 
protrusions into the intestinal lumen and directly sample the contents, suggesting 
that this may be a property of all intestinal MP and not only CX3CR1
+ m!. As well 
as tissue resident scavengers, there is also growing appreciation that through their 
production  of  IL10,  intestinal  m!  contribute  to  the  maintenance  of  peripheral 
tolerance  through  the  secondary  expansion  and  maintenance  of  Treg  in  the 
mucosa. In addition, they contribute to epithelial integrity and ablation of resident   237 
m! results in increased susceptibility to chemically-induced colitis, showing these 
cells are playing a crucial regulatory role under normal circumstances. 
  My  findings  also  show  that  pro-inflammatory  m!  arise  from  the  same 
Ly6C
high monocyte precursor and accumulation of these cells during experimental 
colitis  is  in  part  due  to  the  breakdown  in  the  local  differentiation  process.  The 
CCR2-dependent  accumulation  of  Ly6C
high  monocytes  and  their  derivatives  in 
acute  inflammation  is  important  for  pathology,  but  may  also  be  essential  for 
protective immunity to bacterial and parasitic infections in the intestine (25, 295, 
296), due to their enhanced ability to produce pro-inflammatory cytokines such as 
TNF!.  Importantly  my  studies  demonstrate  for  the  first  time  that  so-called 
'inflammatory' Ly6C
high monocytes give rise to both resident and pro-inflammatory 
monocytes,  a  concept  that  contradicts  the  current  theory  of  monocyte 
heterogeneity.  Furthermore  these  results  show  that  'resident'  and  'pro-
inflammatory' m! in the colon are not independent cell types, but rather represent 
different differentiation outcomes of the same monocyte precursor and highlight 
the  plastic  nature  of  cells  of  the  MPS.  Reassuringly,  an  analogous  monocyte 
differentiation process appears to be present in the normal human ileum and its 
breakdown may result in the accumulation of CD14
+ pro-inflammatory m! during 
IBD  (Bain  et  al.,  manuscript  submitted).  That  Ly6C
high a n d  C D 1 4
+  monocytes 
replenish  steady  state  m!  populations  in  mice  and  humans,  respectively,  is 
contrary to their classification as 'inflammatory' monocytes, and thus I would agree 
with  the  recent  proposal  that  these  cells  should  be  referred  to  as  'classical' 
monocytes,  in  contrast  to  Ly6C
low  murine  or  CD14
+CD16
high  human  monocytes 
which should be termed 'non-classical' (316). 
  These  findings  are  important,  as  the  selective  blockade  of  inflammatory 
monocyte infiltration has been an attractive potential strategy for the treatment of 
human IBD. However given that these monocytes also replenish the resident m! 
population,  the  depletion  or  selective  targeting  of  these  monocytes  may  cause 
collateral  reductions  in  'resident'  m!  populations  and  therefore  a  loss  of  the 
essential immunoregulatory functions these cells perform. In light of these findings, 
future  studies  should  focus  on  identifying  the  local  factors  that  drive  monocyte 
differentiation in the steady state mucosa and assess why this process is arrested 
in  inflammation,  rather  than  attempting  to  block  monocyte  recruitment. 
Identification of such factors could lead to therapies that aim to manipulate the   238 
intestinal  cytokine/chemokine  milieu  in  order  to  favour  differentiation  into  anti-
inflammatory 'resident' m! during active inflammation in IBD.   239 
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Figure 8.1: The Phenotype, Function and Origin of Intestinal Macrophages in the Normal and 
Inflamed Intestine 
A. Resident m! in the intestinal LP are crucial for maintaining local homeostasis by capturing and 
eliminating  any  bacteria  that  breach  the  epithelial  barrier  without  provoking  an  inflammatory 
response. It is likely that they also clear apoptotic and senescent cells, as well as other cellular 
debris. In resting mucosa, the majority of m! (identified in my work as P4) express unusually high 
levels of CX3CR1, the receptor for the chemokine CX3CL1 (fractalkine) expressed by enterocytes 
and goblet cells. M! may also extend cellular processes through the epithelial layer to sense and 
perhaps  sample  the  luminal  contents,  a  process  dependent  on  CX3CR1.  M! a l s o  p r o d u c e  
immunoregulatory cytokines such as IL10, which may act in an autocrine manner to control m! 
activation, as well as facilitating terminal differentiation and maintenance of FoxP3
+ Treg within the 
mucosa. In turn, Treg produce TGF$ and IL10, which together with other local factors, are likely to 
maintain resident m! in their state of partial inertia. The results in this thesis indicate that resident 
intestinal m! are continuously replenished by CX3CR1
intCCR2
+Ly6C
high ‘inflammatory’ monocytes 
(P1), through a process of local differentiation that involves CX3CR1
int intermediaries (P2 and P3). 
B. D u r i n g  i n t e s t i n a l  i n f l a m m a t i o n  i n d u c e d  b y  p a t h o g e n  i n v a s i o n  o r  d a m a g e ,  t h e r e  i s  i n t e n s e  
recruitment and accumulation of CX3CR1
intCCR2
+Ly6C
high monocytes due an arrest in the normal 
differentiation process. This gi ves r i se t o pr o-inflammatory  m! di st i ngui shed from their resident 
counterparts  by  their  lower  levels  of  CX3CR1.  They a r e  p o t e n t  p r o d u c e rs  of  pro-inflammatory 
cytokines  and  appear  to  perpetuate  the  inflammatory  response  through  the  recruitment  and 
maintenance of other effector cells, such as T cells, eosinophils and neutrophils. Some CX3CR1
high 
m! remain in the inflamed mucosa and they continue to make IL10, perhaps in an attempt to 
restore homeostasis by influencing the differentiation of recently recruited monocytes.   241 
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